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Abstract 
The tumor suppressor p16INK4a is strongly expressed in HPV-transformed precursor lesions 
and cervical cancer, whereas in normal tissues barely any p16INK4a expression is detectable. 
It is thus used as a diagnostic marker since several years and it was speculated that 
targeting p16INKa-overexpressing cells with a therapeutic vaccine could have high benefit for 
patients suffering from HPV induced neoplasia and cancer. 
We designed chimeric capsomeres consisting of full-length p16INK4a and HPV16 L1, the 
major capsid protein of HPV and antigen of the available prophylactic HPV vaccines, with 
the aim of using the adjuvant-like effects of L1 particles to potentiate an effective p16INK4a 
immune response. For this purpose, three constructs were generated to evaluate the 
antigenic effect of different structural isoforms. The complete p16INK4a encoding cDNA 
sequence was cloned downstream (pGex-L1ΔN10Δh4ΔC29-p16INK4a) and upstream (pGex-
p16INK4a-L1ΔN10Δh4ΔC29) of a modified HPV16 L1 sequence into a pGex-4T-2 expression 
vector. For the third construct (pGex-L1ΔN10Δh4-p16INK4a-L1ΔC29) the helix 4 region of L1 
was replaced by p16INK4a. The proteins were inducible expressed in E. coli. Due to the low 
solubility of the chimeras, an inclusion body (IB) purification protocol was developed to 
purify the proteins in high amounts. After IB purification, the proteins were extracted under 
denaturing conditions with N-Lauroylsarcosine and refolded by dialysis. The capsomere 
preparations were found to be free of endotoxins after refolding from IBs. The produced 
particles were then evaluated for their structural properties and the in vivo immunogenicity 
of the capsomeres was tested in a C57BL/6 mouse model. Besides good stability 
characteristics, the capsomeres were found to be of rather heterogeneous structure and the 
immunological comparison of the three different constructs revealed different 
characteristics. GST-L1ΔN10Δh4-p16INK4a-L1ΔC29 induced highest L1-specific T cell 
numbers, GST-p16INK4a-L1ΔN10Δh4ΔC29 showed the best antibody response in the VLP-
capture ELISA and GST-L1ΔN10Δh4ΔC29-p16INK4a seemed to induce the most efficient 
anti-p16 humoral immune response. Also the induction of p16-specific T cells could be 
demonstrated with the GST-L1ΔN10Δh4-p16INK4a-L1ΔC29 construct. 
The objective of this thesis was to generate, purify and evaluate a cost-effective second 
generation therapeutic vaccine based on chimeric capsomeres. The presented vaccine 
candidates can be cost-efficiently produced in bacteria and purified from inclusion bodies 
with high yields. The proteins were also found to be stable at room temperature and their 
immunogenicity was demonstrated in first in vivo mouse experiments. A protein-based 
vaccine with these properties could have substantial benefit, especially for unindustrialized 
countries where most of the cervical cancer cases occur. The possibility to generate an 
effective immune response to p16INK4a further opens new opportunities in the field of cancer 
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immunotherapy. Not only patients with HPV-associated cancers would benefit from such a 
vaccine as many other cancers express high levels of p16INK4a, too. Also several 
precancerous neoplasias were shown to elicit increased p16INK4a expression and a p16INK4a-
directed vaccine might even prevent development of invasive cancer.  
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Zusammenfassung 
Das Tumorsuppressorprotein p16INK4a wird in HPV-transformierten Vorläuferläsionen und 
Karzinomen stark überexprimiert, wohingegen p16INK4a in normalem Gewebe kaum  
nachweisbar ist. Aus diesem Grund wird es seit Jahren als diagnostischer Marker 
verwendet und könnte auch als Ziel eines therapeutischen Impfstoffs hohen Nutzen für 
Patienten mit HPV-assoziierten Krebserkrankungen und Vorstufen haben.  
Im Rahmen dieser Arbeit wurden chimäre Kapsomere rekombinant hergestellt, welche aus 
der vollständigen Sequenz des humanen Zellzyklusregulators p16INK4a und dem HPV16 
Kapsidprotein L1 bestehen. Der  L1 Anteil zeichnet sich durch eine bekannte starke 
Immunogenität aus, die vor einer Infektion mit HPV16 schützen kann und deshalb auch als 
Antigen in den vorhandenen prophylaktischen Impfstoffen verwendet wird. L1 kann aber 
auch die Immunantwort gegen andere Antigene verstärken und diese Adjuvansfunktion der 
Viruskapsomere soll genutzt werden um eine effektive Immunantwort gegen p16INK4a zu 
generieren. Es wurden 3 Konstrukte getestet, um die antigene Wirkung verschiedener 
Struktur Isoformen zu vergleichen. Die komplette p16INK4a-kodierende cDNA-Sequenz 
wurde N- und C-terminal einer modifizierten HPV16 L1 Sequenz eingefügt, wobei ein pGex-
4T-2 -Expressionsvektor verwendet wurde. Die beiden Klonierungsprodukte pGex-p16INK4a-
L1ΔN10Δh4ΔC29 und pGex-L1ΔN10Δh4ΔC29-p16INK4a wurden mit einem dritten Konstrukt, 
pGex-L1ΔN10Δh4-p16INK4a-L1ΔC29, ergänzt, für welches die Helix-4 Region von L1 mit der 
p16INK4a-Sequenz ersetzt wurde. Diese Proteine wurden dann in E. coli induzierbar 
exprimiert. Aufgrund der geringen Löslichkeit der Chimären wurde ein Inclusion Body (IB, 
Einschlusskörper) Reinigungsprotokoll entwickelt um die Proteine in großen Mengen zu 
gewinnen. Nach der Reinigung wurden die Proteine unter denaturierenden Bedingungen 
mit N-Lauroylsarcosin extrahiert und durch Dialyse rückgefaltet. Es wurde festgestellt, dass 
die Kapsomerpräparate keine Endotoxin-Kontaminationen nach der Gewinnung aus IBs 
enthalten. Die hergestellten Partikel wurden auf ihre strukturellen Eigenschaften untersucht 
und ihre in vivo - Immunogenität wurde in einem C57BL/6 Mausmodell getestet. Neben 
guten Stabilitätseigenschaften weisen die Kapsomere eine eher heterogene Struktur auf 
und der Vergleich der drei verschiedenen Konstrukte ergab unterschiedliche 
immunologische Eigenschaften. GST-L1ΔN10Δh4- p16INK4a-L1ΔC29 induzierte die höchste 
Anzahl L1-spezifischer T Zellen; GST-p16INK4a-L1ΔN10Δh4ΔC29 zeigte die beste 
Antikörperantwort im VLP-Capture-ELISA und mit GST-L1ΔN10Δh4ΔC29-p16INK4a wurde 
die beste humorale anti-p16INK4a Immunantwort erreicht. Auch die Induktion p16INK4a -
spezifischer T-Zellen konnte mit dem GST-L1ΔN10Δh4-p16INK4a-L1ΔC29 Konstrukt 
nachgewiesen werden. 
Zusammenfassung  4 
 
Ziel dieser Arbeit war es, einen Capsomer-basierten, kostengünstigen therapeutischen 
Impfstoff der zweiten Generation herzustellen, zu reinigen und zu evaluieren. Die hier 
präsentierten Impfstoffkandidaten können kostengünstig in Bakterien hergestellt und aus 
Inclusion Bodies mit hoher Ausbeute gereinigt werden. Die Proteine sind stabil bei 
Raumtemperatur und ihre Immunogenität wurde in ersten in vivo Mausexperimenten 
demonstriert. Ein Impfstoff auf Proteinbasis mit diesen Eigenschaften könnte wesentliche 
Vorteile haben in der Behandlung von Gebärmutterhalskrebs, besonders in 
Entwicklungsländern in denen die meisten Fälle auftreten. Die Möglichkeit, eine wirksame 
Immunantwort gegen p16INK4a zu erzeugen, eröffnet zudem weitere Möglichkeiten im 
Bereich der Krebs-Immuntherapie. Nicht nur Patienten mit HPV-assoziierten Krebsarten 
würden von einem solchen Impfstoff profitieren; auch viele andere Krebsarten exprimieren 
hohe Mengen an p16INK4a. Zudem wurde gezeigt, dass verschiedene präkanzeröse 
Neoplasien erhöhte p16INK4a Level aufweisen und eine Vakzine, die gegen dieses zelluläre 
Protein gerichtet ist, könnte möglicherweise sogar die Entwicklung invasiver Karzinome 
verhindern. 
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I. Introduction 
Cancer is a multifaced disease with numerous possibilities of origin. One of these are 
infectious agents like bacteria, e.g. the bacterium Helicobacter pylori which causes 5.5% of 
all cancers. Viruses are even more prominent as some play an important role as 
oncoviruses. Examples are the human papilloma viruses (HPV; cancers of anogenital tract 
and head and neck region), the hepatitis B and C viruses (HBV, HCV; hepatocellular 
carcinoma), Epstein-Barr virus (EBV; Burkitt’s lymphoma, nasopharynx carcinoma), or the 
human herpes virus 8 (HHV8; Kaposi's sarcoma) [1]. Especially human papillomaviruses 
are attributable to almost all cervical cancers and are therefore an important target for 
global research. First successes were achieved with the release of two prophylactic 
vaccines but therapeutic intervention for already infected individuals is still challenging. 
 
1 Human papillomaviruses 
Infections with human papillomaviruses and the associated risk of cancer development are 
a major public health burden worldwide. HPVs are commonly transmitted by sexual contact 
and infect exclusively epithelial cells [2]. If the infection remains persistent due to ineffective 
clearance by the immune system, both benign papillomas and several types of head and 
neck tumors and anogenital, particularly cervical carcinoma [3] can develop. The small 
DNA-viruses have a high prevalence as overall ~ 27 percent of women were tested positive 
for one or more strains of HPV in a US prevalence study [4]. Especially amongst young 
women at ages 20 to 24, HPV infections are very common and the prevalence in this age 
group is typically approx. 20–40 % depending on geographical location [4-6]. The incidence 
declines with age as infections are often resolved and brought under control by the host 
immune system [7, 8]. Women who cannot resolve their infection and who maintain per-
sistent active infection for years or decades have an increased rsik to develop cervical 
intraepithelial neoplasia (CIN) and cancer [7]. Cancer of the cervix is usually slow-growing 
and may not have symptoms, but premalignant and malignant processes can be found with 
regular Pap tests (Papanicolau test, a gynecological screening test) [9]. The incidence of 
invasive cervix carcinomas varies worldwide between 3.6 cases in Finland and 45 cases 
per 100,000 women in Columbia [10]. In Germany, the frequency of occurrence is declining 
since introduction of the Pap test in the 1970s/1980s and in 2004 14 cases per 100,000 
women were registered. However, cervical intraepithelial neoplasisas are 50- to 100-fold 
more common and severe precancers of the cervix have an incidence of ~1 percent [11]. 
Altogether, due to their high prevalence, HPVs are medically very important pathogens. 
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1.1 HPV classification and distribution 
Until now, more than 150 different HPV types could be identified, whereby alpha and beta 
papillomaviruses (supergroups A and B) represent ~ 90 % of the currently known HPVs [7, 
12, 13]. HPVs from the three genera Gamma, Mu and Nu mostly cause cutaneous 
papillomas and verrucas which do not lead to cancer development [7]. The largest is the 
alpha group that contains most of the genital / mucosal HPV types. Benign and neoplastic 
diseases of the anogenital tract include cervical, vaginal, penile and anal cancers [14]. 
Besides their oncogenic properties in the genital tract, HPVs also infect squamous epithelial 
tissues in the head and neck region [15]. A subset of squamous cell carcinomas (SCCs) of 
the head and neck (HNSCC) is HPV-positive and resembles HPV-positive cervical SCC [16, 
17]. HPV-associated HNSCCs emerge in the airway mucosa of the oral cavity and 
oropharynx, but other sites in the head and neck region can also be infected by HPVs, e.g. 
the nasal sinuses, the eye conjunctiva and ear canals. However, there seems to be an 
affinity for the oropharynx, especially for the base of the tongue and the tonsils [14, 16]. 
Furthermore, it was found that viruses from the B supergroup are involved in the 
development of nonmelanoma skin cancer (NMSC) whereby epidermodysplasia 
verruciformis (EV) HPV types are most plausibly linked to the development of NMSC [18]. 
EV is an inherited disease and patients show an increased susceptible to HPVs of the skin 
[19]. 
Alpha papillomaviruses are further subdivided into three groups: high risk, low risk and 
cutaneous. Low-risk HPV types, e.g. HPV 6 and 11, are rarely associated with cervical 
cancer but are nevertheless medically important as they can cause genital warts. High risk 
HPVs belonging to the alpha 5, 6, 7 ,9 and 11 species specifically target genital squamous 
epithelia and are present in almost all cervical cancers [7, 20]. HPV16 is the most prevalent 
type of the high-risk category in the general population and is responsible for approximately 
half of all cervical cancers, followed by HPV18 as the second most common HPV type (see 
figure 1) [7, 14]. In a study performed in the US in 2003/2004 the prevalence of high-risk 
HPV was 15.2 % among all participating women [4]. 
 
 
Figure 1: HPV type-specific distribution in cervical cancer. 
HPV DNA was detected in 93% of the tumors and there 
was no significant variation in HPV positivity among 
countries. HPV16 was present in 50% of the specimens, 
HPV18 in 14%, HPV45 in 8%, and HPV31 in 5%. HPV16 
was the predominant type in all countries except 
Indonesia, where HPV18 was more common. Data 
obtained from Bosch 1995, Journal of the National 
Cancer Institute [20]. 
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HPV types 16 and 18 account for approximately 70 percent of all cervical cancer cases 
worldwide [21], whereby HPV16 is predominantly associated with squamous cell 
carcinomas appearing at the transformation zone and HPV18 with cancers of the 
endocervix [13]. The consequences of HPV infection depend on the infecting virus type and 
site of infection. Further important factors are the regulation of virus persistence, regression 
and latency. Strategies to reduce the risk of cervical cancer include Pap screening, HPV 
tests and other biomarkers (e.g. p16INK4a [22]), as well as prevention of HPV infection with 
vaccines [23]. Whereas the widespread use of these tools has reduced mortality in the 
industry nations, cervical cancer is still the second leading cause of death among women in 
developing countries where more than 80 percent of cases occur [1].  
 
1.2  HPV genome and viral proteins 
Despite the apparent heterogeneity amongst HPVs, they share some crucial features. 
Papillomaviruses have a conserved icosahedral capsid architecture [24] with a diameter of 
55 nm [25] and contain double-stranded circular DNA. Their genome typically contains 
about 8000 base pairs (HPV16: 7904 bp) and encodes 8 or 9 ORFs (open reading frames; 
see figure 2). The encoded genes can be divided into early and late ones depending on 
their time point of expression during epithelial differentiation. 
 
Figure 2: (A) The HPV16 genome (7904 bp) is 
shown as a black circle with the early (p97) and late 
(p670) promoters marked by arrows. The six early 
ORFs E1, E2, E4 and E5 (green) and E6 and E7 
(red) are expressed from either p97 or p670 at 
different stages during epithelial cell differentiation. 
The late ORFs L1 and L2 (yellow) are located 
downstream of the early region and are also 
expressed from p670. The long control region 
(LCR) also referred to as upstream regulatory 
region (URR) reaches from base pairs 7156 to 
7184. One strand of the double-stranded circular 
DNA genome encodes all the viral genes. Adapted 
from Doorbar 2006, Clinical Science [7] 
1.2.1 Proteins expressed by early genes E1, E2, E4, E5 and oncogenes E6 and E7 
All HPVs are epitheliotropic and produce infectious virions in the upper epithelial layers 
where the p670 promoter is up-regulated, and the viral replication proteins E1, E2, E4 and 
E5 facilitate viral genome amplification. [2, 7] After infection that requires access to the 
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basal epithelial layer and invasion to dividing basal cells, probably stem cells [26], the viral 
genome establishes as a stable episome with low copy number. This process is driven by 
the expression of E1 and E2 directly after entry into the host cell. The viral replication 
proteins E1 and E2 are responsible for the regulation of early transcription [27] and have 
several functions like maintenance of the viral genome in the basal layer. E1 encodes a 
helicase that contributes to replication and virus load by interacting with the origin of 
replication, requiring interaction with E2 [2, 28]. E2 also controls the expression of the viral 
oncogenes E6 and E7 in the lower epithelial layers. E2 binds to the viral DNA, precisely, it 
has multiple binding sites in the long control region (LCR), leading to its replication and it is 
also assumed to activate expression of the late genes [29]. E4 is expressed in terminally 
differentiated keratinocytes [27] and its accumulation at the epithelial surface is thought to 
improve the release of the virus [7]. E5 is another viral replication protein playing a role in 
early tumor development but it is not expressed in transformed cells [30]. 
Concerning E6 and E7 there are functional differences between high and low risk types, 
whereby the role for the latter, which are generally not associated with malignant 
neoplasias, is somehow uncertain. In high risk lesions a clear role in cell proliferation is 
attributable to these oncoproteins [13]. The expression of E6 and E7 is directed by the p97 
promoter. Protein E6 (158 aa, ~19 kDa) plays a key role in transcriptional activation and 
degradation of the cellular tumor antigen p53, thereby deregulates proliferation and leads to 
impaired apoptosis [31]. E7 (98 aa, ~11 kDa) interacts with the retinoblastoma protein and 
histone deacetylases. The expression of E6 and E7 in the lower epithelial layers is 
necessary for entry to S-phase during epithelial differentiation. This provides an 
environment that is advantageous for viral genome replication and cell proliferation [2]. Both 
E6 and E7 are accountable for transformation of infected cells. Their function as 
oncoproteins in the cellular context is described in more detail in 1.3 (Virus life cycle). 
 
1.2.2 Structural proteins L1 and L2  
The virus capsid is composed of two proteins, L1 and L2 which play important roles in 
mediating infectivity. The major capsid protein L1 (monomer: see Figure 3) is the primary 
structural element and has the ability to form pentamers (see Figure 4) which then self-
assemble into virus like particles (VLPs, see also 1.5) [25]. L1 consists of 503 amino acids 
and has a molecular weigth of 56 kDa (HPV16). The minor capsid protein L2 was found to 
be located in the central internal cavity of the L1 pentamer [32]. It has a size of 473 aa 
(HPV16) and a molecular weight of 51 kDa. L2 interacts with the viral genome and is 
essential for the encapsidation process of the viral DNA [33]; it also seems to play a role in 
infection and immune escape mechanisms of HPV [34]. The natural virus capsid consists of 
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72 L1 pentamers (360 L1 molecules) and approximately 30 L2 molecules [35]. L1 side 
chains lining the axial cavity are highly conserved between different HPV types whereby the 
rim of the L1 pocket is more variable [36].  
 
        
 
Figure 3: 3D structure of the HPV16 L1 monomer 
including residues 20-474. β-strands are labeled with 
capital letters, helices 1-5 are also indicated. helix 4 
(h4) (aa 414-431) is essential for VLP assembly. 
Adapted from Chen et al. 2001, J Mol Biol 307 [37] 
Figure 4: L1 pentamer, viewed along the five-fold axis 
from outside the particle. Helices 2 and 3 form a groove 
to which binds h4 of another pentamer via strong 
hydrophobic contact.  
Adapted from Chen et al. 2000, Mol Cell 5 [36]  
 
1.3  Virus life cycle and transforming potential 
HPVs display a strong tropism for the basal cell layers at a metaplastic epithelial site of the 
cervix, the so called transformation zone. This is a ring of mucosa where the glandular 
epithelium of the endocervix is replaced by squamous epithelium of the ectocervix [38]. 
Cells close to this squamo-columnar junction have a higher susceptibility for persistent 
infections wherefrom transformation to malignant cells can occur [13]. Other sites of the 
body where HPV associated cancers can arise from show similarities as there is also some 
kind of intersection epithelium like the linea dentata in the anal canal [39] or the uneven 
reticulated epithelium lining the crypts of the palatine tonsils and the base of the tongue [40, 
41] (head and neck squamous cell carcinoma (HNSCC)). 
Initially, HPVs bind to the surface of the epithelium or the basement membrane of 
keratinocytes via the interaction of the major capsid protein L1 with heparan sulfate 
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proteoglycans [42-44]. Thereby, a role of (micro-) trauma or epithelial wounding and 
subsequent healing processes is thought to be required as active cell division seems to be 
necessary for establishing an infection [45-47]. Virus internalization and transfer of the 
genome to the nucleus is then propagated by changes in the capsid structure [2, 45] but 
although many studies attempted to elucidate the mechanism of infection, the details of 
endocytosis are not yet fully understood. It is possible that not only one but various 
internalization and/or infectious entry pathways exist which may use different cell surface 
molecules [48] and that this process also depends on the virus type [13]. After 
internalization the virus is uncoated and entry of the viral genome to the nucleus is 
facilitated by a complex of L2 and DNA [49, 50].  
HPV infection leads to deregulation of the cell cycle whereby high-risk E6 and E7 proteins 
are crucial for malignant transformation and increased proliferation of suprabasal epithelial 
cells [7]. In high-risk HPV infected cervical epithelium, cell cycle progression does not 
depend on external growth factors, but it is stimulated by E7. The transforming activity of E7 
is attributable to its interaction with the retinoblastoma (RB) tumor suppressor protein  [51]. 
E7 binds to RB and dissociates the complex between RB and the E2F family of transcription 
factors. In non-infected cells, the expression of proteins necessary for cell-cycle progression 
is controlled by RB, which in non-cycling cells associates with E2F and acts as a repressive 
subunit. In the presence of growth factors, cyclinD/Cdk4/6 is activated, leading to RB 
phosphorylation and the release of E2F, which drives protein expression. HPV E7 also 
associates with other proteins involved in cell proliferation, including components of the AP1 
transcription complex, enzymes that mediate histone acetylation and the cyclin dependent 
kinase (Cdk) inhibitors p21 and p27 [7, 52].  
A newer study by McLaughlin et al. [53] proposes an alternate mechanism for the E7-
mediated p16INK4a overexpression that is independent of pRB-inactivation. They discovered 
that E7 induces epigenetic reprogramming by activating the histone demethylases KDM6A 
and KDM6B. These methyl transferases remove the histone H3 lysine 27 trimethyl 
(H3K27me3) repressive mark from promoters encoding for RB-binding proteins (KDM6A) 
and p16INK4a (KDM6B). E7 thereby simultaneously inactivates p16INK4A  and pRB.  
p16INK4a levels rise as HPV-mediated cell proliferation is not dependent on cyclinD/Cdk4/6. 
In the absence of p16-mediated feedback, the level of p14Arf also rises. p14Arf is encoded 
by the alternative reading frame of the CDKN2A gene and normally regulates the activity of 
the MDM (murine double minute) ubiquitin ligase, which maintains p53 at a level below that 
required for cell cycle arrest and/or apoptosis. Increased p14Arf leads to the inhibition of 
MDM function and an increasing level of p53 [54-56]. 
The function of E7 is complemented by the viral E6 protein. E6 associates with the E6AP 
ubiquitin ligase and mediates p53 degradation. This in turn prevents growth arrest or 
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apoptosis in response to E7-mediated cell-cycle entry in the upper epithelial layers. [7, 17] 
The final stage in the papillomavirus productive cycle requires packaging of the replicated 
genome into infectious particles. Therefore, the capsid proteins L1 and L2 are transported 
to the nucleus where L1 assembles into capsomeres and L2 contributes to efficient 
packaging [33] and enhances virus infectivity [57]. 
Integration of the HPV genome into the host cell chromosome is a critical event in the 
development of cervical cancer. As infected basal cells migrate towards the epithelial 
surface, their integration leads to deregulated E6/E7 expression which is critical for the 
enhanced growth characteristics of cervical cancer cells [2, 7].  
 
1.4  HPV immunology  
Most of the cervical HPV infections are cleared as a result of humoral and cell-mediated 
immune response. However, some infections persist over long periods of time and can 
progress to cervical intraepithelial neoplasia (CIN) or cancer. 
Dendritic cells (DCs) that normally reside in cervical tissue have a unique ability to induce 
primary immune responses. DCs are antigen-presenting cells (APCs) which capture and 
transfer information to the cells of the adaptive immune system. They may also be important 
in immunological tolerance, as well as for the regulation of T cell-mediated immune 
response. T cells recognize antigens presented on the surface of the major histocompa-
tibility complex (MHC) proteins. In an inflammatory milieu, DCs are activated and up-
regulate MHC class I and II molecules, co-stimulatory molecules (CD80 and CD86), and the 
chemokine receptor-7 (CCR7), and increase the secretion of cytokines. This in turn primes 
naive CD4+ and CD8+ T cells. Histological examination revealed large infiltrates of T cells 
in HPV infected epithelium. Natural killer (NK), cytotoxic T lymphocytes (CTL) and additional 
T cell subsets play important roles in the elimination of virus-infected and tumor cells as 
they promote their lysis through activation of natural killer group 2 member D (NKG2D) 
receptors [58]. A successful immune response to HPV infections is characterized by strong, 
local, cell-mediated immunity that is associated with lesion regression and the generation of 
serum neutralizing antibodies mostly directed against the L1 capsid protein [59, 60]. 
Nevertheless, HPVs are very successful pathogens as they induce chronic infections but 
rarely kill their host. With this strategy they are able to shed large amounts of infectious 
viruses for transmission to naive individuals [8]. To cause persistent infections, which is the 
greatest risk factor for the development of HPV associated cervical and other cancers, the 
virus must escape host immunity. Papillomaviruses have evolved a number of mechanisms 
to limit the chance of detection by the immune system [7]. One strategy that HPV has 
evolved to avoid detection is to expose only minimal amount of virus to the immune system 
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thereby maintaining a very low profile. The virus infects basal cells at low copy number and 
the expression of oncogenes E6 and E7 is tightly controlled. The viral early proteins are 
expressed at levels below those required for an effective host immune response [7, 8, 61]. 
Furthermore, the oncoproteins E6 and E7 interact directly with components of the interferon 
(IFN) signaling pathways. Interferons are soluble factors that can limit viral infections and 
activate or attract cells of the immune system including macrophages, neutrophils, DCs and 
NK cells. The type 1 interferons, IFN-α and IFN-β connect innate and adaptive immunity by 
activating immature DCs. However, HPV has evolved mechanisms to inhibit interferon 
synthesis and signaling [8, 61]. Papillomaviruses also modulate antigen presentation. T 
cells normally recognize infected cells through interactions of their receptors with viral 
peptides bound to MHC complexes on the surface of infected cells. Dysregulation of the 
antigen processing machinery results in down-regulation of peptide-MHC complexes and 
protects infected cells from immune attack. [61, 62] The inhibition of cytokines and chemo-
attractants is another escape-mechanism of HPV. Cytokines, chemokines, adhesion mole-
cules and proteases are molecules that direct the migration of cells of the immune system. 
They elicit local infiltration of inflammatory and immune cells. E6 and E7 proteins of HPV 
inhibit the production of those immune mediators thus interfering with cytokine patterns and 
inhibiting DC activation. Further strategies to escape immune surveillance include 
prevention of apoptosis, inhibition of APC migration, modulation of adherence molecules 
and molecular mimicry by sequence similarity to human proteins [61]. The HPV productive 
life cycle itself is an immune evasion strategy as it is coupled to the cellular differentiation 
cycle of the host [8, 61]. The virus is present during the whole life cycle of the keratinocyte 
as it infects it as a primitive basal cell and replicates and assembles during cell cycle 
progression whereby only minimal virus amounts are exposed to the immune system. The 
Langerhans cell (LC), which is the intraepithelial DC, is the first APC the virus comes into 
contact with during infection. This professional APC of squamous epithelia should 
theoretically detect HPV invasion, but evidence indicates that LCs are not activated by the 
uptake of HPV capsids [8, 63]. In fact, reduced numbers or even absence of Langerhans 
cells was observed in viral lesions [64]. The cell later dies by natural causes; thus there is 
no inflammation and the essential signals required for initiation of immune responses are 
absent [60, 61]. The milieu becomes HPV antigen tolerant [8] as the virus is practically 
invisible to the host. This is further supported by the non-lytic life cycle of the virus and the 
resulting lack of pro-inflammatory signals that could activate DCs. HPV antigen-specific 
effector cells are poorly recruited to the infected area and their activity is down-regulated [8]. 
Furthermore, viral protein expression and assembly only occurs in the upper epithelial 
layers and this also restricts the immune system to encounter capsid antigens [59]. 
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Altogether, HPV efficiently evades the innate immune response and delays the activation of 
the adaptive immune response. 
 
1.5 Virus like particles and capsomeres 
A virus like particle (VLP) is the empty capsid of a virus without genetic material inside. 
VLPs can be produced by genetic engineering and are highly immunogenic: they resemble 
the native, infectious virions in size and shape and are thereby able to induce high titers of 
virus-neutralizing antibodies, which provide protection from further virus challenge [65-67]. 
As described above, the L1 major capsid protein is primarily responsible for virus capsid 
assembly. After expression in eukaryotic and prokaryotic systems, L1 is able to self-
assemble into empty VLPs with similar immunogenicity compared to infectious virions [67]. 
HPV virions and VLPs usually consist of 72 L1 pentamers [68], also called capsomeres, 
which are arranged in an T = 71 icosahedral architecture with a diameter of 55 nm [25]. 
VLPs are endocytosed, processed, and presented by APCs to naive T cells [70]. They 
deliver multiple B and T cell epitopes as immunogens to the MHC class I and class II 
pathways, thereby extending their utility as self-adjuvanting immunogen delivery systems 
[71]. Consequently, VLPs can be used as carriers for synthetic or small antigens for the 
development of subunit vaccines [72]. Especially papillomavirus VLPs are able to induce 
strong immune responses and allow antigen presentation within a highly organized context 
as part of the regular array of assembled capsomeres [73, 74]. It was found that the conju-
gation of mouse self-peptide TNF-α to papilloma VLPs leads to efficient induction of 
protective auto-antibodies [74]. Also the conjugation of influenza type A M2 protein to HPV 
VLPs was found to be highly immunogenic and conferred good protection against lethal 
challenge of influenza virus in mice [72]. This demonstrates that HPV VLP systems can be 
used as an antigen carrier for developing conjugate vaccines. 
Capsomeres represent a potentially lower cost alternative to VLP-based vaccines as they 
can be produced in large amounts from prokaryotic expression systems and are considered 
to be more stable at room temperature [75]. Although it was reported that capsomeres are 
less immunogenic than VLPs [75], another study showed that certain L1 constructs form 
highly immunogenic capsomeres [76]. The L1 protein was modified in different ways and 
immunogenicity of the constructs was compared. A construct with an N-terminal deletion of 
10 amino acids, named L1ΔN10, proved to be the most immunogenic. L1ΔN10 induced 
antibody titers equivalent to those generated in response to VLPs [76]. Several other 
studies present further evidence for the potential of capsomeres as antigen carriers and 
                                                
1
 T = Triangulation number. T describes size and complexity of an icosahedral capsid (for more details see 
 69. Caspar DL, Klug A: Physical principles in the construction of regular viruses. Cold Spring 
HarbSympQuantBiol 1962, 27:1-24. ) 
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immune stimulators. Yuan et al. produced a GST-L1 fusion protein in E. coli that formed 
pentameric capsomeres and was capable of protecting dogs from oral papillomavirus 
challenge [77]. Rose et al. showed that the capsid-neutralizing antigenic domains are fully 
conserved in capsomeres and that antisera generated with capsomeres elicit neutralization 
titers comparable to that of entire VLPs [78]. This was also demonstrated by Fligge et al. 
with capsomeres of a HPV type 33. When combined with an appropriate adjuvant, 
capsomeres induce neutralizing antibody titers as high as VLPs do [79].  
 
2 HPV Vaccination 
Despite relatively low serum antibody titers, seropositive animals are protected against 
further viral challenge [80] and passively transferred serum immunoglobulins from 
immunized to naive animals confer protection from experimental infection [81]. Other 
experimental studies revealed that immunization with L1 VLPs induces circulating 
neutralizing antibodies to the L1 capsid protein and thereby offers protection against larger 
virus amounts [82]. These results provided the background for attempts to develop 
prophylactic vaccines against human high-risk HPV types based on L1 VLPs [66]. 
There are diverse vaccination strategies for prevention and treatment of HPV-associated 
lesions (Figure 5): (I) vaccines for uninfected females to prevent HPV infection/spread, (II) 
vaccines for the reduction of viral load at the cervical mucosa in females with low-SIL 
(squamous intraepithelial lesion) and prevention of its progression, (III) vaccines for the 
treatment of high-SIL, and (IV) immunotherapy for cervical cancer. Currently used HPV 
vaccines are represented by group I. Possibly, they are able to eliminate persistent HPV 
infection and if so, they work to suppress HPV infection (II). III and IV are considered to be 
therapeutic vaccines used for females with disease [83]. 
 
 
Figure 5: Possible strategies for 
prophylaxis and treatment of HPV-
associated lesions (squamous intra-
epithelial lesion, SIL) and the target viral 
proteins. Modified from: Kawana 2009, 
Indian J Med Res 130 [83] 
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2.1 Prophylactic Vaccines 
Currently available, prophylactic vaccines contain only two, respectively four, of the HPV 
types. The bivalent vaccine Cervarix was developed by GlaxoSmithKline and is comprised 
of a mixture of VLPs derived from the L1 capsid proteins of HPV types 16 and 18 formu-
lated with the AS042 adjuvant system [84, 85]. In clinical trials it was found to be safe and 
protective and it prevents both persistent HPV16/18 infection and the development of low-
grade intraepithelial lesions [86]. Gardasil is a quadrivalent vaccine by Merck & Co. protects 
against the high-risk types 16 and 18 as well as against the low-risk types 6 and 11. With 
this vaccine, the combined incidence of persistent infection or disease with HPV6, 11, 16, or 
18 fell by 90% in the group that received the vaccine compared to the placebo group [87].  
Both vaccines were found to be safe, immunogenic, and efficacious in various randomized 
controlled trials and confer protection against CIN induced by the respective HPV types 
[60]. For these reasons they are expected to yield significant public health benefits [60].  
Exogenously expressed L1 proteins are able to self-assemble into VLPs in vitro thereby 
providing a potentially effective sub unit vaccine. Currently available HPV L1 VLPs vaccines 
are produced in yeast or insect cells after inserting the L1 gene into expression vectors. [67, 
82] VLPs induce strong humoral and cell-mediated responses. They bind to the cell surface 
of monocytes, macrophages and DCs resulting in their acute phenotypic activation and 
production of inflammatory cytokines [88]. It is worth mentioning that the Langerhans cells 
(LC) do not get activated when incubated with VLP and do not initiate epitope-specific 
immune responses due to a different endocytosis mechanism [63, 89]. Activated stromal 
DCs stimulate HPV-specific T-cells [88, 90], but as the virus remains in the epithelium, the 
probability of encountering stromal DCs is relatively low [8]. Contrary, DCs of the muscle do 
encounter the highly immunogenic repeat structure of the VLP and the vaccines circumvent 
viral epithelial evasion strategies since they are delivered by intramuscular injection [8]. DCs 
migrate to the lymph node and initiate an immune cascade that results in a robust T-cell 
dependent B-cell response followed by generation of high levels of L1-specific serum 
neutralizing antibodies and immune memory [8]. 
Despite these promising perspectives, the neutralizing antibodies generated by HPV L1 
VLP vaccines appear to be type-specific and thus only protective against the corresponding 
virus type [91]. Although there is some evidence for cross-protection against HPV types 
other than those incorporated in the vaccines [92], it is not clear how and to what extend 
cross-protection against other types occurs. Current research efforts are directed towards 
this question. Furthermore, the prophylactic vaccines lack any therapeutic function against 
                                                
2
 AS04: 3-O-desacyl-40-monophosphoryl lipid A and aluminium hydroxide, a combination of adjuvants used in 
various vaccine products by GlaxoSmithKline 
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established HPV infections [93, 94] what could be associated to the fact that the virus 
capsid proteins are not detectable in high grade dysplasias and cervical carcinomas [95].  
Prophylactic vaccines are therefore only effective in women that have not yet encountered 
HPV infection. This explains the need for developing therapeutic strategies for the control 
and treatment of existing HPV infections and associated malignancies. 
 
2.2 Therapeutic Vaccines 
In contrast to preventive vaccines which induce the generation of neutralizing antibodies 
[96], therapeutic vaccines aim to initiate a strong cellular immune response, particularly T 
cell-mediated, to HPV antigens expressed in transformed cells [94]. The patient’s own 
immune response shall be stimulated to recognize and kill cancer cells that express foreign 
proteins [94]. The most frequently targeted antigens for this purpose are E6 and E7 
because they are oncogenic and their overexpression is required for the maintenance of the 
cancerous phenotype [94]. As T cell-mediated immunity is one of the most crucial compo-
nents to defend against HPV infections and HPV-associated lesions, effective therapeutic 
vaccines should generate strong E6/E7-specific T cell-mediated immune responses to the 
early proteins E6 and E7 [59, 93]. 
There are various therapeutic HPV vaccines for cervical cancer currently being under 
clinical investigation. These include live vector-based, peptide or protein-based, nucleic 
acid-based, and cell-based vaccines targeting the HPV E6 and/or E7 antigens [96]. 
Ongoing studies show the general applicability of tumor vaccination and prove the 
correlation of immune and clinical response [97]. So far, the success of therapeutic 
vaccines is limited [97] although clinical responses could be shown, e.g. in grade 3 vulvar 
intraepithelial neoplasia (VIN) with a long-peptide E6/E7 peptide [98]. Also a DNA vaccine 
based on E6 and E7 fragments (ZYC101a) that was tested in a phase 2 trial led to more 
resolved infections in the vaccine group compared to placebo [99]. Another trial investigated 
the effect of Imiquimod followed by vaccination with an E6E7L2 fusion protein and reported 
complete regression in up to 63% of women with VIN grades 2 and 3 whereby the 
therapeutic effect depended on the differential immune response [100]. Even a live-
attenuated vaccine based on E7 secreting Listeria monocytogenes (Lovaxin-C, Lm-LLO-E7) 
was tested in a phase I trial where relatively safe administration was demonstrated despite 
the occurrence of severe adverse events in 40% of patients [101, 102].  
ProCervix is another therapeutic vaccine candidate developed by Genticel. It is based on 
the adenylate cyclase vector system derived from Bordetella pertussis which targets 
dendritic cells with high efficiency. The E7 antigen presented within the CyaA context was 
found to induce T-cell responses in most of the vaccinated HPV 16/18 positive women. 
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Furthermore, enhanced viral clearance of the infected cervix cells and also more sustained 
clearance could be shown for the ProCervix (plus Imiqiumod) group [103, 104]. However, 
this vaccine is designed to prevent progression to cervical dysplasia and cancer before 
appearance of high grade lesions and therefore is kind of a preventive vaccine for already 
infected women rather than a therapeutic one for patients.  
Altogether, the challenge for therapeutic vaccines is to overcome the immunosuppresion of 
the host, to create an inflammatory environment in which immature DCs can be activated to 
present HPV antigens to CTLs and to mount an effective immune response that can 
eliminate the HPV-infected and transformed cells [59]. As the current vaccines do not 
appear to be an ultimate strategy, study on new therapeutic HPV vaccines is needed [83]. 
The development of chimeric vaccines seems to be an appropriate step in this direction [95, 
105]. 
 
3 p16INK4a as a potential tumor antigen in HPV-associated 
cancers  
The tumor suppressor p16INK4a shows increased expression with worsening grades of 
cervical intraepithelial neoplasia (CIN) and is strongly overexpressed in HPV induced 
cervical cancer [106]. Therefore, p16INK4a is considered as a marker for early diagnosis and 
is routinely used as a highly specific marker for CIN and transforming HPV infections [106-
110]. p16INK4a overexpression increases with the severity of cytological/histological 
abnormality and immunostaining correlates with it [22, 108, 111] as shown in Figure 6. 
 
 
Figure 6: Representative examples 
of p16
INK4a
 immunohistochemistry. 
1: Tissue overview, 2: Enlargement. 
A: p16
INK4a
 negative normal epithe-
lium, B: p16
INK4a
 positive epithelium 
of grade II cervical intraepithelial 
neoplasia (CIN2), C: invasive carci-
noma with strong p16
INK4a
 
immunoreactivity. (The IHC image 
was kindly provided by Dr. M. 
Reuschenbach.) 
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3.1 Structure and function  
p16INK4a is a tumor suppressor protein with a molecular weight of 16 kDa (156 aa). The 
protein structure shows four contiguous ankyrin repeats (see Figure 7) [112], a protein motif 
consisting of two alpha helices separated by loops. p16INK4a is encoded by chromosome 
9p21 within the INK4a/ARF locus [113]. The INK4 family of CDK inhibitors includes four 
members with similar biochemical properties: p15INK4b, p16INK4a, p18INK4c and p19INK4d [114-
116]. Mutations and deletions of p15INK4B and p16INK4a are frequently observed in different 
malignancies and p16INK4a is one of the most direct links between cell cycle control and 
cancer [117, 118]. 
 
Figure 7: Structure of the cyclin-dependent Kinase 4 Inhibitor a 
(p16
INK4a
) containing 4 helix-turn-helix motifs linked by three 
loops. 
Structure obtained from MMDB [119]: Solution NMR Structure 
of Tumor Suppressor p16
INK4a
, MMDB ID: 11736 
 
Cyclin-dependent kinases (CDKs) form complexes with cyclins and are thereby activated. 
The Cyclin-dependent kinase inhibitor 2A, also known as p16INK4a, acts as a negative 
regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. 
This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma 
protein (RB). Precisely, p16INK4a expression keeps RB in a hypophosphorylated state what 
promotes binding of E2F to RB and thereby leads to G1 cell cycle arrest.  
HPV oncogene expression and evidence of its deregulation can be monitored through 
detection of the cellular protein p16INK4a [120] as E6 and E7 disrupt cell cycle checkpoints 
and affect almost all CDK inhibitors which are linked to the G1 and G2 checkpoints [117]. 
E7 expression causes an addiction of cervical cancer cell lines to the H3K27 targeting 
histone lysine demethylase (KDM6B) [53] (see also 1.1.3). E7 triggers oncogene induced 
stress (OIS), a cell-intrinsic tumor-suppressive mechanism, but on the other hand targets 
pRB for proteosomal degradation as pRB is a key mediator of OIS. The E7 caused 
epigenetic de-repression is mediated by p16INK4a that was reported to be an important 
KDM6B downstream target and its expression is necessary for the survival of E7-
expressing cells [121]. Therefore, the role of p16INK4a as a tumor suppressor protein is 
somehow controversial, at least in HPV16 E7 expressing cells, as its biological activity is 
more akin to that of an oncogene [121]. 
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E7 inactivates pRB and thereby indirectly induces p16INK4a expression and accumulation 
[117, 122]. Similarly, the degradation of the tumor suppressor p53 due to elevated E6 levels 
can also result in upregulation of p16INK4a expression [118]. In summary, the increased 
p16INK4a expression in HPV-associated tumors can be interpreted as attempt to stop 
uncontrolled proliferation [123]; but as p16INK4a is released from its negative feedback 
control by pRB inactivation and KDM6B overexpression, elevated levels of this protein do 
not lead to cell cycle arrest in tumor cells. 
 
3.2 Chimeric constructs containing p16INK4a and L1  
In HPV-transformed precursor lesions and invasive carcinomas the cellular tumor 
suppressor p16INK4a is strongly overexpressed, whereas in normal tissues barely any 
p16INK4a expression is detectable. Therefore, p16INK4a is considered to be an interesting 
target for immunotherapy in patients with HPV-associated cancers. In fact, there is evidence 
for spontaneous immune responses against p16INK4a  since antibodies against p16INK4a can 
be found in some individuals  indicating no complete tolerance against this self-antigen 
[124]. The first clinical vaccination trial with a p16 peptide in patients with advanced HPV-
associated cancers is currently being conducted [125]. 
In contrast to E6 and E7, HPV L1 decreases gradually according to the severity of cervical 
neoplasia. p16INK4a expression also increases with infection progression (see Figure 8). 
Combined expression patterns of p16INK4a and L1 may thus serve as useful biomarkers for 
the early diagnosis, prognosis and follow-up of cervical dysplastic lesions [126-128]. 
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Figure 8: HPV-mediated progression from CIN to invasive cervical carcinoma. HPVs invade the basal 
membrane through micro abrasions in the epithelial layer. The early genes E1, E2, E4, E5, E6 and E7 are 
expressed from episomal DNA while the genome is further replicated. The late genes L1 and L2 are expressed 
in the midzone and superficial zone. Some HPV infections progress to high grade CIN and cervical cancer as 
the HPV genome becomes integrated into the host chromosomes. This leads to a disruption of E2 and 
upregulation of oncogene E6 and E7 expression. L1 is barely found in progressing lesions, but p16
INK4a
 
expression increases with severity of neoplasia. Modified from Woodman et al. 2007, Nat Rev Cancer 7 [53] 
 
An approach that targets p16INK4a and HPV16 L1 simultaneously could provide a combined 
prophylactic and therapeutic vaccine with global impact. If it would be possible to raise 
sufficient and functional immune responses against p16INK4a and thereby guide the immune 
system to the deregulated malignant cells, a variety of cancers could be treated with such a 
medicament. 
 
4 Rational and Aims of the project  
Despite substantial progress in prophylactic vaccination, there are several challenges left:  
 The prophylactic vaccines only induce type-specific immunity and have therefore a 
negligible prophylactic effect on other HPV types.  
 Furthermore they are costly due to the production in mammalian, respectively insect 
cells.  
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 A cold chain for transportation is necessary as these vaccines are not stable at room 
temperature what further increases the cost factor.  
 Apart from that it would be necessary to apply prophylactic vaccination widely to 
achieve an effect for the society and this is hard to accomplish in developing countries, 
where health systems are problematic, vaccine coverage is poor but need is significant.  
 Even screening is not available to all women and mortality and morbidity of HPV-
associated malignancies are therefore still high.  
This reveals an urgent need for an effective therapeutic HPV vaccine, especially in 
developing countries.  
The objective of this thesis was to generated, purify and evaluate a cost-effective second 
generation therapeutic vaccine based on chimeric capsomeres as a protein-based vaccine 
that can be easily produced in bacteria and is stable also when cold-chains are interrupted. 
This could have substantial benefit, especially for unindustrialized countries.  
The tumor suppressor p16INK4a was found to be strongly expressed in CIN and cervical 
cancer, although its function is abolished in these conditions. It is thus used as a diagnostic 
marker for several years with high success and targeting p16INKa-overexpressing cells with a 
therapeutic vaccine could have high benefit for patients suffering from HPV induced 
neoplasia and cancer. This strategy is a promising alternative to currently investigated 
vaccination attempts based on the induction of an E6 and/or E7-specific immune response. 
Like the prophylactic vaccines, E6 and E7 based formulations again present the problem of 
type-specific immunity whereas p16INK4a expression is universal. 
To achieve the ambitious aim of developing a therapeutic vaccine the following tasks had to 
be implemented.  
1. Cloning of three different constructs into the bacterial expression system: 
To evaluate the antigenic effect of different structural isoforms three constructs 
containing L1 and p16INK4a should be generated. Therefore, the complete p16INK4a 
encoding cDNA sequence will be cloned a) upstream and b) downstream of a modified 
HPV16 L1 sequence [76] into a pGex-4T-2 expression vector. For the third construct c) 
the helix 4 region of L1 will be replaced by p16INK4a [129]. 
 
2. Expression of the fusion proteins in E. coli: 
The GST-fusion proteins will be expressed in E. coli strains BL21 and Rosetta and the 
expression characteristics of the fusion proteins will be evaluated in terms of solubility 
and yield. 
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3. Purification of bacterial fusion proteins: 
Different purification strategies will be evaluated in consideration of purity, protein 
structure and yield. Endotoxin removal will be achieved by Triton X-114 phase 
separation as this method was shown to be suitable for the removal of LPS [130]. 
 
4. Evaluation of protein purification and structural characterization: 
Protein expression and purification will be evaluated by Coomassie staining and 
Western blot analysis. Particle assembly will be verified by electron microscopy, ELISA 
and sedimentation analysis.  
 
5. Immunological trials: 
The immunogenicity of the chimeric capsomeres will be evaluated in a CL57BL/6 mouse 
model. Therefore, the animals will be immunized and the humoral and cellular immune 
response will be measured with ELISA, respectively ELISpot assay. 
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II. Materials and Methods 
5 Materials 
5.1 Biological Materials 
5.1.1 Bacteria 
Competent cells: 
Table 1: Competent E. coli cells. Resistance, genotype, key features and suppliers are listed. 
 
Strains Resistance Genotype and Key Features Supplier 
BL21-T1R no 
F- ompT hsdSB (rB- mB-) gal dcm tonA 
 does not contain the lon protease.  
 is also deficient in the outer membrane protease, OmpT.  
 lack of these proteases reduces degradation of 
heterologous proteins expressed in this strain. 
Sigma-Aldrich, 
Steinheim 
Rosetta 
Chlor-
amphenicol 
F- ompT hsdSB (rB- mB-) gal dcm pRARE (argU, 
argW, ilex, glyT, leuW, proL) 
 Express rare tRNAs for AGG, AGA, AUA, CUA, CCC, 
GGA codons 
 facilitates expression of genes that encode rare E. coli 
codons 
Novagene 
(Merck), 
Darmstadt 
Top10 no 
F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ( araleu)7697 galU 
galK rpsL (StrR) endA1 nupG 
 hsdR for efficient transformation of unmethylated DNA 
from PCR amplifications 
 mcrA for efficient transformation of methylated DNA from 
genomic preparations 
 lacZM15 for blue/white color screening of recombinant 
clones   
 endA1 for cleaner preparations of DNA and better results 
in downstream applications due to elimination of non-
specific digestion by Endonuclease I   
  recA1 for reduced occurrence of non-specific 
recombination in cloned DNA 
Invitrogen,  
Carlsbad, USA 
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5.1.2 Cell lines 
RMA-S a sub-line of the Rauscher-virus-induced lymphoma RBL-5 of C57BL/6   
 (H-2h) background [131, 132] 
 Cultivation medium: RPMI (see 5.3.2 for receipt) 
 
TC-1  derived from lung epithelium of C57BL/6 mice, cotransformed with HPV16 E6 
and E7 and c-Ha ras oncogenes [133] 
 Cultivation medium: TC-1 medium (see 5.3.2 for receipt) 
 
C3 C57BL/6 mouse embryo cells transfected with full-length HPV16 genome 
[134] 
 Cultivation medium: C3-medium (see 5.3.2 for receipt) 
 
2F11 RMA-E7 (HPV-16 E7 WT gene) transfectant [135] 
 Cultivation medium: RPMI (see 5.3.2 for receipt) 
 
Hela cervical cancer cell line of a tumor of a patient named Henrietta Lacks [136] 
 Cultivation medium: RPMI (see 5.3.2 for receipt) 
 
5.1.3 Animals 
Female C57BL/6J (H2Db) mice at an age of 7 weeks were specified pathogen-free and kept 
under pathogen-free conditions in individually ventilated cages at the animal facility of the 
German Cancer Research Center (DKFZ, Heidelberg, Germany). Mice were purchased 
from Charles River WIGA Laboratories (Sulzfeld, Germany)  
 
5.2 Molecular biological materials 
5.2.1 Plasmids 
Original vectors 
pUC57 common used plasmid cloning vector in E. coli; vector length 2,710 bp; 
isolated from E. coli strain DH5α (GeneScript, Piscataway, NJ,  USA) 
pmaxGFP  plasmid encoding maxGFP, a green fluorescent protein from the copepod 
Pontellina plumata, used to test transfection efficiency with fluorescent 
microscopy (Lonza, Walkersville, MD, USA) 
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pGex-4T-2 glutathione S-transferase fusion vector with a thrombin protease site to 
cleave protein from fusion, vestor length 4,970 bp (GE Healthcare, Uppsala, 
Sweden)   
The original pGex-4T-2 vector did not contain a HindIII restriction site. It was introduced in 
previous trials upstream of the SaII site by PCR. This work was conducted in the division of 
Genome Modifications and Carcinogenesis (DKFZ Heidelberg, Germany) under supervision 
of Prof. Lutz Gissmann. The modified pGex-4T-2 vector pGex-L1ΔN10Δ408-431ΔC29-E7 
including the HPV16 L1 and E7 genes was kindly provided by Dr. Lysann Schädlich.  
 
Expression plasmids 
The following modification key gives an overview of the used abbreviations for the 
description of expression plasmids 
 
Table 2: Modification key for the generated expression plasmids. 
L1 HPV16 L1 gene (wildtype) 
ΔN10 deletion of 10 aas at the N-terminus 
ΔC29 deletion of 29 aas at the C-terminus 
Δh4 deletion of aas 408-431 that comprise the helix 4 region of HPV16 L1  
p16INK4a 
full length cyclin-dependent kinase inhibitor 2A protein (CDKN2A, p16INK4a), 
human 
 
The following pGex plasmids were cloned (BamHI / HindIII) and used for the expression of 
GST fusion proteins in E. coli during this thesis.  
 
pGex-L1ΔN10Δh4ΔC29: modified HPV16 L1, forms capsomeres 
pGex-p16INK4a: full length human p16INK4a gene 
pGex-L1ΔN10Δh4ΔC29-p16INK4a (construct 1): contains the full-length human p16INK4a gene 
fused to the C terminus of the modified L1 
pGex-p16INK4a-L1ΔN10Δh4ΔC29 (construct 2): contains the full-length human p16INK4a gene 
fused to the N terminus of the modified L1 
pGex-L1ΔN10Δh4-p16INK4a-L1ΔC29 (construct 3): contains the full-length human p16INK4a 
gene inserted at the helix 4 position of the modified L1 
 
Plasmid maps for the three chimeric pGex-4T-2 constructs consisting of L1 and p16INK4a can 
be found in VII (Appendix). 
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Figure 9: HPV16 L1 - p16
INK4a
 capsomere constructs depicted in cartoon format. The wild-type L1 protein is 
displayed at the top. Modified L1 and p16
INK4a
 alone were used as controls during immunization studies and 
were therefore also cloned and expressed in E. coli. 
 
5.2.2 Oligonucleotides 
Oligonucleotide primers were synthesized by Thermo Scientific (Ulm, Germany). Restriction 
sites are underlined. 
Cloning of pGex-L1ΔN10Δh4ΔC29-p16INK4a 
p16_NsiI_forward 5’: TTTTATGCATATGGAGCCGGCGGCGGGG 
p16_HindIII_reverse 3’: TTTTAAGCTTTCAATCGGGGATGTCTGA 
for amplification of p16INK4a from Hela cDNA and introduction of restriction sites 
 
Cloning of pGex-p16INK4a-L1ΔN10Δh4ΔC29 with overlap PCR 
p16_BamHI_forward 5’: TTTTGGATCCATGGAGCCGGCGGCGGGG  
for amplification of p16INK4a from Hela cDNA and introduction of BamHI restriction site 
 
p16L1_reverse 3’: GACAGGAGGCAAGTAGACATCGGGGATGTCTGAGGG 
for amplification of p16INK4a from Hela cDNA and introduction of overlap for combination with 
L1 insert 
 
p16L1_forward 5’: CCCTCAGACATCCCCGATGTCTACTTGCCTCCTGTC 
for amplification of L1 DNA (L1ΔN10Δh4ΔC29) from pGex-L1ΔN10Δh4ΔC29-E7 
 
L1_HindIII_reverse 3’: TTTTAAGCTTTTAGGCCTTCAATCCTGC 
for amplification of L1 DNA (L1ΔN10Δh4ΔC29) from pGex-L1ΔN10Δh4ΔC29-E7 and 
introduction of HindIII restriction site 
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p16INK4a insert check primer 
p16INK4a_forward 5’: CTTCCTGGACACGCTGGT 
 
p16INK4a_reverse 3’: GCATGGTTACTGCCTCTGGT 
 
L1 insert check primer 
L1d_forward 5’: TTTTGAACCATATGGCGACAGCTT 
 
L1d_reverse 3’: TTTTATTATTGTGGCCCTGTGCTC 
 
L1-p16 overlap check primer 
L1p16_forward 5’: CAGTTTCCTTTAGGACGCAAA 
 
L1p16_reverse 3’: CATCATCATGACCTGGATCG  
 
p16-L1 overlap check primer 
seq_p16L1_reverse 3’: TAGGGATGTCCAACTGCAAG 
 
p16INK4a_forward 5’: CTTCCTGGACACGCTGGT 
 
Sequencing primer 
L1d_forward 5’: TTTTGAACCATATGGCGACAGCTT 
L1p16_forward 5’: CAGTTTCCTTTAGGACGCAAA 
p16INK4a_forward 5’: CTTCCTGGACACGCTGGT 
pGex-4T-2_reverse 3’: GGCAGATCGTCAGTCAGTCA 
pGex-4T-2_seq 5’: GGGCTGGCAAGCCACGTTTGGTG 
seq_L1p16_forward 5’: CACCTCCAGCACCTAAAGAAG  
seq_p16L1_forward 5’: TTGAAGCTATCCCACAAATTGA 
 
5.2.3 Peptides 
Peptides were synthesized by Genaxxon Bioscience GmbH (Ulm, Germany). 
HPV16 L1 165-173 AGVDNRECI, H2-Db-restricted CTL epitope of HPV16 L1 [137] 
p16INK4a 1-20 MEPAAGSSMEPSADWLATAA “1” 
p16INK4a 13-32 ADWLATAAARGRVEEVRALL “2” 
p16INK4a 25-44 VEEVRALLEAGALPNAPNSY “3” 
p16INK4a 37-56 LPNAPNSYGRRPIQVMMMGS “4” 
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p16INK4a 49-68 IQVMMMGSARVAELLLLHGA “5” 
p16INK4a 61-80 ELLLLHGAEPNCADPATLTR “6” 
p16INK4a 73-92 ADPATLTRPVHDAAREGFLD “7” 
p16INK4a 85-104 AAREGFLDTLVVLHRAGARL “8”  
p16INK4a 97-116 LHRAGARLDVRDAWGRLPVD “9” 
p16INK4a 109-128 AWGRLPVDLAEELGHRDVAR “10” 
p16INK4a 121-140 LGHRDVARYLRAAAGGTRGS “11” 
p16INK4a 133-152 AAGGTRGSNHARIDAAEGPS “12” 
p16INK4a 145-156 IDAAEGPSDIPD “13” 
p16INK4a 137-145 TRGSNHARI, H2-Db-restricted CTL epitope of p16INK4a 
p16INK4a 113-121 LPVDLAEEL, H2-Db-restricted CTL epitope of p16INK4a 
p16INK4a 55-63 GSARVAELL, H2-Db-restricted CTL epitope of p16INK4a 
(these 3 peptides were predicted using the SYFPEITHI epitope prediction algorithm [138].) 
 
p16INK4a 37-63 LPNAPNSYGRRPIQVMMMGSARVAEL (“Vicoryx peptide”, [125]) 
 
All peptides were delivered lyophilized and dissolved in sterile DMSO at a final 
concentration of 1 mg/ml or 5 mg/ml. For ELISA (6.6.2) and ELISpot assay (6.6.3), peptide 
working solutions of 0.5 µg/µl in PBS were prepared. 
 
5.2.4 Antibodies 
Designation Specificity Species Conc. Application 
Source / 
Reference 
D7D7 -HRP 
human 
p16INK4a 
(monoclonal) 
mouse  WB 1:5000 
MTM 
Laboratories, 
Heidelberg 
E6H4 -HRP 
human 
p16INK4a 
(monoclonal) 
mouse  WB 1:5000 
MTM 
Laboratories, 
Heidelberg 
F-4 (sc-74401) 
murine 
p16INK4a 
(monoclonal) 
mouse 0.2 mg/ml WB 1:500 
Santa Cruz 
Biotechnology, 
Heidelberg 
MD2H11 
HPV16 L1 
(monoclonal) 
mouse 0.2 mg/ml WB 1:500 
Santa Cruz 
Biotechnology, 
Heidelberg 
#4543 
HPV16 L1 
(polyclonal) 
rabbit 0.2 µg/ml ELISA 1:500 
Prof. Martin 
Müller, DKFZ, 
Heidelberg 
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#1.3.5.15 
(Ritti01) 
HPV16 L1 
(monoclonal) 
mouse  ELISA 1:1000 
Prof. Martin 
Müller, DKFZ, 
Heidelberg 
9A1/2 
E. coli GroEl 
(monoclonal) 
mouse 1 mg/ml 
WB 
1:1000 
Abcam, 
Cambridge, UK 
rabbit α-mouse 
IGG -HRP 
mouse 
(polyclonal) 
rabbit 0.8 mg/ml 
WB 1:5000 
ELISA 1:5000 
Thermo 
Scientific, 
Rockford, USA 
goat α- rabbit 
IGG-HRP 
rabbit 
(polyclonal) 
goat  WB 1:2000 
Cell Signaling, 
Cambrigde, UK 
IFNγ 
(clone R4-6A2) 
murine IFNγ 
(monoclonal) 
rat 1 mg/ml 
ELISpot 
(5 µg/ml) 
BD Biosciences 
Pharmingen, 
Heidelberg 
IFNγ biotin-
conjugate 
(clone XMG1.2) 
murine IFNγ 
(monoclonal) 
rat 0.5 mg/ml 
ELISpot 
(1 µg/ml) 
BD Biosciences 
Pharmingen, 
Heidelberg 
LS-C15 
schistosoma 
japonicum 
(polyclonal) 
goat 10 mg/ml 
CnBr 
chromatography 
Biozol, Eching, 
Germany 
H1JG, clone 7 
schistosoma 
japonicum 
(monoclonal) 
rabbit  
ProteinG affinity 
chromatography 
Prof. Martin 
Müller, DKFZ, 
Heidelberg 
 
5.3 Media and Supplements 
5.3.1 Bacteria Culture 
LB medium 
(Luria Bertani): 
1 % tryptone 
0.5 % yeast extract 
1 % NaCl 
in aqua bidest. 
adjust pH to 7.0 with 5 M NaOH;  
sterilized by autoclaving 
LB medium for agar plates: 1 % tryptone 
0.5 % yeast extract 
1 % NaCl 
2 % Difco-Bacto-Agar 
in aqua bidest. 
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adjust pH to 7.0 with 5 M NaOH 
sterilized by autoclaving 
after cooling to 50°C addition of relevant antibiotics 
Terrific broth medium 
Component A: 
12 g tryptone 
24 g yeast extract 
4 ml glycerol 
Ad 900 ml aqua bidest.  
sterilized by autoclaving 
Ad 1 L component B before use 
Terrific broth medium 
Component B: 
23.12 g KH2PO4 
125.41 g K2HPO4 
ad 1 L aqua bidest. 
sterilized by autoclaving 
Antibiotics 
Ampicillin final conc. 100 µg/ml Sigma Aldrich, Steinheim, Germany 
Chloramphenicol final conc. 200 µg/ml  Sigma Aldrich, Steinheim, Germany 
 
Chemicals 
Sorbitol  Sigma Aldrich, Steinheim, Germany 
Betaine  Sigma Aldrich, Steinheim, Germany 
IPTG solution 100 mM 40 mg/ml IPTG in aqua bidest. 
 
5.3.2 Mammalian cell culture 
Trypan Blue solution 0.4% Sigma Aldrich, Steinheim, Germany 
Media 
RPMI 1640 liquid with L-Glutamine PAA Cell Culture Company, Cambridge, UK 
 Gibco Life Technologies, Carlsbad, CA, USA 
Opti-MEM Gibco Life Technologies, Carlsbad, CA, USA 
 
Supplements 
Penicillin/Streptomycin solution 100 x  
(5.000 U/ml Pen, 5.000 U/ml Strep) Gibco Life Technologies, Carlsbad, CA, USA 
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Fetal Bovine Serum PAA Cell Culture Company, Cambridge, UK 
Geneticin (G418) Gibco Life Technologies, Carlsbad, CA, USA 
L-Glutamine Sigma Aldrich, Steinheim, Germany 
β-mercaptoethanol Sigma Aldrich, Steinheim, Germany 
MEM Non-essential amino-acid solution Sigma Aldrich, Steinheim, Germany 
Sodium pyruvate solution (100 mM) Sigma Aldrich, Steinheim, Germany 
Trypsin (0.25 %)/EDTA PAA Cell Culture Company, Cambridge, UK 
 
Specific media – recipes 
RPMI RPMI 
 10 % FCS  
 1 % Penicillin/Streptomycin 
 1 % L-Glutamine 
 
TC-1 medium RPMI 
 10 %  FCS  
 1 % Penicillin/Streptomycin 
 100 µM β-mercaptoethanol 
 0.4 mg/ml Geneticin 
 1  mM Sodium pyruvate 
 1 x MEM Non-essential amino-acid solution 
 
C3-medium RPMI 
 10 % FCS  
 1 % Penicillin/Streptomycin 
 2 mM L-Glutamine 
 100 µM β-mercaptoethanol 
 0.1 mg/ml Kanamycin 
 
5.4 Material for molecular biological and protein technical methods 
5.4.1 Preparation, manipulation and analysis of DNA  
Kits 
High pure PCR product purification kit Roche, Mannheim, Germany 
QIAQuick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAGEN Plasmid Mini Kit Qiagen, Hilden, Germany 
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QIAGEN Plasmid Maxi Kit Qiagen, Hilden, Germany 
QIAGEN EndoFree Plasmid Maxi Kit Qiagen, Hilden, Germany 
 
Enzymes 
A Restriction Enzymes 
 HindIII HF New England Biolabs, Frankfurt/M, Germany 
 BamHI-HF New England Biolabs, Frankfurt/M, Germany 
 NsiI Promega, Medison, USA 
 
B Polymerases  
 Taq DNA Polymerase Invitrogen, Life Technologies, Carlsbad, USA 
 HOT FIREPol® DNA Polymerase Solis Biodyne, Tartu, Estonia 
 
C Ligation Enzymes 
 T4 DNA Ligase Roche, Mannheim, Germany 
 Alkaline Phosphatase Sigma-Aldrich, St. Louis, USA 
 
Chemicals 
dNTP Mix (2.5 mM per nucleotide) Invitrogen, Life Technologies, Carlsbad, USA 
DMSO  
MgCl2 Solis Biodyne, Tartu, Estonia 
 Invitrogen, Life Technologies, Carlsbad, USA 
10 x PCR Buffer Solis Biodyne, Tartu, Estonia 
 Invitrogen, Life Technologies, Carlsbad, USA 
 
DNA marker/ ladder 
100 bp DNA ladder Invitrogen, Life Technologies, Carlsbad, USA 
1 kbp ladder Gibco Life Technologies, Carlsbad, CA, USA 
 
DNA Sequencing GATC, Konstanz, Germany 
 
In-house DNA Sequencing 
BigDye® Terminator v3.1 Cycle Sequencing Kit including  
 Ready Reaction Mix (RR-Mix)   
 BigDye Terminator v1.1/3.1 Sequencing Buffer (5X)  
by Applied Biosystems, Life Technologies, USA 
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Agarose gel electrophoresis 
10 x Loading Dye 250 mg bromphenol blue in 33.0 ml 150 mM Tris pH 7.6  
 60 ml glycerol 
 7.0 ml aqua bidest 
 add 66.7 ml aqua bidest. to receive 6 x Loading Dye 
 ready for use 
  
10 x TBE Buffer 121.14 g Tris 
 51.32 g boric acid 
 3.72 g EDTA 
 ad 1 L with aqua bidest. 
 
Agarose Gel 1% 1 % Agarose (w/v) 
 0.3 µg/µl Ethidium Bromide 
 in 1 x TBE Buffer 
 
5.4.2 Protein purification  
Columns and Concentration Filters 
Amicon Ultra-15 Centrifugal Filter Units 100kDa Merck Millipore, Billerica, MA, USA 
Amicon Ultra-30 Centrifugal Filter Units 100kDa  Merck Millipore, Billerica, MA, USA 
CNBr-Activated Sepharose 4 FF GE Healthcare, Uppsala, Sweden 
Gelfiltration Calibration Kit GE Healthcare, Uppsala, Sweden 
GST Detection Module GE Healthcare, Uppsala, Sweden 
GSTrapTM FF column 1 ml GE Healthcare, Uppsala, Sweden 
GSTrapTM FF column 5 ml GE Healthcare, Uppsala, Sweden 
Protein G Sepharose FF GE Healthcare, Uppsala, Sweden 
Q-Sepharose FF GE Healthcare, Uppsala, Sweden 
Superdex 200 10/300  GE Healthcare, Uppsala, Sweden 
 
Chemicals and Materials 
cOmplete® Protease Inhibitor Cocktail (EDTA free) Roche, Mannheim, Germany 
Dialysis Tube Spectra/Por Membrane 3.500 Spectrum, Serva, Heidelberg, Ger 
Dithiothreitol (DTT) Roth, Karlsruhe, Germany 
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Enzymes: 
Thrombin protease GE Healthcare, Uppsala, Sweden 
Lysozyme Roche, Mannheim, Germany 
 
Buffers and Solutions - Chromatography 
Glutathione solution  20 mM Glutathione S reduced in appropriate buffer 
Column storage solution  20 % Ethanol 
 
 GSTrap Affinity Chromatography: 
Buffer L 50 mM Tris 
 0.2 M NaCl 
 1 mM EDTA 
 2 mM DTT 
 pH 8.2  
 
Buffer Lmod 50 mM Tris 
 0.5 M NaCl 
 1 mM EDTA  
 5 mM DTT 
 0.01% Tween80 
 pH 8.2 
 
Buffer Lp16 50 mM Tris 
 0.1 M NaCl 
 1 mM EDTA 
 1 mM DTT 
 pH 8.0 
 
ATP 0.5 M 
MgCl2 1 M 
Thrombin incubation solution 40 u / ml Buffer L  
Column cleaning solution 6 M Guanidinium hydrochloride 
 
 Ion Exchange Chromatography: 
IEX Buffer 10 mM Tris 
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 0,1 mM TCEP 
 0,05 mM EDTA 
 0,01 % Tween80 
 pH 8.0 
 
 Protein G Affinity Chromatography 
Buffer Lp16 50 mM Tris 
 0.1 M NaCl 
 1 mM EDTA 
 1 mM DTT 
 pH 8.2  
 
Buffer 2 50 mM Tris 
 0.1 M NaCl 
 1 mM EDTA 
 1 mM DTT 
 20 % (v/v) Glycerol 
 pH 8.0 
Buffer Lmod 50 mM Tris 
 0.5 M NaCl 
 1 mM EDTA 
 5 mM DTT 
 0.01 % Tween80 
 pH 8.2 
 
 CnBr Affinity Chormatography 
 10 mM Tris 
 0.05 mM EDTA 
 0.1 mM DTT 
 0.045 % (v/v) L-Sarkosine 
 pH 8.0  
 
Column cleaning solution 3 M KCl 
 
 Size exclusion chromatography: 
Buffer Lmod 50 mM Tris 
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 0.5 M NaCl 
 1 mM EDTA 
 5 mM DTT 
 0.01 % Tween80 
 pH 8.2 
Column cleaning solution 20 % EtOH (regular cleaning) 
 
Buffers and Solutions - Inclusion Body Purification 
 Inclusion Body Preparation - Buffers: 
IB Resuspension Buffer 50 mM Tris-HCl 
 50 mM NaCl 
 0.5 mM EDTA 
 1 mM DTT 
 5 % Glycerol 
 pH 8.0 
IB Wash Buffer 50 mM Tris-HCl 
 50 mM NaCl 
 0.5 mM EDTA 
 1 mM DTT 
 5 % Glycerol 
 1 % Triton X-100 
 pH 8.0 
 Denaturing Solutions: 
Urea 4, 6, 8 M in Denaturing Buffer  
Guanidinehydrochlorid 7 M in Denaturing Buffer 
N-Lauroylsarcosine 3.5 % (v/v) 
GuHCl Denaturing Buffer 50 mM Tris 
 0.2 M NaCl 
 2 mM EDTA 
 5 mM DTT 
 0.01 % Tween80 
 pH 8.0 
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L-Sarcosine Denaturing Buffer 50 mM Tris 
= Urea Denaturing Buffer  0.05 M NaCl 
 0.5 mM EDTA 
 5 mM DTT 
 5 % Glycerol 
 pH 8.0 
 Dialysis / Refolding Buffer: 
For protein refolding after denaturing with urea or GuHCl the corresponding denaturing 
buffers were also used for refolding with step-wise decreasing concentrations of the 
denaturing agent. 
L-Sarcosine Dialyis Buffer 10 mM Tris 
 0.05 mM EDTA 
 0.1 mM DTT 
 0.06 % (v/v) L-Sarcosine 
 pH 8.0   
 
Dialysis / Refolding Buffer Screen  
 50 mM Tris 
 2 mM DTT 
  
NaCl [M] Glycerol [%] NaCl [M] + 10 % Glycerol 
0.05  0 0.05  
0.1 5 0.1 
0.2 10 0.2 
0.35 20  
 
Rapid Dilution Refolding: 
Buffer 1 50 mM Tris 
 0.05 M NaCl 
 0.5 mM EDTA 
 5 mM DTT 
 5 % (v/v) Glycerol 
 pH 8.0 
Buffer 2 50 mM Tris 
 0.1 M NaCl 
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 1 mM EDTA 
 1 mM DTT 
 20 % (v/v) Glycerol 
 pH 8.0 
 
5.4.3 Endotoxin detection, quantification and removal  
QCL-1000 Endpoint Chromogenic LAL Assay Lonza, Walkersville, MD, USA 
LAL Reagent Water  Lonza, Walkersville, MD, USA 
LAL reagent grade multi-well plates  Lonza, Walkersville, MD, USA  
Triton X-114  Sigma, Steinheim, Germany 
 
5.4.4 Analysis of proteins  
Standard Solutions 
1 x PBS 140 mM NaCl 
 2.7 mM KCl 
 8.1 mM Na2HPO4 
 1.5 mM KH2PO4 
 pH 7.4 
 
PBS-T  0.05 % Tween20 
 in 1x PBS 
 
Blocking solution (ELISA) 0.05 % caseine (w/v) 
 In PBS-T 
 
1 x TBS 50 mM Tris 
 150 mM NaCl 
 pH 7.6 
 
TBS-T 0.05 % Tween20 
 in 1x TBS 
 
Blocking solution (WB) 5 % milk powder (w/v) 
 in TBS-T 
 
Stripping buffer (WB) 33.5 ml aqua bidest. 
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 10 ml SDS 10 % 
 6.25 ml 0.5 M Tris pH 6.8 
 350 µl ß-mercaptoethanol 
 
Coomassie G-250 Staining Solution  
a) SimplyBlue™ SafeStain 
b) Coomassie Staining Solution: 0.02 % Coomassie Brilliant Blue G-250 100 mg  
 2 % (w/v) phosphoric acid 10 ml 
 5 % aluminium sulfate 25 g 
 10 % ethanol (96 %) 50 ml 
 in aqua bidest. ad to 500 ml 
First of all, aluminium sulfate was dissolved in 250 ml aqua bidest. Then, ethanol was 
homogenized and subsequently Coomassie Brilliant Blue G-250 was added and 
dissolved. In a last step, phosphoric acid was added and the solution was filled up with 
aqua bidest to 500 ml. 
 
Kits 
2-D Quant Kit GE Healthcare, Uppsala, Sweden 
SilverQuest™ Silver Staining Kit Invitrogen, Life Technologies, Carlsbad, USA 
 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blot 
 
20 x NuPAGE MES SDS Running Buffer 
Nitrocellulose Membrane Filter Paper Sandwich 0.45 µm 
NuPAGE 10 x Reducing agent 
NuPAGE 4 x LDS sample buffer 
NuPAGE Novex 4-12% Bis-Tris Gels, 1.0 mm, 12 well and 17 well  
X-Cell Blot Module 
X-Cell Sure Lock gel chamber  
The above listed SDS-PAGE and western blot equipment was all supplied by Invitrogen Life 
Technologies, Carlsbad, USA. 
 
Power supply Consort E853 Consort, Turnhout, Belgium 
 
Protein Marker: 
Precision Plus Protein Standard Bio-Rad, Munich, Germany 
Precision Plus WesternC Standard  Bio-Rad, Munich, Germany 
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5.4.5 Electron microscopy  
Carbon-coated copper grid (400 meshes)  Plano, Wetzlar, Germany 
CCD-Camera  Proscan, Lagerlechfeld, Germany 
Electron microscope EM 912  Zeiss, Jena, Germany 
Uranyl acetate solution  1 % uranyl acetate in aqua bidest. 
Whatman paper No.10  Schleicher&Schuell, Dassel, Germany 
 
5.4.6 Sedimentation analysis 
Gradient mixer  kindly provided by Dr. Daniele Viarisio 
  (DKFZ, Heidelberg, Germany) 
Ultracentrifugation tubes (14 x 95 mm, PA) Beckmann, Palo Alto, CA, USA 
Refractometer  Schmidt-Haenisch, Berlin, Germany 
Sucrose solutions:  5 % Sucrose (w/v) 
 50 % Sucrose (w/v) 
  in dialysis buffer (5.4.2), sterilized by filtration 
 
5.5 Material for the immunization of mice and analysis of immune response 
5.5.1 Immunizations 
Needles G23 B Braun, Melsungen, Germany 
Lancets Solofix  B Braun, Melsungen, Germany 
Electric razer Ermila, Harotec GmbH, Berlin, Germany 
Montanide ISA-51 adjuvant Seppic, Puteaux Cedex, France  
Syringes 0.01 - 1 ml Injekt-F B Braun, Melsungen, Germany 
Ear mark pincer KN-292B 2.0 Napox, Natsume Seisakusho, Tokyo, Japan 
 
5.5.2 ELISA 
F96 Maxisorp Immuno plates NUNC Fisher Scientific, Denmark 
TMB (3,3` 5,5` Tetramethylbenzidine) Sigma, Steinheim, Germany 
1 x PBS  coating buffer 
PBS-T 0,05 % Tween20  wash buffer 
5 % milk powder (w/v) in PBS-T  blocking buffer (6.6.1) 
0.5 % (w/v) caseine in PBS-T  blocking buffer (6.6.2) 
1 M H2SO4  stop solution 
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HPV16 VLPs for VLP-capture ELISA (6.6.1) were purified from baculovirus-infected insect 
cells and kindly provided by Prof. Martin Müller, DKFZ, Germany. 
 
5.5.3 IFNy ELISpot 
3 x 5 cm metal meshes (0.5 mm mesh size)  DKFZ, Heidelberg, Germany 
 
ACT lysis buffer:  17 mM Tris 
 160 mM NH4Cl 
 pH 7.2, sterilized by filtration 
 
PBS-T 0,01 %  0,01 % Tween20 
 in PBS 
 
Concavalin A Sigma, Steinheim, Germany 
Ionomycin calcium salt  Sigma, Steinheim, Germany 
NBT/BCIP, ready-to-use  Sigma, Steinheim, Germany 
Multiscreen IP 96 well filter plates MSIPN45  Merck Millipore, Billerica, MA, USA 
PMA (Phorbol 12-myristate 13-acetate) Sigma, Steinheim, Germany 
Pokeweed Mitogen  Sigma, Steinheim, Germany 
Streptavidin Alkaline Phosphatase  BD Pharmingen, Durham, NC, USA 
 
5.6 Chemicals 
Acetic acid 96 %  Merck, Darmstadt, Germany 
Agarose Gibco BRL, Eggenstein, Germany 
Albumin from chicken egg white Sigma-Aldrich, St. Louis, USA 
Ammonium persulfate (APS)  Serva, Heidelberg, Germany 
Ampicillin  Sigma-Aldrich, St. Louis, USA 
Bacto-Agar Difco Laboratories, Detroit, USA 
BCIP-NBT Sigma-Aldrich, St. Louis, USA 
Betaine Sigma-Aldrich, St. Louis, USA 
Boric acid Merck, Darmstadt, Germany 
Bovine serum albumin (BSA)  Sigma-Aldrich, St. Louis, USA 
Bradford reagent Dye Reagent Concentrate Bio-Rad, Munich, Germany 
Bromphenol blue Serva, Heidelberg, Germany 
Coomassie Brilliant Blue  Sigma-Aldrich, St. Louis, USA 
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Developer for photographic processing Adefo-Chemie, Dietzenbach 
Dimethylsulfoxide (DMSO)  Merck, Darmstadt, Germany 
D-Sorbitol >98% Sigma-Aldrich, St. Louis, USA 
Ethanol p.a.  Merck, Darmstadt, Germany 
Ethidium bromide  Sigma-Aldrich, St. Louis, USA 
Ethylenediaminetetraacetate (EDTA)  Merck, Darmstadt, Germany 
Fixer for photographic processing Adefo-Chemie, Dietzenbach 
Formaldehyde 37 % Roth, Karlsruhe, Germany 
Glacial acetic acid   Serva, Heidelberg, Germany 
Glutathione  Sigma-Aldrich, St. Louis, USA 
Glycerol 86 %  Roth, Karlsruhe, Germany 
Hydrochloric acid 37 %  Roth, Karlsruhe, Germany 
Imidazole  Roth, Karsruhe, Germany 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)  Sigma-Aldrich, St. Louis, USA 
Luminol reagent (ECL)  Santa Cruz, Santa Cruz, USA 
Mercaptoethanol Merck, Darmstadt, Germany 
Methanol  Merck, Darmstadt, Germany 
Milk powder  Roth, Karlsruhe, Germany 
N-Lauroylsarcosine sodium salt solution Sigma-Aldrich, St. Louis, USA 
p-Nitrophenylphosphate Sigma-Aldrich, St. Louis, USA 
Ponceau red solution Sigma-Aldrich, St. Louis, USA 
Potassium dihydrogen phosphate  Gerbu Biochemicals, Gaiberg, Germany 
RIPA Buffer Sigma-Aldrich, St. Louis, USA 
Roti-Quant Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium carbonate   Merck, Darmstadt, Germany 
Sodium chloride   AppliChem, Darmstadt, Germany 
Sodium dihydrogen phosphate dihydrate  J.T. Baker, Deventer, Netherlands 
Sodium dihydrogenphosphate monohydrate J.T.Baker, Deventer, Netherlands 
Sodium hydrogene carbonate Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH)  Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS)  Roth, Karlsruhe, Germany 
Sulfuric acid (H2SO4) Roth, Karlsruhe, Germany 
Tetramethylethylenediamine (TEMED)  Serva, Heidelberg, Germany 
Tris-(hydroxymethyl)aminomethane  Roth, Karlsruhe, Germany 
Triton-X100 Sigma-Aldrich, St. Louis, USA 
Tryptone  Difco, Detroit, USA 
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Tween20  Calbiochem, Merck, Darmstadt, Germany 
Tween80 Sigma-Aldrich, St. Louis, USA 
Yeast extract Difco Laboratories, Detroit, USA 
 
5.7 General materials and consumables 
10 ml incubation tubes (bacteria) Greiner, Frickenhausen, Germany 
50 ml centrifuge tubes (SS-34 rotor, Sorvall)  Beckmann Coulter, Brea, CA, USA 
500 ml centrifuge tubes (874 rotor)  Heraeus Sepatech, Hanau, Germany 
6-, 12-, 24-, 48-, 96 well plates (cell culture)  Costar, Corning, NY, USA 
96-well plates, U-bottom BD Falcon, Durham, USA 
Bottle top filter  Costar, Corning, NY, USA 
Cell culture flasks (25, 75, 175 cm2) CellStar, Greiner, Frickenhausen, Germany 
Cell scraper Greiner Bio-One, Frickenhausen, Ger 
Cryo vials, 2 ml  CellStar, Greiner, Frickenhausen, Ger 
disposable bags PP Brand, Wertheim, Germany 
disposable hemocytometer C-Chip DigitalBio, Nanoentek, Washington, USA 
Disposable scalpel  Feather, Osaka, Japan 
DNAzap Ambion, Life Technologies, Carlsbad, USA 
Electroporation cuvettes Steinbrenner, Wiesenbach, Germany 
Falcon tubes, 15 ml und 50 ml  Greiner, Frickenhausen, Germany 
Gloves nitril Sempermed,Wien, Austria 
Kimtech Wipes  Kimberley-Clark, Irving, USA 
LoBind reaction tubes 1.5 & 2 ml Eppendorf, Hamburg, Germany 
Needles  BD Microlance, Durham, USA 
Parafilm PM-996 Pechiney, Paris, France 
Pasteur pipettes Costar, Corning, NY, USA 
Pasteur pipettes Sarstedt, Newton, USA 
PCR reaction tubes  Eppendorf, Hamburg, Germany 
Petri dishes  Greiner, Frickenhausen, Germany 
Photographic film Kodak Biomax light  Sigma-Aldrich, St. Louis, USA 
Pipette tips Tip One  Star Lab, Merenschwand, Switzerland 
Pipette tips Greiner, Frickenhausen, Germany 
PVDF-Membrane Hybond N+  Amersham, Buckinghamshire, UK 
Reaction tubes, 0,2 - 2 ml  Eppendorf, Hamburg, Germany 
Reagent reservoirs 50 ml Costar, Corning, NY, USA 
Sterile filter tips DeckWorks Corning, NY, USA 
Materials and Methods  44 
Sterile plastic inoculation loops  Neolab, Heidelberg, Germany 
Syringe filters, 0.2 & 0.45 µm Corning, NY, USA 
Syringes  Beckton Dickinson, New Jersey, USA 
Toothpicks (sterilized by autoclaving) Papstar, Kall, Germany 
Ultracentrifugation tubes 14 x 95 mm, PA Beckmann, Palo Alto, CA, USA 
 
5.8 Equipment  
Agarose gel carriage Tecnomara, Fernwald, Germany 
Agarose gel running chamber Sub Cell GT  Bio-Rad, Munich, Germany 
Analytical Balance BP 210D  Sartorius, Goettingen, Germany 
Autoradiography cassettes Siemens, Berlin, Germany 
Balance BP 310S  Sartorius, Goettingen, Germany 
CCD Camera  Proscan, Lagerlechfeld, Germany 
Centrifuge 1K15 Sigma, Osterode a.H., Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
Centrifuge Biofuge 13 Heraeus, Hanau, Germany 
Centrifuge RC-5B Refrigerated Superspeed Sorvall, Thermo Fisher Scientific, MA, USA 
Centrifuge Varifuge 3.0R Heraeus, Hanau, Germany 
Culture Shaker Certomat R  Sartorius, Goettingen, Germany 
Culture Shaker Multitron Infors, Basel, Switzerland 
DNA-Sequencer ABI 3100 Genetic Analyser Applied Biosystems, Foster City, USA 
Electron Microscope EM 912 Omega Zeiss, Jena, Germany 
Elektrophoresis chamber Mini Protean II  Bio-Rad, Munich, Germany 
French Press EmulsiFlex-C5 Avestin, Canada 
Gel documentation GelDoc 2000 Bio-Rad, Munich, Germany 
Incubation hood Certomat H Sartorius, Goettingen, Germany  
Incubator  Heraeus, Hanau, Germany 
Laminar Flow Hood Biowizard Silverline Kojair, Vilppula, Finland  
Magnetic stirrer MR 2002  Heidolph, Schwabach, Germany 
Microscope CK 40 Olympus, Tokio, Japan 
Microwave oven Siemens, Berlin, Germany 
Mikrotiter plate reader Multiskan EX Thermo Electron Corp., Karlsruhe, Ger 
Peristaltic pump Econo Pump Bio-Rad, Munich, Germany 
pH-meter PB-11  Sartorius, Goettingen, Germany 
Pipettes Pipetman  Gilson, Bad Camberg, Germany 
Pipettor Pipetboy 8-5010 Neolab, Heidelberg, Germany 
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Potter-Elvehjem-Homogenizer B. Braun, Melsungen, Germany 
Power Supply EV 231 Consort, Turnhout, Belgium 
Power Supply Power Pac 300  Bio-Rad, Munich, Germany 
Roller mixer RM5 CAT, Staufen, Germany 
rotor 874 Heraeus, Hanau, Germany 
rotor SS-34 Sorvall, Thermo Fisher Scientific, MA, USA 
rotor SW 32 Ti Beckmann, Palo Alto, CA, USA 
Shaker Promax 2020 Heidolph, Schwabach, Germany 
Sonicator Sonopuls HD/UW 2070 MS72 Bandelin, Berlin, Germany 
Speed Vac DNA Speed Vac 110  Savant, Holbrook, USA 
Table top centrifuge 2K14  Eppendorf, Hamburg, Germany 
Thermocycler Mastercyler Gradient  Eppendorf, Hamburg, Germany 
Thermomixer 5436  Eppendorf, Hamburg, Germany 
Ultracentrifuge Discovery 90 SE  Sorvall, Thermo Fisher Scientific, MA, USA 
Vortex MS1 Minishaker  IKA, Staufen, Germany 
Waterbath SW 20 Julabo, Seelbach, Germany 
 
5.9 Software 
Adobe Acrobat Reader 6  Adobe, San Jose, CA, USA 
Adobe Photoshop Elements 4 Adobe, San Jose, CA, USA 
AID ELISpot Software  AID, Strassberg, Germany 
BLAST - Basic Local Alignment Search Tool National Center for Biotechnology 
Information, Bethesda, MD, USA 
ChromasLite 2.01 Technelysium, South Brisbane, Australia 
Endnote X6  Thomson Reuters, New York, NY, USA 
GIMP 2.8 GNU General Public License (GPL & LGPL) 
SYFPEITHI software Rammensee et al. [138] 
GraphPad Prism 6.04  GraphPad Software, San Diego, CA, USA, 
HP Precision Scan Pro 3.1 Hewlett-Packard, Palo Alto, CA, USA 
ImageJ 1.4.7  NIH, Bethesda, MA, USA 
Magellan Standard  Tecan Group Ltd., Männedorf, Switzerland 
Microsoft Office Professional Plus 2010 Microsoft Corp., Redmond, WA, USA 
Microsoft Windows 7 Microsoft Corp., Redmond, WA, USA 
SnapGene 2.2.2 GSL Biotech LLC, Chicago, IL, USA 
Unicorn 2.0  GE Healthcare, Uppsala, Sweden 
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6 Methods 
6.1 Manipulation of DNA 
6.1.1 Purification of plasmid DNA (Mini and Maxi preparation) from E. coli 
Plasmid DNA was isolated with the Qiagen Plasmid Mini or Maxi Kit according to the 
manufacturer’s instructions. For small scale preparations, 2 to 5 ml of an overnight grown 
bacteria culture were used; for large scale production of plasmid DNA, 200 ml culture 
volume was applied. 
 
6.1.2 Determination of DNA concentration and purity 
DNA concentrations and purity were determined spectrophotometrically by measuring the 
absorption at 260 and 280 nm. Thereto, the DNA was diluted in aqua bidest. and 
transferred to a UV cuvette. H2O was also used to set the blank value of the photometer. 
The DNA concentration was calculated according to the following equation: 
A260nm x 50 µg/µl x dilution factor = c [µg/µl] 
The absorption at 280 nm was used to determine the purity of the preparation. A ratio of 
A260 / A280 of 1.8 to 2.0 was considered to be pure; ratios of less than 1.8 indicate protein 
contaminations. 
 
6.1.3 Enzymatic cleavage of DNA 
Restriction endonucleases were used for the digestion of DNA according to the 
manufacturer’s instructions. If the optimal buffer differed for a double digest, a 
compromising buffer was used if possible. If the reaction buffers were not compatible to 
each other, the digest was performed sequential. After digestion with the first enzyme, 
purification of the DNA was performed with the Roche PCR Purification Kit (6.1.4). DNA 
was eluted in 30 µl water and introduced to the next digest. 
Enzymatic cleavage reactions were usually carried out at 37 °C for at least 2 hours. 
Cleaved products were separated and identified with agarose gel electrophoresis. For 
preparative digests, DNA was purified from the agarose gel with the QIAQuick Gel 
Extraction Kit. Introduced DNA amounts depended on the intended use of the products; for 
analytical digestions only 0.5 to 1 µg DNA was used in contrast to preparative digestions 
were 10 to 20 µg were applied. 
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Reaction mix for digestion:  10 - 20 µg  DNA 
 10 - 20  U  per enzyme 
 2.5  µl 10 x reaction buffer 
 ad 25  µl  H2O 
 
6.1.4 Purification of DNA 
DNA was purified (i.e. after enzymatic cleavage to remove buffer compounds) with the 
Roche PCR Purification Kit according to the manufacturer’s instructions. DNA was eluted in 
30 to 50 µl DNAse free water whereby remaining traces of column material were strictly 
avoided to be co-transferred as this was found to inhibit further enzymatic reactions. 
 
6.1.5 Precipitation of DNA 
DNA had to be precipitated, e.g. before sequencing, to exchange the diluent or to reduce its 
volume. DNA fragments were supplemented with 3 M sodium acetate pH 4.6 (1/10 of the 
total volume). Subsequently, two volumes of 100% ethanol were added and thoroughly 
mixed. After incubation for 20 min at -20°C, the DNA was centrifuged for 15 min at 13,000 
rpm. The pellet was then washed with 250 μl of 75% ethanol and centrifuged again 
(identical settings). The supernatant was carefully discarded and the pellet was left to dry 
for 10 minutes before 6 min Speed-Vac centrifugation was performed to remove remaining 
ethanol. Finally, the DNA was resuspended in H2O or an appropriate buffer for subsequent 
procedures. 
 
6.1.6 Dephosphorylation of 5’ends of DNA 
DNA was treated with calf-intestinal alkaline phosphatase (CIP) after digestion with only one 
enzyme or after blunt end cutting. CIP removes phosphate residues of 5’ends and thereby 
avoids re-ligation of a DNA vector without insertion of the desired insert. After the digest, 2 
μl of CIP enzyme were added directly to the vector DNA. The reaction was carried out for 
15 min at 37°C and for 15 min at 56°C. Phosphatase was removed by DNA purification with 
the Roche PCR Purification Kit (6.1.4). 
 
6.1.7 Analytic and preparative agarose gel electrophoresis 
DNA molecules carry negatively charged phosphate residues which move towards the 
positively charged anode in an electrical field. The velocity of the DNA thereby depends on 
the fragment size. These characteristics are utilized for gel electrophoresis.  
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To prepare a 1 % agarose gel, 1 g of powdered agarose was dissolved in 100 ml 1 x TBE 
buffer by boiling in a microwave. After cooling to approx. 60 °C, ethidium bromide was 
added and the solution was poured in a gel casting tray containing a comb. The solidified 
gel was transferred into a 1 x TBE buffer containing chamber. Samples were mixed with 6 x 
loading dye and - depending on the expected product size - 100 bp or 1 kb ladder was 
used. After loading into the gel slots, electrophoresis was performed for 20 to 30 minutes at 
110 - 140 V. Analytical gels were imaged under UV light (254 nm) to visualize DNA bands 
stained with fluorescent ethidium bromide. Preparative gels were only exposed to 366 nm 
UV light to avoid UV induced mutations. Size and concentration of DNA fragments were 
determined by comparison to the marker. 
 
6.1.8 Purification of DNA fragments from agarose gels 
For cloning, plasmid DNA or PCR products were digested in a preparative scale (6.1.3) and 
separated by preparative agarose gel electrophoresis (6.1.7). The desired fragments were 
visualized by UV light (366 nm) and excised using a scalpel. Subsequently, the DNA was 
purified from the agarose using the QiaQuick Gel Extraction Kit following the manufacturer’s 
instructions. 
 
6.1.9 Ligation of DNA fragments 
After digestion and purification of vector and insert DNA, the ligation reaction was carried 
out. The linearised vector DNA was mixed with the insert DNA fragment in a ratio of 1:3. To 
insert the target DNA into the expression plasmid, the following mixture was used: 
Ligation reaction mixture: 0.1 - 0.5 µg linearised plasmid DNA (vector) 
 0.5 – 1  µg  insert-DNA fragment 
 1  µl T4-DNA-ligase 
 2 µl 10 x ligation buffer 
 Ad 20  µl  H2O 
The ligation reaction was incubated over night at 12 °C in a water bath and was then used 
to transform bacteria (6.2.2). 
 
6.1.10 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify DNA fragments with specific 
primers to prepare DNA for cloning experiments, to check for a desired DNA sequence or to 
provide DNA for subsequent sequencing reactions. The p16INK4a-coding DNA region for 
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cloning of the recombinant protein was amplified from Hela cDNA. The following mixture 
was used by default: 
 
Standard and 50 ng template DNA (for colony PCR: 0.3 µl inactivated culture) 
Colony PCR: 0.5 µl primer forward (10 pmol/µl) 
 0.5 µl primer reverse (10 pmol/µl) 
 0.5 µl dNTPs (10 mM) 
 2.5 µl 10 x PCR buffer 
 1.5 µl MgCl2 
 0.3 µl  DMSO 
 0.3 µl DNA Taq-polymerase 
 ad 25 µl H2O 
 
After transformation of bacteria (6.2.2), colony PCR was performed to check selected 
clones for containing the correct plasmid. To obtain template DNA, a single colony was 
tipped with an autoclaved wooden toothpick and transferred to 25 µl aqua bidest. This 
mixture was inactivated for 10 minutes at 99 °C and further used as template for the colony 
PCR reaction. 
 
DNA Sequencing 
 
Cloning products were sequenced with the ABI 3100 device to confirm the correct DNA 
sequence. The method of choice is called dye terminator “Sanger” sequencing. The test 
sequence was first amplified by PCR in presence of the BigDye terminator reagent. The 
reagent contains four di-deoxynucleotide chain terminators which are labeled with 
fluorescent dyes, each of which with different wavelengths of fluorescence and emission. 
The growing chain is simultaneously terminated and labeled with the dye that corresponds 
to that base. During sequencing, all four colors are assessed within the same capillary and 
false stops go undetected because no dye is attached. These signals generated by capillary 
electrophoresis are then converted to an electronic DNA sequence trace chromatogram. 
For In-house DNA Sequencing a special Sequencing PCR had to be performed: 
 
Sequencing PCR: 0.5 µg template DNA (~ 1 µl of miniprep DNA sample) 
 1.5 µl primer forward (10 pmol/µl) 
 4 µl RR-Mix BigDye terminator reagent 
 4 µl  Sequencing Buffer 
 ad 20 µl  H2O 
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The DNA was precipitated and the resulting pellet was re-suspended in 12 µl Hidi buffer, 
transferred to a 96 well sequencing plate and closed with the appropriate cap. Probes were 
stored at 4 °C or directly sequenced. 
 
All PCR reactions were prepared on ice, mixed and put in the pre-heated PCR machine. 
The following PCR programs were used to amplify the DNA fragments: 
 
Standard PCR Colony PCR DNA Sequencing 
94°C  4 min or 
          15 min (HotStart Taq) 
95°C  4 min or 
          15 min (HotStart Taq) 
96°C  10 min 
94°C  30 sec 
55°C  45 sec 
72°C  90 sec 
x 35 
95°C  40 sec 
56°C  40 sec 
72°C  90 sec 
x 35 
96°C  25 sec 
56°C  35 sec 
60°C  4 sec 
x 25 
 72°C  6 min  
 
The PCR products were analyzed by agarose gel electrophoresis (6.1.7) and purified using 
the Roche PCR purification kit following the manufacturer’s instructions. 
 
6.2 Microbiological methods 
6.2.1 Culture and storage of bacteria 
Bacteria were cultivated at 37°C either in liquid culture or on agar plates. For selection of 
bacteria with a resistance gene, the appropriate antibiotics were added. Liquid cultures 
were inoculated directly from glycerol stocks or from single colonies picked from agar plates 
and were subsequently incubated shaking with 200 rpm at 37°C overnight. Clones were 
obtained by streaking bacteria onto agar plates with the help of a glass pipette. 
For long term storage, glycerol stocks were prepared by mixing 500 µl of an overnight 
bacteria culture with 500 µl sterile glycerin (86 %) in a cryo-conservation tube. The 
suspension was stored at -80°C.  
 
6.2.2 Transformation of bacteria by heat shock 
Free DNA, usually in plasmid form, can be transferred into competent E. coli strains by 
different methods, e.g. electroporation, chemical or heat shock transformation. During this 
thesis, bacteria were transformed using heat shock. For enhanced effectiveness, plasmids 
and respectively ligation reactions were first introduced into competent E. coli Top10 as this 
strain is suitable for highly efficient transformation and plasmid isolation. A 50 µl aliquot of 
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competent bacteria was thawed and incubated on ice with 2-5 µl of the ligation reaction (or 
100 - 200 ng of isolated Plasmid DNA) for 30 minutes. The cells were then heat shocked in 
a 42°C water bath for exactly 30 seconds, thus allowing the DNA to enter the cells. After 
subsequent replacement on ice for 2 minutes, 250 μl of room temperature SOC medium 
was added and the mixture was shaken for 1 hour. To select transformed clones, 60-80 µl 
were spread onto an ampicillin-containing agar plate and incubated over night at 37°C. 
Colony PCR (6.1.10) was performed to check selected colonies for the appropriate insert 
and successfully transformed clones were used to isolate plasmid DNA from an overnight 
culture. 
This plasmid DNA was then transformed into the expression strains E. coli BL21 and 
Rosetta. Thereto, a 20 µl aliquot of competent cells was transformed with 1 µl plasmid DNA 
as described above and 80 µl SOC medium were added before plating onto an LB-agar 
plate containing the appropriate antibiotics.  
 
6.3 Cultivation and manipulation of eukaryotic cells 
6.3.1 Cryo-conservation and thawing of eukaryotic cells 
For long-term storage, cells were harvested (usually from T175 flasks) and pelleted by 
centrifugation. Between 5x106/ml and 1x107/ml cells were re-suspended in freezing medium 
(10% DMSO in FCS) and 0.5 or 1 ml of this cell suspension was transferred to cryo-vials. 
Cells were gradually cooled to -80°C in a cell freezing box overnight. Frozen cell vials were 
either stored at -80°C or transferred to liquid nitrogen tanks. For re-utilization, cell vials were 
topped up with pre-warmed medium and transferred to a centrifuge tube where 5 ml of the 
appropriate cultivation medium was added. After centrifugation for 7 min at 1,200 rpm, cells 
were resuspended in 5 to 10 ml medium (specific for cell type) and transferred to T25 or 
T75 culture flasks depending on frozen cell number and expected culture viability. 
6.3.2 Determination of cell number and vitality 
Cells were counted using Neubauer counting chambers (hemocytometer). Live and dead 
cells were discriminated by dilution in trypan blue; depending on the expected cell numbers 
different ratios of cells to trypan blue were used, usually 1:2 for cultured cells and 1:20 for 
mouse splenocytes. 
 
              
                        
                         
           
 
The mean number of cells in one square multiplied with the dilution factor and 104 
represents the number of cells per ml in the original suspension. 
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6.3.3 Transfection of mammalian cells 
For in vivo tumor protection and regression experiments, a p16INK4a -expressing mouse cell 
line is needed. To generate this cell line, different transfection methods were tested in a 
preliminary test with a pmaxGFP test plasmid to determine transfection efficacy and to 
choose the best method for further experiments. To this end, RMA-S cells were grown to 
~70% confluency and transfected with  
a. Nucleofection, 
b. Effectene Transfection Reagent, 
c. xtremeGENE 9 DNA Transfection Reagent, 
d. PromoFectin Transfection Reagent or 
e. FuGENE HD Transfection Reagent 
according to the manufacturers’ instructions. Brief protocols under specification of the 
applied cell numbers and DNA amounts are given below. For transfections b) - e), 7 x 104 
RMA-S cells were seeded the day before transfection in 500 µl medium per well in a 48 well 
plate. For each transfection reagent b) - e) triplicates were prepared.  
Transfection efficacy was monitored by fluorescence microscopy and the percentage of 
green fluorescent cells was evaluated in comparison to non-fluorescent cells 3, 20 and 48 
hours post transfection. 
 
a) Two days before transfection 5-7 x 106 cells were seeded into 10 cm cell culture dishes. 
For one nucleofection sample 2 x 106 cells were used, 2 µg maxGFP plasmid and 100 µl 
Nucleofector solution were added. Programs X001, A023, A024, A030, A20, T20, T30, X05, 
L29 and D23 were tested in duplicates. Negative controls were treated equally but without 
plasmid added.  
 
b) The day before transfection, 7 x 104 cells per well in 500 µl medium were seeded in a 48 
well plate. For one transfection, 0.15 µg test plasmid (maxGFP) was dissolved in DNA 
condensation buffer to a total volume of 50 µl and 1.2 µl enhancer was added. After room 
temperature incubation and spin down, 4 µl Effectene transfection reagent was added and 
mixed. Cells were washed with PBS during the 5 - 10 min incubation (RT) and 150 µl fresh 
growth medium was added to the cells. The transformation mixture was supplemented with 
200 µl medium, mixed and added drop-wise to the cells. 
 
c) 7 x 104 cells per well in 500 µl medium were seeded one day before transfection in a 48 
well plate. 3 µl X-tremeGENE 9 DNA transfection reagent was diluted in 100 µl Opti-MEM 
(3:1 ratio). 1 µg pmaxGFP DNA was added and mixed gently. After 15 min room 
temperature incubation, 15 µl of the transfection reagent:DNA complex was added drop-
wise to the cells and evenly distributed.   
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d) One day before transfection, 7 x 104 cells per well in 500 µl medium were seeded in a 48 
well plate. For each well, 0.5 µg plasmid DNA (maxGFP) was diluted into 25 µl Opti-MEM 
and 1 µl PromoFectin / well was also diluted into 25 µl Opti-MEM. Both dilutions were mixed 
and incubated 15 - 30 minutes at room temperature. Then the 50 µl mixture was added 
drop-wise to the cells in serum containing RPMI medium. 
e) Cells were plated 24 hours before transfection (7 x 104 cells / well in 500 µl medium in a 
48 well plate). On the day of transfection, 2 µg pmaxGFP were diluted in 100 µl Opti-MEM 
and 6 µl FuGene was added. After 15 min RT incubation of the FuGene / DNA mixture, 
12.5 µl were added per well. 
 
6.3.4 Production of Ripa-lysates for protein analysis 
Cells were cultured in 10 cm dishes till ~90% confluence. The medium was aspirated and 
the cells were gently washed with 3 ml PBS which was aspirated again. 1 ml PBS was 
added; cells were removed from the culture vessel with a cell scraper and transferred to a 
sterile tube. The cell suspension was centrifuged 10 min at 1200 rpm and PBS was 
discarded. The cell pellets were stored at -20°C or subsequently re-suspended in 200 µl 
RIPA buffer. This re-suspension and all of the following steps were performed at 4°C on ice. 
After addition of RIPA buffer, cells were sonicated for 30 seconds and put on a rotation 
incubator at 4 °C for one hour. The protein containing supernatant was then transferred to 
another reaction tube and frozen at -20°C for further use. 
 
6.4 Purification and analysis of recombinant proteins 
6.4.1 Purification of HPV16 L1 capsomeres and chimeric fusion proteins combining 
HPV16 L1 and p16INK4a from E. coli 
Protein expression 
For the expression of GST-HPV16 L1 and the chimeric proteins containing GST, HPV16 L1 
and p16INK4a, E. coli Rosetta or BL21 bacteria were transformed with the pGex-4T-2 vector 
containing the respective genes (5.2.1). TB medium was inoculated in a ratio of 1:100 with 
an overnight culture (LB) of the plasmid containing bacteria and incubated while shaking at 
200 rpm at 37°C. As soon as the cultures reached an optical density (OD600nm) of ~ 2.0 to 
3.0 (respectively two following OD600 values indicated stationary phase entry), bacteria 
were cooled for 5 min on ice before adding IPTG to a final concentration of 0.1 mM to 
induce protein expression. After 16 to 18 h incubation at 200 rpm at 22 °C, bacteria were 
harvested by centrifugation for 20 min at 4,000 rpm at 4°C (874 rotor). 
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The HPV16 L1 expressed in E. coli was predominantly found to build intracellular inclusion 
bodies what also holds true for the chimeric capsomeres containing p16INK4a and L1. 
Although a small percentage of the protein was expressed in soluble form, sufficient 
amounts could not be purified with the available techniques. Therefore, we decided to 
establish an inclusion body purification protocol to overcome quantity issues. Shortly, the 
inclusion bodies were washed, cells were disrupted with a French press and the protein was 
extracted from the resulting pellet. Denatured protein was then refolded by dialysis and 
could be used for further studies. 
Inclusion body preparation 
HPV16 L1 capsomeres and chimeric capsomeres were purified using an adapted protocol 
described in the iFOLD® Protein Refolding System 1 User Protocol by Novagene [101]. 
Fresh or frozen cell pellets were re-suspended in IB Resuspension Buffer (5.4.2; 10 ml / 1 g 
cell paste) supplemented with protease inhibitor cocktail (1 tablet per 50 ml). 20 µl Lysonase 
were added per gram cell pellet and stirred for 15 minutes. Bacteria were lysed using a 
high-pressure homogenizer (French press). Subsequently ATP and MgCl2 were added to 
the lysate to final concentrations of 2 and 5 mM, respectively. After 1 h incubation at room 
temperature, Triton X-100 was added to a final concentration of 1 % and incubated for 15 
minutes on a roller mixer. Cell lysates were centrifuged at 8.000 x g (~10.000 rpm - SS-34 
rotor, Sorvall) for 15 minutes and the supernatant was discarded. The resulting pellets were 
washed with IB Wash Buffer (10 ml buffer / 1 g cell pellet) whereby complete resuspension 
was achieved with the help of a Potter Elvehjem Homogenizer. The suspension was 
centrifuged again and the Triton X-100 washing was repeated one more time. After the 
second washing and centrifugation, remaining Triton X-100 was removed by washing the 
pellet twice in Resuspension Buffer, as described above. The purified inclusion body pellets 
were stored at -80°C until further use. 
Denaturing of inclusion bodies and refolding of the protein 
Per 0.5 g washed inclusion body pellet 10 ml Denaturing Buffer (5.4.2) was added and 
complete homogenization was achieved with a Potter Homogenizer. The solution was 
supplemented with 1.75 ml 30 % N-Lauroylsarcosine (5 % final conc.) and agitated on a 
roller mixer until it cleared after 30 min to 2 h. The solubilized, denatured protein was 
cleared by centrifugation at 25.000 x g (~18.000 rpm - SS-34 rotor, Sorvall) for 15 minutes 
at 4 °C. The supernatant was collected and dialyzed (MWCO 3.500 Da) against Dialysis 
Buffer (5.4.2) whereby a volume of 0.5 L was used per 10 ml denatured protein solution. 
After 4 hours of dialysis, the buffer was exchanged by freshly prepared buffer and dialyzed 
over night at 4°C. The refolded protein was then removed from the dialysis tube and further 
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analyzed by electron microscopy (6.4.9). Protein concentration was determined with the 2-D 
Quant Kit (GE Healthcare). 
 
6.4.2 Purification of p16INK4a from E. coli 
Protein expression 
For the expression of GST-p16INK4a, bacteria were transformed with the pGex-4T-2 vector 
containing the full-length p16INK4a gene (5.2.1.). TB medium was inoculated in a ratio of 
1:100 with an overnight culture (LB) of the plasmid containing bacteria and incubated while 
shaking at 200 rpm at 37°C. As soon as the cultures reached an optical density (OD600nm) 
of 2 - 3, bacteria were cooled for 5 min on ice before adding IPTG to a final concentration of 
0.1 mM to induce protein expression. After 16 to 18 h incubation at 200 rpm at 22 °C, 
bacteria were harvested by centrifugation for 20 min at 4,000 rpm at 4°C (874 rotor). 
As p16INK4a was found to be soluble expressed from E. coli cultures, the protein was purified 
by means of affinity chromatography. Endotoxin removal was achieved by triton X-114 
treatment (6.4.11).  
Preparation of cell lysates 
The fusion protein was purified based on a protocol originally developed by Chen and co-
workers [37]. We decided not to remove the GST tag from the p16INK4a protein to ensure 
highest possible equality for immunological studies, as the GST tag was also not removed 
for the HPV16 L1 protein and the chimeric capsomeres purified from inclusion bodies 
(6.4.1). Fresh or frozen cell pellets were re-suspended in IB Resuspension Buffer (5.4.2; 10 
ml / 1 g cell paste) supplemented with protease inhibitor cocktail (1 tablet per 50 ml). 20 µl 
Lysonase were added per gram cell pellet and stirred for 15 minutes. Bacteria were lysed 
using a high-pressure homogeniser (French press). Subsequently ATP and MgCl2 were 
added to the lysate to final concentrations of 2 and 5 mM, respectively. After 1 h incubation 
at room temperature, cell lysates were centrifuged at 8.000 x g (~10.000 rpm - SS-34 rotor, 
Sorvall) for 15 minutes and the p16INK4a containing supernatant was used for further 
purification. 
Affinity Chromatography 
The cell lysate containing the GST-p16INK4a protein was slowly (0.1 ml/min) loaded onto a 5 
ml GSTrap FF column (GE Healthcare) equilibrated in buffer L at 4°C. After washing the 
column with 10 to 20 bed volumes of buffer L (1.5 ml/min) the bound protein was eluted with 
3 fractions of 3 ml Buffer L + 20 mM glutathione. The GSTrap columns were cleaned by 
washing with 2 CVs of 20 mM glutathione solution and 5 CVs of 6M GuHCl cleaning 
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solution. Afterwards columns were washed with 20-30 CVs of PBS and stored in 20% 
ethanol at 4°C.  
 
6.4.3 Explorative protein purification methods 
Denaturing of inclusion bodies 
Inclusion bodies were denatured with 5 % N-Lauroylsarcosine, urea (4, 6 and 8 M) and 6 M 
guanidine hydrochloride. The protein lysate was incubated with the respective denaturing 
agent at RT on a roller mixer until the solution became clear. 
Dialysis / Refolding screen  
Dialysis conditions for denatured proteins were tested in small scale to determine optimal 
protein concentration and buffer receipts for refolding. Thereto, a 3,500 Da dialysis 
membrane was cut into 2 x 2 cm squares and equilibrated in aqua bidest. 1.5 ml Protein 
LoBind Eppendorf reaction tubes were cut at the 1.5 mark and the lid was filled with 100 µl 
of the denatured protein; diluted in denaturing buffer if required. Then, the dialysis 
membrane was clamped between the lid and the remaining reaction tube and put into the 
dialysis buffer of choice over night at 4°C. The next day, absorption at 340 nm was 
measured to quantify the amount of precipitated protein. The lower the value, the more 
soluble protein was present in the solution. This method allows testing of different buffer 
conditions and protein dilutions in an easy and economy way. 
 
Other refolding methods  
Refolding of denatured protein was attempted by rapidly diluting it into the buffer of choice. 
A fructose-based polymer, NV10 (NVoy) was also tested for refolding purposes. 
 
Other purification attempts  
The soluble expressed fractions of HPV16 L1 capsomeres and p16INK4a fusion proteins were 
also purified using affinity chromatography (GSTrap) followed by size exclusion 
chromatography: Bacteria cell lysates were cleared by centrifugation and then slowly 
(0.1 ml/min) loaded onto a GSTrap column (GE Healthcare) at 4°C. After washing the 
column with 10–20 bed volumes of buffer L, 40 U per ml bed volume of thrombin protease 
(GE Healthcare) in buffer L was added and the cleavage reaction was performed at RT for 
18 h. Subsequently, the protein was eluted in buffer L. For further purification the GSTrap 
eluate was dialyzed against modified buffer L (Lmod) for 2 h at RT and subsequently run on 
the SEC column Superdex200 (GE Healthcare). 
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Also ProteinG and CnBr coupled anti-GST antibodies as well as size exclusion and ion 
exchange chromatography were applied to purify refolded proteins after IB purification 
(6.4.1). 
 
6.4.4 Denaturing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Analytical protein electrophoresis was performed using the Novex NuPAGE® SDS-PAGE 
gel system which is a polyacrylamide gel electrophoresis system that simulates the 
denaturing conditions of the traditional Laemmli system (Tris-Glycine SDS-PAGE gels) 
[139]. SDS-PAGE facilitates the separation of denatured proteins depending on their 
electrophoretic mobility which is a function of the molecular weight, charge and 
conformation of the molecule. 
Samples were prepared according to the manufacturer’s instructions as reduced samples 
and heated for 10 min at 70°C before loading onto the gel. The reaction tubes were spun 
down shortly to collect the liquid at the base of the tube. The appropriate volume and 
protein mass was then loaded and the gel was run for 35 minutes at 200 V. 
 
6.4.5 Coomassie-staining of protein gels 
Protein gels were Coomassie-stained after electrophoresis (6.4.4) using either the 
Coomassie G-250 SimplyBlue™ SafeStain reagent following the manufacturer’s instructions 
or a self-made Coomassie Staining Solution (see 5.4.4 for details) over night. To reduce 
background staining of coomassie gels (e.g. after overnight staining), gels were waved for 
10 to 60 minutes in 10 % ethanol and subsequently washed with aqua bidest. 
 
6.4.6 Silver-staining of protein gels 
Silver staining of protein gels was performed according to the manufacturer’s instructions 
using the SilverQuest Silver Staining Kit (Invitrogen). 
 
6.4.7 Western blot analysis 
The western blot technique is a sensitive method to detect even small amounts of s special 
protein. The sample is separated by means of gel electrophoresis (6.4.4) and subsequently 
transferred to a nitrocellulose membrane where they can be stained with antibodies 
specifically binding to the target protein. 
The western blot was performed according to the manufacturer’s instructions (Invitrogen, 
“Using the XCell II Blot module”). Shortly, the transfer buffer was prepared while the gels 
were still in process. After ending of the run, the gels were carefully removed from the gel 
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cassette with the help of a special knife and placed in the pre-soaked nitrocellulose 
membrane filter paper sandwich. Trapped air bubbles were removed by gently rolling over 
the prepared sandwich using a glass pipette. Pre-soaked blotting pads were added as 
depicted in Figure 10; then, the blot module was inserted into the buffer chamber, filled with 
transfer buffer and run at 30 V for 1 hour.  
 
 
Figure 10: Western Blot - sandwich setup (adapeted from 
Invitrogen, XCell II™ Blot Module EI9051 [140]) 
 
 
Afterwards, the membrane was waved in aqua bidest. and immobilized, separated proteins 
were stained with Ponceau Red solution (Sigma-Aldrich) to ensure successful transfer. The 
membrane was transferred to a 50 ml falcon tube with the protein side oriented to the inside 
of the tube without overlaps. To avoid unspecific antibody binding, the membranes were 
blocked with blocking solution (5.4.4) for 1 h under gentle agitation. The antigen-specific 
antibody of interest (5.2.4) was diluted in blocking solution and incubated for 1 at room 
temperature or at 4 °C over night on a roller mixer. Unbound antibody was removed by 
washing the membrane 3 times with PBS-T for 15 minutes. Afterwards, the secondary HRP-
labeled antibody (if needed) was applied same way as the first antibody and incubated 1 h. 
The membrane was then washed again and imaged. Thereto, luminol reagent (ECL) was 
applied to the membrane to start the chemiluminescence reaction. In a dark chamber, the 
membrane was exposed 5 sec to 5 min to x-ray films and developed subsequently. 
Membranes could be re-used with another antibody after treatment with stripping buffer 
(5.4.4). Thereto, membranes were completely covered in this buffer and heated for 45 
minutes at 50°C in a water bath. After washing with PBS-T, the above described procedure 
could be repeated starting with the blocking step. 
 
6.4.8 Determination of protein concentrations 
Protein concentrations were determined using the 2-D Quant Kit (GE Healthcare) following 
the manufacturer’s instructions, by Bradford assay or densitometrically using the ImageJ 
software. 
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Bradford assay: 
Protein samples were diluted if necessary and 5 μl were loaded into the wells of a 96well 
plate. BSA was used as calibration standard (5 μl/well) in a 1:2 serial dilution (500, 250, 
125, 63, 32, 16 and 8 µg/ml). H2O was used to determine the blank value with 5 μl per well. 
The Bradford reagent (Bio-Rad) was diluted 1:5 with H2O and 195 μl per well were added to 
the samples. All samples were tested in duplicate. After 2-10 min the absorption was 
measured at 595 nm (reference wavelength 405 nm) using an ELISA reader. With the help 
of the Magellan Software, a BSA standard curve was generated and used for the calculation 
of the protein concentrations of the analysed samples.  
Densitometry: 
Samples were analyzed by SDS-PAGE (6.4.4) and subsequent Coomassie-staining (6.4.5) 
whereby BSA (5, 2.5, 1.25, 0.63 μg) was used as a calibration standard and run on the 
same gel. SDS-PAGE gels were scanned and with the help of ImageJ the intensity of each 
band was measured (peak area). The values for the different BSA amounts were used to 
generate a standard curve and the protein concentrations of the analyzed samples were 
calculated from the standard curve equation. 
 
6.4.9 Sedimentation analysis 
50 μg of purified chimeric fusion proteins (consisting of HPV16 L1 and p16INK4a, 6.4.1) were 
loaded onto 5-50% (w/v; dissolved in dialysis buffer) linear sucrose gradients and 
centrifuged at 36,000 rpm for 3 h at 4°C using the SW41Ti rotor. Fractions of 600 μl (20 
aliquots) were collected from the top of the tube and analyzed by western blotting (6.4.7). 
BSA (4S, Sigma) and HPV16 VLPs purified from insect cells were used for the calibration of 
the gradient. 
 
6.4.10 Transmission electron microscopy 
For evaluation of capsomere preparations by EM, suspensions of interest were prepared by 
'negative staining' with uranyl acetate. Purified proteins were diluted in their appropriate 
buffer to about 0.1 mg/ml protein and 3 µl drops were applied to 400-mesh carbon-coated 
copper-grids, which were rendered hydrophilic by glow-dicharge (0.8 mbar/ 8 µA/ 10 sec). 
After passage through two drops of bi-distilled water, grids were wetted with 1% aqueous 
uranyl acetate, drained with filter paper (Whatman) and air-dried for direct observation in an 
electron microscope (Zeiss EM 912, operated at 120kV; CCD-Camera by Proscan, 
Germany). 
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6.4.11 Determination of endotoxin concentrations and endotoxin removal 
Endotoxin amounts were determined using the LAL (limulus amoebocyte lysate) based 
colorimetric assay QCL-1000 (Lonza) following the manufacturer’s instructions. 
Treatment with Triton X-114 was used to remove endotoxin contaminations from protein 
preparations (6.4.2) purified with affinity and size exclusion chromatography. Inclusion body 
preparations were found to contain no residual endotoxin contaminations what is due to the 
Triton X-100 washing steps that were performed to purify the inclusion bodies. A suitable 
protocol for endotoxin removal was presented by Aida et al. [141] and was also used by 
Schädlich et al. [130] for the purification of HPV 16 L1 from E. coli. The Triton X-114 phase 
separation technique was therefore used in this project as it resulted in no significant protein 
loss or influence on the structural integrity of the particles. The protein preparations were 
mixed with 1 % Triton X-114 (Sigma), incubated first for 5 min on ice and then for 5 min at 
37°C. To remove the Triton X-114 the samples were centrifuged for 5 min at 12,000 rpm 
and supernatants were collected. The procedure was repeated and endotoxin 
concentrations were measured in the supernatants. 
 
6.4.12 Antigen Capture ELISA 
96-well microtiter plates (Nunc) were coated overnight at 4°C with 50 μl of a polyclonal 
rabbit antiserum (#4543) raised against HPV-16 L1, diluted 1:500 in PBS-TM. The plates 
were washed with PBS-T and blocked for 1 h at 37°C with a blocking solution containing 
PBS, 5% skimmed milk and 0.1% Tween-20 (PBS-TM). Purified proteins were added to the 
wells and incubated for 1 h at 37°C. After four washing steps (200 µl PBS-T / well), 50 μl of 
a HPV-16 L1 conformation specific mouse monoclonal antibody (#1.3.5.15) were added to 
each well in a dilution of 1:1,000 and the plates were incubated for 1 h at 37°C. The plates 
were washed four times and 50 μl of a rabbit anti-mouse peroxidase conjugate was added 
(Thermo Scientific; 1:5,000 in PBS-TM). After 1 h incubation at 37°C the plates were 
washed thoroughly before 100 μl of TMB substrate was used to detect HRP activity. The 
reaction was stopped with 50 µl 1 M H2SO4 after 5 - 20 minutes and the plates were read at 
450 nm in an ELISA reader (reference wavelength: 620nm). 
 
6.5 Immunization of mice 
6.5.1 Immunization by subcutaneous injection  
Mice were immunized subcutaneously at the neck using a blue G23 needle. 5 to 50 μg of 
recombinant antigen was diluted in PBS and mixed; if necessary, with adjuvant. Mice were 
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usually immunized 3 times at biweekly intervals with an injection volume of 100 µl unless 
mentioned otherwise. Negative control mice were treated with PBS with purified irrelevant 
antigens.  
 
6.5.2 Immunization by topical application 
Mice were immunized by topical application with 50 µg recombinant protein formulated in 
50% DMSO. Thereto, it was necessary to shave the back of the mice with an electric 
clipper. Mice were held at their tail and carefully shaved across the grain. Between the first 
shaving and the first antigen application, three days were paused to heal potential wounding 
of the skin.  
Mice were creamed daily for about 1 minute till the mixture was absorbed through the skin. 
This procedure was carried out 2 x 5 days with 2 days rest in-between. Blood and spleens 
were sampled (6.5.3 and 6.5.4) 4 days after the last topical application and analyzed for 
humoral and cellular immune response (6.6). 
 
6.5.3 Blood sampling of immunized mice 
Before each immunization, blood samples were taken by puncture of the superficial 
temporal vein. Final blood samples were taken by cardiac puncture. The blood samples 
were incubated for 30 min to 3 h at room temperature, to allow for complete clotting, and 
then centrifuged for 9 min at 3,000 rpm at 4°C. Supernatants (sera) were transferred into 
clean microcentrifuge tubes and stored at -80°C. 
 
6.5.4 Splenectomy and preparation of spleen cell suspensions 
Mice were sacrificed using carbon dioxide and sterilized with 70% ethanol. All steps were 
carried out in a flow hood under sterile conditions. Spleens were dissected by cutting 
through the skin and peritoneum at the left abdomen below the lowest rib. The connective 
tissue was removed and the spleens were placed in 10 ml sterile PBS on ice until further 
use. To generate a single cell suspension, the spleen was pressed through a metal mesh 
(mesh size: 0.5 mm) into a Petri dish using the plunger of 5 ml-syringe. The cell suspension 
was then transferred into a 15 ml centrifuge tube and harvested by centrifugation (8 min, 
1,200 rpm). The cell pellet was re-suspended in 3 ml pre-warmed ACT lysis buffer (5.5.2) 
and incubated for 5 min in a 37°C water bath in order to lyse erythrocytes. Cells were 
centrifuged again for 8 min at 1,200 rpm, re-suspended in 3 ml RPMI medium and were 
subsequently used in an IFNy ELISpot assay (6.6.3). 
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6.6 Analysis of humoral and cellular immune responses 
6.6.1 VLP-capture ELISA to determine L1-specific antibodies 
96well microtiter plates (Nunc) were coated with 50 μl/well of the purified polyclonal HPV16 
L1-specific serum (#4543) in a 1:500 dilution in PBS at 4°C overnight. All incubation steps 
were performed 1 h at 37°C unless mentioned otherwise and plates were washed after 
each incubation step 4 times with PBS-T. After washing off unbound coating antibody, 
plates were blocked 1 h with 5 % milk in PBS-T. HPV16 VLPs were diluted 1:500 (0.3 
μg/well in blocking solution) and 50 µl per well were added and incubated. Plates were 
washed and sera of immunized mice were applied in duplicates in a 1:10 dilution (100 
µl/well). The positive control “1.3.5.15” (HPV16 L1) was also diluted 1:10. Incubation was 
followed by another washing step and a horseradish peroxidase conjugated anti-mouse IgG 
antibody (50 μl/ well; 1:5000) was applied. After 1 h, plates were washed and 50 µl TMB 
substrate were added to the wells and incubated at room temperature. The reaction was 
stopped after 5 to 10 minutes with 50 µl per well of 1 M H2SO4 and absorbance at 450 nm 
(reference wavelength: 620 nm) was measured in an ELISA reader. Sera were considered 
to be L1 antibody positive if the absorption value was above cut-off. The cut-off value is 
based on the distribution of absorbance values of control sera and was calculated as the 
mean value of negative controls plus three times standard deviation. 
 
6.6.2 p16INK4a - peptide pool ELISA to determine p16INK4a -specific antibodies 
p16INK4a specific antibodies were detected with overlapping peptides covering the complete 
sequence (5.2.3). To this end, 5 peptide pools consisting of 2 or 3 peptides were used by 
default. 96well microtiter plates (Nunc) were coated with a dilution of 40 µg per petide per 
ml in PBS. 50 µl per well were incubated at 4°C overnight. Plates were washed 4 times with 
PBS-T after each step and incubation was performed for 1 h at 37°C. After peptide coating, 
remaining binding sites were blocked with 0.5 % casein in PBS-T (coating for 1 h at room 
temperature. After washing, sera of immunized mice were applied in duplicates in a 1:10 
dilution (50 µl/well) and incubated. Plates were washed again and a horseradish peroxidase 
conjugated anti-mouse IgG antibody (50 μl/ well; 1:5000) was applied and incubated. TMB 
substrate was used to detect HRP activity and the reaction was stopped after 30 minutes 
with 50 µl 1 M H2SO4. The yellow reaction product was read at 450 nm in an ELISA reader 
(reference wavelength: 620nm). Individual sera were scored as antibody-positive or 
negative using a cut-off value that was calculated as the mean value of negative controls 
plus three times standard deviation Sera were considered to be positive if at least one of the 
tested peptide pools showed a value above cut-off. 
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6.6.3 Detection of antigen-specific cytotoxic T-lymphocytes by IFNγ-ELISpot 
An ex vivo IFNγ-ELISpot assay was performed 7 days after the last immunization and all 
steps on day one and two were carried out under sterile conditions in a flow hood. On 
day 1, 96well MultiScreen-HA plates (Millipore) were incubated for 5 minutes with 70 µl of 
70% Ethanol, washed 4 times with 200 µl PBS /well and coated with 100 µl/well anti-mouse 
IFNγ capture antibody (0.6 µg per well, 5.2.4) diluted in PBS. The plates were wrapped in 
aluminium foil and incubated at 4°C over night or at 37°C for 1 - 2 hours. On day 2, plates 
were washed with PBS 4 times and then blocked with 200 µl RPMI culture medium 
supplemented with 10% FCS and Pen/Strep (5.3.2) for 1-2 hours at 37°C. Splenocytes of 
the sacrificed mice (6.5.4) and peptide working solutions (5.2.3) were further processed 
during this incubation time. The blocking medium was removed stepwise and 1.3 - 1.5 x 106 
cells/well were seeded in a volume of 100 µl. Per mouse three wells were used for the 
assay positive control which were stimulated unspecifically with 2 µg ConA per well in 
100 µl; three wells were toped up with 100 µl culture medium for the background negative 
control. Also the test peptides or the p16 peptide pool were each tested in triplicates with 10 
ng/well antigenic peptide in 100 µl medium. A typical loading scheme is depicted in Figure 
11, yet it was adapted corresponding to the number of mice and peptides tested. After 
incubation for 18 to 20 hours at 37°C cells were removed and plates were washed 4 times 
with PBS-0.01% Tween20 and once with PBS. 0.1 µg of a biotinylated rat anti-mouse IFNγ 
antibody diluted in PBS (100 µl) were added per well and incubated 1 - 2 h at room 
temperature. After removing the secondary antibody, plates were washed 6 times with PBS-
T and once with PBS. Then, 100 µl per well streptavidin-alkaline phosphatase diluted 
1:1,000 in PBS were added and incubated for 30 min at room temperature in the dark. 
Plates were subsequently washed 3 times with PBS-T and 3 times with PBS and 100 µl/well 
BCTP/NBT substrate (Sigma) were added and incubated in the dark. After 5 to 10 minutes, 
the staining reaction was stopped by rinsing the plates extensively with distilled water and 
plates were left to dry over night. Spots were then quantified with an ELISpot reader. 
 
 
Figure 11: Exemplary loading scheme for 
IFNγ ELISpot. Negative control: RPMI 
medium; positive control: Concavalin A 
mitogen; test peptides: antigen-specific 
CTL epitope peptide L1 or p16
INK4a
 
overlapping peptides (pooled). 
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III. Results 
In the field of prophylactic HPV vaccination much advancement was achieved in the recent 
years leading to reduced incidence of HPV-associated lesions [142]; although this only 
holds true for high-income countries. The need for effective therapeutics targeting 
neoplastic precursors and cancer is still high, especially in low-resource countries with 
inadequate screening coverage. Furthermore, women who are already infected with 
papillomaviruses do not benefit from the available prophylactic vaccines as these do not 
have any therapeutic effect [140, 143]. This led to various strategies in the development of 
therapeutic vaccines, with more or less effect considering clinical outcome. 
In this thesis, three different constructs containing L1 and p16INK4a were cloned into the 
bacterial expression system. The GST-fusion proteins were expressed in E. coli and a 
suitable purification protocol was established. The purified proteins were then evaluated for 
their structural characteristics and immunological potential. These chimeric capsomeres 
produced in bacteria present a cost effective alternative to established VLP-based vaccines 
and could present a unique therapeutic approach by activating the immune system to target 
p16INK4a overexpressing cancer cells. 
 
7 Generation and validation of the expression vectors 
To evaluate the antigenic effect of different structural isoforms three constructs containing 
L1 and p16INK4a were generated by means of PCR cloning (7.1) and evaluated by restriction 
digestion and sequence analysis (7.2). Therefore, the complete p16INK4a encoding cDNA 
sequence was cloned a) upstream and b) downstream of a modified HPV16 L1 sequence 
[76] into the pGex-4T-2 expression vector. For the third construct c) the helix 4 region of L1 
was replaced by p16INK4a [129]. The pGex-4T-2 vector was used to enable expression as 
GST-fusion proteins and purification by GSTrap affinity chromatography and was kindly 
provided by Dr. Lysann Schädlich and Prof. Lutz Gissmann (DKFZ Heidelberg, Germany). 
The vector construct used as a starting point for all further cloning attempts contained the 
modified HPV16 L1 sequence (L1ΔN10Δ408-431ΔC29) and the full length HPV16 E7 
oncogene which was fused to the C-terminus of the L1 sequence. 
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7.1 Cloning of the expression plasmids 
pGex-L1-p16INK4a 
The pGex-L1ΔN10∆h4ΔC29-p16INK4a construct was cloned by means of PCR, whereby the 
p16INK4a sequence was amplified from HeLa cDNA with primers containing the appropriate 
restriction sites NsiI and HindIII. The E7 sequence was cut out of the origin vector pGex-
L1ΔN10∆h4ΔC29-E7 at the restriction sites and replaced with p16INK4a DNA (see Figure 12).  
 
  
Figure 12: Cloning of pGex-L1-p16
INK4a
.  
L1-p16
INK4a
 was cloned into pGex-4T-2 (6.1) by cutting out the E7 insert from the original plasmid and replacing 
it with p16
INK4a
. The plasmid was transformed into in the E. coli strains BL21 and Rosetta. 
 
During digestion with the restriction enzymes, processing was kept under surveillance with 
agarose gel electrophoresis (Figure 13). Each step entails a loss of DNA which is especially 
due to purifications after each digestion. These purifications are necessary because the two 
restriction enzymes require different buffer conditions. The decreasing DNA amount is 
visualized by gel electrophoresis shown in Figure 13. The DNA amount of the p16INK4a insert 
is initially lower as this is a purified PCR product.  
 
 
Figure 13: Single steps of the restriction digest were monitored by agarose gel electrophoresis. a: vector DNA, 
b: insert DNA. I) before digestion, II) after HindIII digest, III) after NsiI digest, IV) after final purification. Cut out 
E7 is present in III and IV a but hardly visible due to the very low DNA amount.  
 
To avoid excessive re-insertion of the original E7 insert, the vector DNA was separated from 
the cut out insert and excised from an agarose gel before it was used for the ligation 
reaction with the p16INK4a insert. E. coli Top10 cells were transformed with the ligation 
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mixture and colony PCR was applied to select clones with the desired insert. Figure 14 
shows the PCR products that were obtained with plasmid DNA of a selected Top10 clone. 
This clone was (amongst others) picked from an agar plate after transformation and its DNA 
was isolated from a saturated over night culture. Column I shows a PCR product of 162 bp 
which was generated with primers binding within the p16 site. The size of the product in II 
was expected to be 216 bp as it is shown in Figure 14. This product was amplified from the 
overlapping region of L1 and p16INK4a with a forward primer binding at the end of the L1 
sequence and a reverse primer that binds at the beginning of p16INK4a. Column III shows a 
568 bp product that was amplified with a forward primer binding at the end of the L1 region 
and a reverse primer binding within the p16 sequence. These results indicate the presence 
of the desired L1-p16INK4a insert due to successfully ligated and transformed plasmid DNA. 
 
 
Figure 14: Colony PCR of a selected E. coli Top10 clone containing pGex-L1-p16 
(template: isolated plasmid DNA). PCR product sizes: I) 162 bp, generated with 
primers p16
INK4a
_forward and p16
INK4a
_reverse, II) 216 bp, generated with L1-p16_ 
forward and L1-p16_reverse, III) 568 bp, generated with seq_L1-p16_forward and 
p16
INK4a
_reverse. 
 
To validate the presence of the correct sized insert after transfection into E. coli Rosetta and 
BL21, isolated plasmid DNA was digested with NsiI and HindIII. Figure 15 shows the cut out 
insert which is 471 bp heavy and therefore in line with the calculated size of the p16INK4a 
insert. 
 
 
Figure 15: Control digest of pGex-L1ΔN10Δh4ΔC29-p16
INK4a
 plasmid DNA with 
restriction endonucleases NsiI and HindIII. Isolated plasmid DNA from I) E. coli 
Rosetta and II) BL21. The expected insert size of 471 bp could be confirmed. 
 
 
The generated pGex-L1-p16INK4a plasmid was used to express the GST-tagged L1ΔN10Δh4 
ΔC29-p16INK4a protein. 
 
pGex-p16INK4a-L1 
pGex-p16INK4a-L1ΔN10∆h4ΔC29 was generated by overlap PCR (see Figure 17). Thereto, 
p16INK4a was amplified from HeLa cDNA with a reverse primer containing the beginning of 
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the L1 sequence (5.2.2). The L1 sequence was amplified from the origin vector pGex-
L1ΔN10∆h4ΔC29-E7 using a forward primer containing the end of the p16INK4a sequence. 
Both PCR products were then used as templates for a third PCR to amplify the complete 
p16INK4a-L1 sequence which was then cloned into the expression vector as depicted in 
Figure 16. 
 
  
Figure 16: Cloning of p16
INK4a
-L1.  
p16
INK4a
 -L1 was cloned into pGex-4T-2 (6.1) by using an overlap PCR strategy (see below). The plasmid was 
transformed into in the E. coli strains BL21 and Rosetta. 
 
   
Figure 17: Schematic representation of the overlap PCR strategy used to generate the p16
INK4a
-L1 insert from I) 
HeLa cDNA (for the amplification of the p16
INK4a
 sequence) and II) the origin vector L1ΔN10∆h4ΔC29-E7 (for 
the amplification of L1ΔN10∆h4ΔC29). The fragments I and II were amplified with primers including the overlap 
sequence and the appropriate restriction sites required for insertion to the vector. In an overlap PCR (III) 
products from I and II were used as templates to generate the p16
INK4a
-L1 insert. 
 
Results of the corresponding polymerase chain reactions (PCRs) are shown in Figure 18. 
All PCRs generated products of the expected size. The 1811 bp fragment (overlap PCR III) 
was digested with BamHI and HindIII to provide sticky ends for the ligation reaction with the 
likewise digested and purified pGex vector backbone.  
 
 
Figure 18: Cloning of the p16
INK4a
-L1 insert. PCR I to amplify the 
p16
INK4a
 sequence with primers p16_BamHI_forward and 
p16L1_reverse (product size: 493 bp), PCR II to amplify the L1 
sequence with primers p16L1_forward and L1_HindIII_reverse 
(product size: 1354 bp), PCR III (overlap PCR) was performed with 
primers p16_BamHI_forward and L1_HindIII_reverse (product size: 
1811 bp). The product from PCR III was ligated into the pGex-4T-2 
backbone and transformed into E. coli Rosetta and BL21. 
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After successful generation of the p16INK4a-L1 insert, it was ligated into the expression 
vector pGex-4T-2 and transformed into E. coli Top10. Plasmid DNA was isolated and a 
control digest was performed to verify the correct insert size of 1797 bp (Figure 19). The 
plasmid DNA was then transformed into E. coli Rosetta and BL21 to express chimeric GST-
p16INK4a-L1ΔN10∆h4ΔC29 capsomeres. 
 
 
Figure 19: Control digest of pGex-p16
INK4a
-L1ΔN10∆h4ΔC29 plasmid DNA 
with restriction endonucleases BamHI and HindIII. Isolated plasmid DNA 
from I) E. coli Top10. The expected insert size of 1797 bp could be 
confirmed. 
 
 
pGex-L1-p16INK4a-L1 
The third insert, L1ΔN10∆h4-p16INK4a-ΔC29 was designed on the basis of a study by Murata 
and colleagues [129] who showed that the helix 4 region of the HPV16 L1 capsomeres can 
function as an antigen display site for non-HPV encoded epitopes. The insert sequence was 
synthesized by Genscript and delivered in a pUC57 vector. After cutting the insert at the 
BamHI and HindIII sites, it was ligated into the pGex-4T-2 expression vector (Figure 20). 
 
 
Figure 20: Cloning of L1-p16
INK4a
 -L1.  
L1-p16
INK4a
 -L1 was cloned into pGEX-4T-2 (6.1) after cutting the insert from a pUC57 vector (Genescript). The 
plasmid was transformed into in the E. coli strains BL21 and Rosetta 
 
After transformation into E. coli, colony PCR (6.1.10) with different primer pairs verified the 
presence of the insert (see Figure 21). pGex-L1-p16INK4a-L1 was used to express the 
chimeric GST-L1ΔN10∆h4-p16INK4a-ΔC29 protein. 
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Figure 21: Colony PCR of the E. coli Rosetta clones, transformed with 
pGex-L1-p16
INK4a
-L1. I: primers pGex-4T-2_seq + seq_p16L1_reverse 
(product size: 183 bp); II: primers L1d_forward + L1d_reverse (product 
size: 242 bp); III: primers p16INK4a_forward + pGex-4T-2_reverse 
(product size: 414 bp). With theses primer pairs, the presence of the 
correct sized insert was verified. 
 
pGex- L1 
The expression plasmid containing only the modified HPV16 L1 (pGex-L1ΔN10∆h4ΔC29) 
was generated by PCR whereby the reverse primer was used to add the HindIII restriction 
site. pGex-L1-E7 was used as template DNA for the reaction. This construct was used for 
the expression of GST-L1 for comparative purposes and to be used as an anitgen for the L1 
control group in the in vivo experiments (see chapter 0). 
 
pGex-p16INK4a 
The p16INK4a sequence was amplified from HeLa cDNA with primers p16_BamHI_forward 
and p16_HindIII_reverse to add the appropriate restriction sites. Vector DNA pGex-4T-2 
and the amplified p16INK4a insert were digested with BamHI and HindIII and purified by 
Gelextraction (Quiagen Gelextraction Kit). Afterwards they were ligated and transformed 
into BL21 and Rosetta to express the GST-p16INK4a fusion protein. 
 
GST-p16INK4a was produced for comparative purposes and as an anitgen for the p16-control 
group in the in vivo experiments (see chapter 0). 
 
7.2  Sequence analysis of the generated plasmids 
To finally validate the recombinant chimeric constructs on the DNA level, all pGex-4T-2 
constructs were sequenced after transformation into the expression strains BL21 and 
Rosetta to finally ensure correct orientation of the insert and to exclude mutations and 
thereby resulting frame shifts or amino acid changes. 
In the following, sequencing results are shown for plasmid DNA isolated from E. coli 
Rosetta as this strain was later used for large scale protein expression. BL21 bacteria were 
transformed in parallel with the exact same plasmid DNA that was extracted from E. coli 
Top10 beforehand. The selected BL21 clones were sequenced and analyzed likewise and 
were also found to contain the correct plasmids (data are not shown). 
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pGex-L1-p16INK4a 
To ensure the correct nucleotide sequence, pGex-L1-p16INK4a transformed clones were 
sequenced with the ABI 3100 (6.1.10) and checked with the SnapGene software and the 
Basic Local Alignment Search Tool (NCBI BLAST).  
Figure 22 shows the sequence alignment map generated with SnapGene. The sequences 
were obtained with the indicated primers (pink, pGex-4T-2_seq, L1p16_forward and 
p16INK4a_forward) and alignments that match the subject sequence are depicted as red 
arrows. It is evident that the correct insert is present in the pGex-L1-p16INK4a construct as 
the critical cutting sites, NsiI and HindIII, were the p16 sequence was introduced, are 
covered by the sequence alignment. 
 
 
Figure 22: pGex-L1ΔN10∆h4ΔC29-p16
INK4a
 sequence alignment map (compiled with SnapGene). Aligned 
sequences are shown as red arrows; primers used for sequencing (ABI 3100, see 6.1.10) are depicted in blue. 
The complete plasmid map is provided in the supplementary material (VII, Figure 63) 
 
pGex-p16INK4a-L1 
Plasmid DNA from pGex-p16INK4a-L1 transformed bacteria was sequenced with primers 
binding in the GST tag (pGex-4T-2_seq), right before the p16-L1 overlap (p16L1_forward) 
and at the end of the L1 region (seq_L1-p16_forward) to validate the insert and the 
overlapping region. Sequence alignment was performed with the SnapGene software and 
the Basic Local Alignment Search Tool (NCBI BLAST).  
Figure 23 shows the sequence alignment map generated with SnapGene. The sequences 
were obtained with the indicated primers (pink) and alignments that match the subject 
sequence are depicted as red arrows. It is evident that the correct insert is present in the 
pGex-p16INK4a-L1 construct as the critical cutting sites, BamHI and HindIII, were the p16-L1 
sequence was introduced, are covered by the sequence alignment. 
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Figure 23: pGex-p16
INK4a
-L1ΔN10∆h4ΔC29 sequence alignment map (compiled with SnapGene). Aligned 
sequences are shown as red arrows; primers used for sequencing (ABI 3100, see 6.1.10) are depicted in blue. 
The complete plasmid map is provided in the supplementary material (VII, Figure 64) 
 
pGex-L1-p16INK4a-L1 
The pGex-L1-p16INK4a-L1 plasmid isolated from transformed clones was sequenced (GATC) 
with primers pGex-4T-2_seq, L1d_forward, p16INK4a_forward pGex-4T-2_reverse. The 
results were analysed with the SnapGene software and the Basic Local Alignment Search 
Tool (NCBI BLAST) to validate the correct nucleotide sequence.  
Figure 24 shows the sequence alignment map generated with SnapGene. The sequences 
were obtained with the indicated primers (pink) and alignments that match the subject 
sequence are depicted as red arrows. It is evident that the correct insert is present in the 
pGex-L1-p16INK4a-L1 construct as the critical cutting sites, BamHI and HindIII, were the L1-
p16-L1 sequence was introduced, are covered by the sequence alignment. 
 
 
Figure 24: pGex- L1ΔN10∆h4-p16
INK4a
-L1ΔC29 sequence alignment map (compiled with SnapGene). Aligned 
sequences are shown as red arrows; primers used for sequencing (GATC) are depicted in blue. The complete 
plasmid map is provided in the supplementary material (VII, Figure 65) 
 
7.3 Conclusions 
The desired pGex-4T-2 vector constructs (inserts shown in Figure 25) could be successfully 
cloned and transformed into the expression strains BL21 and Rosetta. The correct insert 
sequences were confirmed by digestion with the appropriate restriction enzymes and 
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sequencing with different primers. Several gaps and nucleotide mismatches could be 
manually excluded by means of the sequence chromatogram.  
 
 
Figure 25: inserts used for protein expression in E. coli. The HPV16 L1 gene was previously modified to prevent 
capsid assembly [76]. The different constructs are depicted in cartoon format. For comparison, the wild-type 
HPV16 L1 gene is shown at the top. The modifications/features of each construct are shown as follows: grey bar 
- modified HPV16 L1, orange bar - p16
INK4a
 sequence; hatched line - deleted region. To the right of each 
construct map is its complete name of the insert. All genes were cloned into the pGex-4T-2 vector to allow their 
expression and purification as GST-fusion proteins. 
 
8 Protein Expression 
After demonstrating successful cloning of the desired chimeric constructs on the DNA level, 
expression of the recombinant proteins in E. coli Rosetta and BL21 was evaluated and 
optimization attempts were made. Preliminary tests were accomplished with 100 ml small 
scale bacteria cultures to identify optimal growth and expression conditions, to check 
whether the protein of interest is expressed at all and to what extend it is present in soluble 
form. The small scale experiments revealed that all proteins that contain the modified L1 are 
particularly expressed as inclusion bodies and only a low percentage of the overall 
expressed protein could be harvested as soluble fraction. For this reason the large scale 
(5 L) production was used to express and accumulate as much protein as possible although 
it was present as insoluble inclusion bodies. These were purified according to an optimized 
protocol described in 6.4.1. 
 
8.1 Small scale expression - evaluation and optimization 
During exponential growth, optical densities of the bacteria cultures were monitored to 
induce protein expression at an appropriate time point. This would be the late exponential 
phase of growth. It was reported that the optimal OD600 for induction is 4.0 [144], however, 
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we found that the cultures can be grown to a maximum OD600 of 3.0 before entering the 
stationary phase. It was therefore decided to start induction at OD600 2.0 to 3.0, when two 
following OD600 values indicated stationary phase entry. The growth curves are shown in 
Figure 26 and indicate slower growth of the Rosetta cultures in comparison to BL21. 
Stationary phase entry is observable for BL21 L1p16 and Rosetta p16L1 at OD600 ~ 2.0.  
 
 
Figure 26: Growth characteristics of E. coli strains BL21 and Rosetta in Terrific Broth (TB) culture medium. 
Optical densities (OD 600 nm) were measured at different time points to monitor growth phase. 
 
After expression of the protein, the cells were lysed by shear stress and decompression 
using a French press homogenizer. It was repeatedly observed that the bulk of the protein 
is of insoluble nature as it was found in the pelleted fractions after centrifugation as shown 
in Figure 27 and Figure 28. It is evident from Figure 27 that the solubility is equal for all the 
chimeric proteins (1: L1p16, 2: p16L1, 3: L1p16L1) independent of expression strain; also 
pGex-L1ΔN10∆h4ΔC29 transformed bacteria showed this specific solubility pattern (data 
not shown). pGex-p16INK4a expression resulted in completely soluble protein (data not 
shown), indicating responsibility of the L1 proportion for inclusion body formation. 
 
 
Figure 27: Protein amount after cell lysis (French press) in 
the pellet and in the supernatant of E. coli BL21 and 
Rosetta. 1: construct L1p16, 2: construct p16L1, 3: 
construct L1p16L1. After disruption of the bacteria, the 
majority of the protein is found in the pellet as insoluble 
fraction. 
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Figure 28: Analysis of protein solubility with Coomassie and 
antibody staining. BL21 expressing p16L1 are shown 
exemplary as the same pattern was observed for all L1 
containing constructs. Bacteria were disrupted via French 
press and analyzed for their p16L1 fusion protein content. The 
bulk protein is present in the pelleted fraction; only small 
amounts that are rarely detectable by Coomassie staining are 
soluble. 
 
Altogether it is evident that the proteins of interest are strongly overexpressed from the 
respective pGex vectors. As the supernatant samples miss this dominant band, it is obvious 
that solubility of the proteins is not optimal. The major proportion remains insoluble in the 
pellet fraction. 
 
8.1.1 Solubility screen 
To improve solubility of the target protein, a small scale solubility screen was performed 
with one of the constructs pGex-p16INK4a-L1ΔN10∆h4ΔC29 as it was determined that the L1 
containing proteins show similar properties regarding solubility. Therefore, the two 
transformed E. coli strains BL21 and Rosetta were induced with IPTG at optical densities 
0.7 and 2.0 indicating early and late exponential growth phase. Furthermore, increasing 
IPTG concentrations were tested and samples were analyzed 3 and 17 hours post 
induction. After harvesting, the cells were disrupted by sonication and the supernatants 
were analyzed for soluble protein content. It is evident from Figure 29 that the different 
conditions resulted in varying amounts of soluble GST-tagged fusion protein that was 
expected to run at 92 kDa in the SDS-Page. However, with none of the tested conditions, a 
clearly improved soluble expression resulting in a dominant gel band was identified. 
Nevertheless it could be concluded that protein expression is more effective after a longer 
induction period and that the induction should be started at an OD600 of 2.0 to 3.0, 
respectively right before entry to the stationary growth phase. As the increasing IPTG 
concentrations tested did not result in increased soluble expression, 0.1 mM IPTG was 
decided to be a sufficient concentration for further trials. 
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Figure 29: Small scale solubility screen (Coomassie gel, supernatants after cell lysis) using the p16-L1 construct 
to compare different induction conditions and expression strains. 25 ml TB-Medium containing the appropriate 
antibiotics were inoculated with BL21 or Rosetta transformed with pGex-p16
INK4a
-L1ΔN10∆h4ΔC29. The cultures 
were grown to optical densities (OD 600nm) of 0.7 or 2.0 and then induced with IPTG in different molarities (0.1, 
0.5 and 1 mM). The proportion of soluble fusion protein varies with the different conditions, however, no striking 
dominant band could be observed indicating independence of solubility from the induction conditions. 
 
Besides testing different induction conditions, different induction temperatures (15, 22 and 
37 °C) were compared (data not shown). However, also this did not lead to enhanced 
soluble expression of the L1 containing proteins. 
 
8.1.2 Osmosis screen 
To achieve soluble protein expression and, at best, avoid inclusion body formation, another 
small scale experiment was performed with application of heat shock and/or additives to 
increase the cellular concentration of osmolytes as osmotic and/or heat stress was reported 
to protect proteins from misfolding and aggregation [145]. 
Figure 30 shows the growth curves of bacteria under influence of the additives NaCl, 
sorbitol, betaine and glucose - added in mixture or alone and combined with heat shock as 
indicated in the legend. The optical density of 0.8 - 0.9 was chosen for protein induction as it 
resembles the end of the log phase for bacteria grown in LB medium. All the cultures show 
similar growth characteristics, whereby a delay can be observed with all additives in 
comparison to LB medium alone. The presence of 0.5 M sorbitol, 0.5 M NaCl and 1 mM 
betaine results in markedly slower growth of bacteria as the OD600 of 0.8 was reached 
after 6 h of growth in contrast to the other cultures where the required OD was reached after 
approximately 3 hours. 
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Figure 30: Growth curves Osmosis Screen. 10 ml LB medium with different additives was inoculated from an 
overnight culture of p16L1-expressing BL21 bacteria and grown to an optical density (OD600) of 0.8 - 0.9. 
Induction of protein expression was achieved by the addition of 100 µM IPTG. 
 
After 17 hours of IPTG induced protein expression, cultures were harvested and lysed by 
sonication. The lysates were then cleared by centrifugation and supernatants and pellets 
were analyzed by Coomassie staining of a protein gel. Protein expression was increased 
under the influence of 0.5 M sorbitol as shown in Figure 31, lane 2 in comparison to LB 
medium without additives (lane 1). Presence of NaCl resulted in decreased expression 
(lanes 3 and 9) and betaine did not show any effect (lane 4), in fact it weakened the positive 
effect of sorbitol (lane 6). The heat shock was conducted right before IPTG induction and 
resulted in markedly decreased overall protein expression as visible in lanes 7 an 9. 
Comparison of supernatant samples with the pellets reveals no effect on soluble 
expression. The 92 kDa band of GST-p16L1 in the supernatant row is equal for all tested 
conditions, except in case a heat shock was applied where it is even weaker. The 
application of osmolytic and heat shock stress did therefore not improve the proportion of 
soluble expressed target protein. 
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Figure 31: Coomassie gel of the osmosis screen. E. coli BL21 were cultured in LB with different additives and 
two cultures were treated with heat shock additionally. Cells were harvested and disrupted by sonication, 
centrifuged and equal amounts of supernatant and pellet were loaded for SDS-Page. A strong overexpression of 
GST-p16L1 could be observed for the sorbitol supplemented culture (in comparison to LB medium alone), 
whereby the addition of betaine did not improve expression. Addition of NaCl and application of heat shock 
resulted in an increased overall expression. From the supernatant samples it is evident that the application of 
osmolytic and heat shock stress did not improve the proportion of soluble target protein. 
 
8.2 Large scale expression - protein production 
As the small scale experiments did not reveal a suitable method for sufficient soluble protein 
expression, large scale cultivation of bacteria was performed in highly enriched TB-medium. 
Compared to LB-medium (data not shown), the expression in TB-medium led to higher 
overall protein yields.   
It was constantly observed that all L1-containing protein lysates show several smaller 
fragments that were probably caused by degradation events or translation terminations, 
indicating problematic gene transcription or protein translation in E. coli. However, the target 
protein was found to represent the major proportion of the overall expressed proteins which 
was confirmed by Coomassie staining. Some of these truncated fragments could be 
removed during the purification process as described in chapter 9. Figure 32 shows the 
anti-L1 western blots of the capsomere preparations. The proteins were also analyzed with 
an anti-p16 antibody (D7D7, data not shown) which revealed truncated fragments likewise, 
except for the GST-p16INK4a fusion protein that showed no signal as expected. 
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Figure 32: Large Scale Expression Rosetta - anti-L1 western blots 
(MD2H11) of GST-tagged L1-p16, p16L1, L1p16L1 and L1 
supernatants. The three chimeric constructs have a size of 92 kDa 
each, L1 is 75 kDa (all including GST-tag). It was constantly observed 
that the expressed proteins show several smaller truncated 
fragments, probably translation terminations or degradation products. 
 
The protein lysates were also analyzed for co-expression of bacterial chaperones, namely 
GroEL. Western blot analysis (see Figure 33) revealed that E. coli BL21 co-expresses large 
amounts of GroEL in contrast to Rosetta where only minimal GroEL traces could be 
detected. It further turned out that the tightly bound GroEL molecules are difficult to remove 
during protein purification. Also for this reason it was decided to use the Rosetta 
transformed clones for large scale purification attempts. 
 
 
 
Figure 33: anti-GroEL Western Blot (A91/2) of cell lysates from E. coli 
BL21 and Rosetta expressing chimeric proteins L1p16 or p16L1. Equal 
protein amounts were loaded (2 µg per well). Strong expression of 
GroEL is visible in BL21 (detectable after 2 min exposure) in 
comparison to Rosetta where GroEL is only detectable with longer 
exposure time of the western blot (15 min). 
 
8.3 Conclusions 
The three chimeric constructs, L1-p16INK4a p16INK4a-L1 and L1-p16INK4a-L1 as well as L1 and 
p16INK4a could be successfully expressed in E. coli. Lysis of the bacteria revealed low 
solubility of the L1 containing proteins whereby p16INK4a was found to be completely soluble. 
As the bulk protein remains in the pellet, this speaks for massive inclusion body production 
whereby inactive aggregates of protein accumulate and form insoluble structures. 
To improve soluble protein expression, several attempts were made but did not result in 
markedly better solubility. The adaption of induction conditions and temperature as well as 
application of osmotic and/or heat stress did not lead to increased amounts of soluble 
expressed proteins. Therefore, the standard expression conditions (induction at OD600 2 - 
3 with 0.1 mM IPTG for 17 h at 22°C) were used for the protein production. The comparison 
of the two tested E. coli strains, BL21 and Rosetta, did not reveal significant differences 
concerning protein yield. However, substantial co-expression of bacterial GroEL was 
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observed for the E. coli BL21 strain. As these chaperones were always found to be co-
purified, it was decided to use E. coli Rosetta for further purification attempts.  
The expressed fusion proteins contain several truncated fragments that could be identified 
by western blot analysis with anti-L1 and p16INK4a antibodies. This may be due to partial 
degradation, non-optimal gene transcription and/or ribosomal protein translation.  
 
9 Protein Purification 
Protein purification aims in the enrichment of a target protein from a complex biological 
mixture. This is often challenging as a great number of parameters has to be considered to 
maximize protein yield. Efficient protein purification is to select the most appropriate 
techniques to optimize performance while minimizing the number of required steps. It is 
often necessary to perform more than one purification step to reach the desired purity. 
Besides this, many proteins are problematic to purify, e.g. if they don’t fold correctly or are 
expressed predominantly in insoluble form. [146] 
This was also found to be the case for all constructs containing the modified 
L1ΔN10∆h4ΔC29 sequence. Although the proteins were expressed as GST fusions from a 
pGex vector, they were found to be hardly soluble independent of varying expression 
conditions as described in chapter 8. Therefore, a special inclusion body purification 
protocol (6.4.1) was developed to reach protein yields in mg range (9.1). In contrast to the 
L1 containing proteins, p16INK4a was perfectly soluble expressed and was therefore purified 
by affinity chromatography (9.2). In 9.3 results are shown for the GSTrap and SEC 
purification of L1 containing capsomere preparations, as this was also performed to test the 
achievable enrichment from the soluble fraction. As the inclusion body purification did not 
contain a step for the removal of the GST-tag, different attempts were made to separate the 
tag from the protein preparation. These are described in 9.4. Contaminating endotoxins 
were removed by Triton X-114 treatment (9.5) and in 9.6 the purified proteins were 
analyzed by electron microscopy, sedimentation analysis and epitope specific ELISA.  
 
9.1 Inclusion body purification of HPV16 L1 and chimeric capsomeres 
Insoluble L1-containing proteins were purified with a special protocol that included several 
washing and re-suspension steps. The purified inclusion bodies were denatured with 5 % N-
Lauroylsarcosine and refolded by dialysis (for details see 6.4.1). Thereby, E. coli host cell 
proteins could be removed and high recovery of the target proteins was ensured. Figure 34 
shows the GST-tagged proteins present in the bacterial lysat after French press 
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homogenization, the supernatants obtained after centrifugation which contained only small 
amounts of soluble protein as described in chapter 8 and the purified inclusion bodies. It is 
evident that the major proportion of the individual proteins could be transferred through the 
inclusion body purification process with minimal losses. This is one of the most striking 
advantages of using inclusion bodies for the preparation of E. coli proteins. As shown in 
Figure 34, the inclusion bodies could be effectively separated from the large proportion of 
bacterial proteins. Several smaller fragments were detected by coomassie staining which 
were identified to be truncated L1 and p16 containing proteins (see Figure 35). 
 
 
Figure 34: Coomassie stained protein gels before and after inclusion body purification. The bacterial lysates 
show strong overexpression of the target proteins; however the supernatants did not contain suitable amounts 
as shown before. After several washing and re-suspension steps, the purified inclusion body pellets still contain 
the majority of the GST-fusion protein. Several smaller bands were observed to co-purify and were identified as 
truncated target proteins. 
 
After purification of the inclusion bodies, the aggregated and probably misfolded proteins 
had to be transformed into a soluble, at its best, native form. Therefore the proteins were 
first denatured and thereby solubilized with the anionic detergent N-Lauroylsarcosine. 
Subsequent refolding was achieved utilizing dialysis with decreasing concentrations of the 
detergent and salts (for details see 5.4.2 and 6.4.1).  
 
 
Figure 35: Analysis of protein preparations obtained from inclusion body purification after Lauroylsarcosine-
denaturation and refolding of the target proteins. The whole protein content analyzed by coomassie staining, the 
anti-L1 (MD2H11) and the anti-p16 (D7D7) western blots are shown. In each case, the major proportion - 
respectively the dominant band in the coomassie gel - is made up of the target protein as analyzed by western 
blotting. Smaller fragments could also be identified to be predominantly of L1 or p16 origin speaking for 
truncated, co-purified proteins.  
Results  81 
Figure 35 shows the results of the protein preparations obtained from inclusion bodies. For 
each of the L1 containing constructs, coomassie staining, anti-L1 and anti-p16 western blot 
are shown in comparison. The intense bands at ~92 kDa, respectively 75 kDa for GST-L1, 
indicate the GST-tagged fusion proteins. Below this upper dominant band, several smaller 
fragments could be identified in all the preparations. Western blot analysis revealed that 
these fragments must be of L1 or p16 origin, and thereby presenting truncated or degraded 
target proteins. Compared to Figure 32 that shows the anti-p16 western blot of the proteins 
right after expression, several smaller bands are missing or less intense after inclusion body 
purification, indicating successful enrichment of the target proteins. 
 
To determine the protein concentration of the full length target protein, densitometry was 
applied (6.4.11) on a coomassie blue-stained sodium dodecyl sulfate-polyacrylamide gel 
(SDS-PAG). Therefore, different bovine serum albumin (BSA) standard solutions were 
compared to the fusion proteins by graphical analysis using ImageJ software. This method 
was chosen as it allows determination of the concentration of the 92 kDa (respectively 75 
kDa for GST-L1) protein present in the sample. The overall protein concentration was 
determined with the 2D-Quant kit. For subsequent immunological trials, the 
densitometrically determined concentrations were applied to ensure correct dosage of the 
target proteins. From Table 3 follows that the full-length target proteins account approx. for 
one third of the whole protein content. 
 
Table 3: Protein concentrations of the GST-fusion proteins purified from inclusion bodies determined by 
densitometry (ImageJ analysis; concentration of the full-length target protein, excluding truncated products), 2D-
Quant analysis (total protein content) and calculated protein amount that was obtained from 100 ml culture 
volume. 
 
Protein  Densitometry [mg/ml] Total protein [mg/ml] 
target protein / 100 ml 
culture volume [mg] 
GST-L1p16  0.94 3.17 28.67 
GST-p16L1 1.32 3.16 40.26 
GST-L1p16L1 1.11 3.66 33.86 
GST-L1 1.79 3.21 54.60 
 
9.2 p16INK4a GSTrap purification 
As GST-p16INK4a was expressed in soluble form, it had to be purified in a different way than 
the insoluble L1 capsomeres. All protein lysates were treated equally as far as possible, e.g. 
they were lysed in the same buffer. Figure 36 shows coomassie and western blot analysis 
of the bacterial lysate after French press, the supernatant containing the soluble protein and 
the purified GST-p16INK4a after GSTrap affinity chromatography. The intense band at 42 kDa 
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in the coomassie gel was confirmed to be p16INKa with western blot analysis. After disruption 
of the bacterial cells, the supernatant was collected and loaded onto a 5 ml GSTrap FF 
column (GE Healthcare). The GST-p16INK4a protein was eluted with 20 mM glutathione to 
sustain the GST-tag. It was also possible to cleave p16INK4a from the GST tag with thrombin. 
However, to ensure best possible comparability for subsequent immunological in vivo 
experiments, p16INK4a was purified along with its GST-tag, at least for the application as 
control group protein in the mouse trials. 
 
 
Figure 36: Coomassie staining and anti-
p16 western blot of GST-p16
INK4a
 
(soluble expressed protein of 42 kDa). 
Several contaminating proteins that are 
visible in lanes 1 and 2 of the 
coomassie gel could be removed during 
the purification process as shown in 
lane 3. The anti-p16 western blot 
(antibody D7D7) reveals presence of 
the correct sized GST-tagged protein. 
 
With this purification, protein concentrations of up to 3 mg/ml were obtained in the first 
GSTrap elution fraction shown in lane 3, figure 35. The protein concentration was 
determined with the densitometry method (6.4.8) utilizing a BSA standard and graphical 
analysis of a coomassie gel. 
The obtained protein was then analyzed for its LPS content and remaining endotoxins were 
removed by Triton X-114 treatment (see 6.4.11 for method and 9.5 for results).  
 
9.3 GSTrap and SEC purification of soluble fusion proteins 
Besides inclusion body purification, the cell lysates obtained from the chimeric L1 containing 
proteins were also purified using the originally planned strategy to evaluate its potential for 
the protein production for immunological studies. The originally planned purification 
procedure includes purification of the crude cell lysate by GSTrap affinity chromatography 
and subsequent SEC polishing as described in 6.4.3. GSTrap affinity chromatography was 
performed to give an impression of the achievable concentration of the target protein and 
SEC was applied to remove residual E. coli chaperones and for further purification. 
 
In the following, data of the GST-p16L1 purification are shown exemplary as the other L1 
containing constructs showed similar characteristics during the purification process.  
The chromatograms for p16L1 GSTrap affinity chromatography are shown in Figure 37. 
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Figure 37: Chromatogram of the GSTrap FF (GE Healthcare) run, exemplary for GST-p16L1. Y-axis: 
absorbance at 280 nm; X-axis: transferred volume in ml. The GST-tagged protein binds to column matrix 
(glutathione sepharose) and contaminating proteins and substances are washed off the column. After thrombin 
cleavage over night, the fusion protein can be eluted. Residual bound GST is washed off with high molar 
glutathione. 
 
The fractions obtained during the GSTrap run were analyzed by coomassie staining of a 
SDS-gel (see Figure 38) and western blot with anti-L1, anti-p16 and anti-GroEL antibodies. 
It was revealed that the protein can be purified with GSTrap, although the concentration in 
the eluted fractions is low. In contrast, high amounts of GST seem to be enriched, as 
demonstrated by the intense bands in the GST wash fractions and the comparable large 
peak area in Figure 37. This also explains a loss of target protein during GSTrap purification 
as free GST and GST-protein fragments occupy the available binding sites on the affinity 
column leading to reduced overall capacity. An anti-GroEL western blot (data not shown) 
showed that GroEL is co-eluted with the protein of interest.  
 
 
Figure 38: The GSTrap AC purification was analyzed by coomassie gel (SDS-PAG). Bacteria cell lysates were 
cleared by centrifugation and the supernatant containing the soluble fraction was loaded onto a GSTrap column. 
After washing the column, thrombin protease was added to cleavage the protein from the bound GST-tag. p16L1 
was eluted and the column was washed with glutathione to remove residual GST. Elution fractions 1 and 2 show 
a slight enrichment of p16L1, however, the purified fractions show a considerable number of other bands. GST 
was bound to a high degree, although the fusion partner could not be retained in this concentration. 
 
To remove E. coli chaperones gel filtration was performed. The corresponding 
chromatogram, exemplary for p16L1, is shown in Figure 39. 
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Figure 39: gel filtration chromatogram of p16L1 (Superdex200, GE Healthcare) exemplary for GST-p16L1. 
Y-axis: absorbance at 280 nm; X-axis: transferred volume in ml. The fusion protein is eluted right after the void 
volume at 7.42 ml indicating agglomerated capsomeres with a molecular weight >850 kDa. 
 
The SEC fractions indicated in Figure 39 were analyzed by silver staining, anti-L1, anti-p16 
and anti-GroEL western blotting. The overall retained protein amount was low, 
nevertheless, anti-p16 and anti-L1 western blots revealed presence of the desired fusion 
protein (Figure 40). Besides the p16L1 fusion protein, substantial amounts of free L1 and 
p16INK4a could be detected indicating breaking or degradation of the chimeric protein. Also 
uncut protein is present; consequently the GST-tag was not completely removed. GroEL 
was found to elute in the fractions 16 and 17 and was thereby separated from the target 
protein. 
 
 
Figure 40: anti-p16 and anti-L1 western blots of the peak fractions of the p16L1 gel filtration run. Besides the 
protein of interest, p16L1, L1 and p16 are also present as truncated proteins indicating a predetermined 
breaking or degradation of the chimeric p16L1 fusion. 
 
With the presented strategy utilizing GSTrap affinity chromatography and gel filtration it is 
possible to purify the proteins of interest, however sufficient protein amounts could not be 
obtained. This is probably due to the relatively low content of soluble target protein in the 
cell lysate after centrifugation as the bulk amount of protein remains in the pelleted fraction. 
An enrichment of the target protein is not possible with these methods. The GSTrap binding 
is potentially ineffective due to fact that free GST was found to occupy the available binding 
sites and thereby limiting capacity for the full length fusion protein. 
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9.4 Other purification attempts and separation of the GST-tag 
The following schema gives a review of the attempts that were made to produce the L1 
containing capsomeres in sufficient amounts and high purity. It shows selected experiments 
that were performed for this purpose, amongst others.  
 
 
Figure 41: Flow chart displaying purification attempts that were made to remove the GST-tag from the refolded 
inclusion body preparations. Abbreviations: AC: affinity chromatography, GuHCl: guanidine hydrochloride, IBs: 
inclusion bodies, IEX: ion exchange chromatography, L-Sarcosine: N-Lauroylsarcosine, SEC: size exclusion 
chromatography, TEM: transmission electron microscopy. 
 
After optimization and evaluation of the protein expression and cell harvesting, the 
purification of inclusion bodies from the insoluble fraction of the cell lysate was found to be 
the only possibility to produce sufficient protein amounts for further studies. As described in 
chapter 9.3, the purification of the soluble protein content did result in very low protein 
concentrations and was therefore postponed. Inclusion bodies were first denatured by N-
Lauroylsarcosine as described in the iFOLD Protein Refolding System 1 User Protocol 
(Novagene, [101]). After refolding by dialysis, GSTrap affinity purification (AC) was 
performed to further purify the protein and cutting off the GST-tag. Thereby it was found that 
the refolded glutathione-S-transferase-tag is completely inactive and it was not possible to 
achieve enzyme mediated binding to glutathione. GSTrap affinity chromatography using 
glutathione sepharose was therefore excluded as not feasible for the separation of the tag. 
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It was further tried to remove the cut GST-tag utilizing anti-GST antibodies, as these bind 
GST independent of its enzymatic activity. Different anti-GST antibodies were coupled to 
ProteinG and/or CnBr sepharose and the protein solution was loaded onto the so prepared 
anti-GST resins. However, these methods did not result in a sufficient separation of the 
GST-tag, as the target protein was predominantly found to precipitate on the resins. Before 
performing ion exchange chromatography and alternatively size exclusion chromatography, 
the GST-tag was also cut with thrombin. For IEX, it was necessary to dialyze the sample to 
remove remaining N-Lauroylsarcosine. This anionic detergent forms micelles and thereby 
solubilizes the protein. As long as sarcosine is present in the sample it will bind to the anion 
exchange resin. Nevertheless, the GST tag was found to elute in exactly the same fractions 
as the target protein does. This speaks for a tight association of GST to the capsomeres 
and/or residual detergent in the sample. IEX was therefore considered to be inapplicable as 
a method to detach GST from the capsomeres. Also a complete separation by gelfiltration 
could not be achieved as the tag was always eluted in parallel to the capsomeres.  
Guanidine hydrochloride denaturation resulted in protein precipitation during refolding 
independent of the molarity of denaturing agent and was therefore not further explored. 
Urea was also used to extract the protein from the purified inclusion bodies, and as 
expected, the protein concentration in the extract increases with the used urea molarity. 
However, during refolding, the proteins denatured with 6 and 8 M urea were found to 
precipitate as well. Only the 4 M urea extract could be successfully refolded, although the 
protein yield was not optimal. The preparations were analyzed by TEM and found to form 
pearl necklace like structures. The GST-tag could be cut by thrombin protease, but could 
not be separated, as described for N-Lauroylsarcosine before.  
Further characterizations (results shown in 9.1) revealed that the L-sarcosine denatured 
and refolded proteins appear to be of high purity and even the absence of contaminating 
endotoxins could be confirmed (9.5). Therefore, these preparations were used for 
subsequent immunological studies (see chapter 10), although it should be mentioned that 
the GST-tag was not removed for this purpose.  
 
9.5 Analysis and removal of endotoxin contaminations in HPV16 L1 protein 
preparations from E. coli 
Endotoxins, or lipopolysaccharides (LPS) are major components of the cell wall of gram-
negative bacteria and present an important source of contamination for protein preparations 
obtained from bacteria cultures [147]. They play an important role in inflammation 
processes and elicit strong immune responses even in minimal concentrations. To avoid 
uncontrolled activation of the immune systems, endotoxins must be removed from vaccine 
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preparations. During this thesis, triton X-114 phase separation was used for this purpose 
[141]. To analyze the LPS content before and after Triton X-114 treatment, the quantitative 
endpoint assay QCL-1000 LAL Assay (Lonza) was used (see also 5.4.3 and 6.4.11). 
Table 4 summarizes the results obtained with the endotoxin detection kit. The samples are 
listed with their corresponding absorption at 405 nm and the calculated EU/ml values that 
were calculated from the standard curve. All L1 containing proteins were purified as 
inclusion bodies and as this protocol (6.4.1) includes several triton X-100 washing steps, the 
LPS amounts in these preparations were found to be negligible low. Concluding from these 
data, the endotoxin removal protocol does not need to be applied on proteins retained from 
inclusion bodies. Contrary, GST-p16INK4a was purified by GSTrap affinity chromatography 
(6.4.2) and contained LPS in high concentration. By triton X-114 treatment, the 
contaminating endotoxins could be entirely removed. Western blot of samples before and 
after LPS removal revealed only minimal loss of p16 protein (data not shown). 
 
Table 4: Quantitative endotoxin analysis of the GST-fusion 
proteins expressed in E. coli Rosetta, obtained with the QCL-
1000 Endpoint Chromogenic LAL Assay (Lonza). 
 
 Sample   A405 nm 
EU/ml 
calc. 
Standards 1 1,864 0,97 
EU/ml 0,5 1,092 0,56 
  0,25 0,541 0,26 
  0,1 0,192 0,07 
Blank 0 0,054 0,00 
pos. control  2 EU 2,3 1,21 
before LPS 
removal 
GST-L1 0,09 0,01 
GST-p16 >3 >1,59 
GST-L1p16 0,077 0,01 
GST-p16L1 0,069 0,00 
GST-L1p16L1 0,061 0,00 
after LPS 
removal 
GST-L1 0,072 0,00 
GST-p16 0,06 0,00 
GST-L1p16 0,056 0,00 
GST-p16L1 0,058 0,00 
GST-L1p16L1 0,071 0,00 
 
 
 
 
Figure 42: Calibration curve QCL-1000 
Endpoint Chromogenic LAL Assay 
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9.6 Structural characterization of chimeric capsomeres 
The purified capsomeres were analyzed for their structural integrity, sedimentation 
characteristics and the presence of conformation-specific epitopes by means of 
transmission electron microscopy, sedimentation analysis and conformation specific ELISA. 
 
9.6.1 Sedimentation analysis 
To verify the capsomere structures, purified protein extracts were subjected to sucrose 
gradient centrifugation. The collected fractions (20 in total, 600 µl each, fraction 1 from the 
top of the tube) were analyzed by western blotting (Figure 43). All expressed and purified 
fusion proteins contain the modified L1 sequence (5.2.1) with a deletion of the helix 4 region 
that prevents assembly into larger particles. Sedimentation analysis of the refolded proteins 
revealed the presence of capsomeres as demonstrated by western blot analysis with the 
L1-specific antibody MD2H11 (Figure 43). BSA (4S) was loaded as calibration marker and 
assembled VLPs were loaded as control. VLPs were found at the bottom of the centrifuge 
tube whereas the capsomeres accumulated at the top of the sucrose gradient (fractions 1 to 
4) due to their low sedimentation coefficient. These sedimentation characteristics indicate 
the presence of small particles and are in line with previous studies [76, 137, 148].  
 
 
Figure 43: Sedimentation characteristics of the different L1 - p16
INK4a
 capsomeres. 50 µg of each protein were 
loaded onto linear sucrose gradients (5-50% in dialysis buffer) and centrifuged for 3h at 36,000 rpm in a SW41Ti 
rotor. The resulting gradients were divided into 20 fractions which were collected from the top of the tube and 
analyzed by immunoblotting with the MD2H11 antibody. The different L1- p16 proteins are all present as 
capsomeres in fractions 1 to 4 as the deletion of helix 4 prevents assembly into larger particles. 
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9.6.2 Transmission electron microscopy  
The purified proteins were analyzed by transmission electron microscopy (TEM) and two 
representative replicas of each sample are shown in Figure 44. All preparations contained 
large amounts of 10 - 12 nm capsomeric structures which is in line with previous reports 
[76, 149, 150]. The characteristic donut-like appearance was also observed in some of the 
capsomeres but this was not a consistent finding. The black dot in the centre of the 
capsomeres originates from the staining of their cylindrical cavity [35]. As we used the C-
terminally truncated L1 construct this dot was only sporadically visible as described before 
[144]. The capsomeres were found to be of variable size with a certain tendency to the 
formation of aggregates. Especially p16L1 and L1p16L1 showed higher grades of 
agglomeration compared to L1 and L1p16. In general, many non-assembled L1 monomers 
were observed as “background noise”. This often resulted in EM images with lower 
resolution as the uranyl acetate staining was challenging.   
 
 
Figure 44: Structural analysis of the HPV16 L1 capsomeres. The structure of the purified proteins was analyzed 
by TEM employing negative staining as described in 6.4.10 (Transmission electron microscopy). All preparations 
formed 10 - 12 nm capsomeric structures with variable tendency to agglomeration. Two representative pictures 
per sample are shown; bars indicate 30 nm. 
 
Altogether it is evident, that all proteins do refold into capsomeric structures after denaturing 
from inclusion bodies and dialysis. The intrinsic ability to assemble into capsomeres was not 
disrupted by the inclusion body purification procedure. Furthermore, these capsomeres 
were handled at room temperature and no negative influence on their stability could be 
observed. 
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9.6.3 Conformation specific ELISA 
The different chimeric constructs were obtained from inclusion bodies including 
denaturation and refolding steps. Therefore it was not clear whether conformation-specific 
epitopes are present after the refolding procedure or not. An ELISA using the L1-directed 
monoclonal antibody #1.3.5.15 (Ritti01) was applied to elucidate this. VLPs from insect cells 
were used as a positive control to determine functionality of the test. The results of the 
conformation specific or ‘antigen capture ELISA’ (6.4.12) are summarized in Figure 45. As 
the absorption values are quite low even for the undiluted proteins, it can be supposed that 
conformation-specific epitopes are only present to low extend, if at all. These data indicate 
that L1 without the p16INK4a fusion presents, at least partly, the desired epitopes and that the 
p16L1 capsomeres are slightly more immunoreactive to the conformation specific antibody. 
The low overall reactivity of the capsomeres in this ELISA indicates the presence of rather 
missfolded L1 protein. At least the antibody-specific epitope seems to be masked although 
this does not exclude the presence of L1 in the form of higher order structures, such as 
capsomeres. However, for these proteins the value of that assay is limited. 
 
 
Figure 45: Antigen capture ELISA of 
protein preparations obtained from 
inclusion body purifications. Refolded 
proteins were applied undiluted (-), 1:5 
and 1:10 diluted in dialysis buffer. VLPs 
(positive control) produced signals of 0.8, 
0.7 and 0.5 AU for dilutions of 1:100, 
1:500 and 1:1000 respectively, showing 
the general applicability of the test. 
 
9.7 Conclusions 
All the initially insoluble proteins could be successfully purified from E. coli inclusion bodies. 
Moreover it was possible to retain the proteins in very high amounts ranging from 29 to 55 
mg per 100 ml bacterial culture. Also the soluble expressed protein, GST-p16INK4a, was 
successfully purified via GSTrap affinity chromatography. We have evaluated different 
strategies to remove the co-expressed GST-tag from the protein preparations that were 
produced from inclusion bodies as the tag was not yet removed during inclusion body 
purification and refolding. It was found that the refolded GST-tag is completely 
enzymatically inactive and sufficient separation from the tag could not be achieved despite 
different attempts. Denaturation using the anionic detergent N-Lauroylsarcosine and 
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subsequent refolding via dialysis resulted in highest protein concentrations and appeared to 
be the mildest of the tested procedures, although the GST activity could not be restored 
with none of the applied strategies. However, structural analysis revealed the presence of 
capsomeres in the refolded samples with concurrent absence of contaminating bacterial 
endotoxins. Therefore, the use of N-Lauroylsarcosine in this context presents a suitable 
method for inclusion body denaturation and refolding. 
 
10 In vivo immunogenicity of the vaccine candidates 
The three purified p16-L1 fusion proteins as well as purified L1 and p16INK4a individually 
were used to immunize C57BL/6 mice. First of all, the p16INK4a (10.1) and the capsomere 
dose (10.2) for further experiments was determined using escalating doses of GST-p16INK4a, 
respectively the GST-p16L1 construct. In 10.3, the results for the comparison of the three 
different structural isoforms are shown. Further, the immune response after a single 
immunization was tested (10.4). The last experiment in frame of this thesis was designed to 
test whether the co-administration of an adjuvant can further improve the immune response, 
especially concerning the p16 T cell response; the results are presented in 10.5.  
L1-specific T cells were stimulated with the AGVDNRECI peptide (H2-Db-restricted CTL 
epitope of HPV16 L1 [137]) and detected by IFNy ELISpot; p16-specific T cells were 
detected with a pool of overlapping peptides covering the complete p16INK4a sequence. For 
the last experiment, Syfpeithi-predicted H2-Db-restricted nonameric peptides were used for 
the ELISpot analysis in addition. All spot numbers obtained from individual mice are 
presented as mean values from assay triplicates and were normalized by subtracting the 
mean spot numbers resulting from un-stimulated cells (assay negative control RPMI), 
unless mentioned otherwise. Mouse sera obtained at the day of ELISpot were checked for 
L1 antibody responses with a VLP-capture ELISA (6.6.1) and for p16INK4a -specific 
antibodies with 5 pools of overlapping peptides covering the complete p16INK4a sequence 
(for details see 5.2.3 and 6.6.2). The presented data are mean values calculated from assay 
duplicates and normalized by subtracting the mean absorption values of ELISA negative 
controls. 
 
10.1 Determination of the p16INK4a dose for control groups 
With the first in vivo experiment, the optimal dose of GST-p16INK4a that should be used in 
the following settings should be determined by vaccinating mice with different doses of this 
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protein. Figure 46 shows the number of IFNy spots counted for each mouse in the different 
dose groups (5, 25 and 50 µg p16INK4a). The ELISspot numbers for L1 and p16INK4a are 
presented in one graph but were determined with the established L1 peptide AGVDNRECI 
for the L1 control group and with the p16 overlapping peptide pool for the p16-immunized 
mice respectively (for methods see 6.6). Based on these results, the middle p16 dose 
(25 µg) was chosen for the following experiments as it seemed to induce the best 
achievable T cell response and highest spot number. Although a dose response effect was 
expected it could not be demonstrated with the available data. However, the dosage was 
later increased to the maximal dose of 50 µg as the second experiment (10.2) did not show 
any p16 T cell reactivity at all. 
 
 
 
Figure 46: p16
INK4a
 dose finding experiment - ELISpot 
results. C57BL/6 mice were immunized three times 
s.c. at biweekly intervals with 5 µg L1 (control group), 
5 / 25 or 50 µg p16
INK4a 
protein (test group). The 
horizontal bar represents the mean titer of each 
group, standard deviations for each groups are 
indicated by vertical bars. 
 
 
10.2 Dose-response effect of p16L1 capsomere immunization 
Cellular immune response determined by IFNy ELISpot 
In this experiment the optimal dose of capsomeres should be determined with one of the 
constructs. The ELISpot results for different concentrations of GST-p16L1 (construct #2) are 
shown in Figure 47 (L1-specific T cells) and Figure 48 (p16INK4a-specific T cells).  
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Figure 47: dose-finding experiment capsomeres - 
HPV16 L1-ELISpot using the AGVDNRECI peptide. 
C57BL/6 mice were immunized three times s.c. at 
biweekly intervals with 5 µg L1, 25 µg p16
INK4a
 
(negative control group) and 5 / 25 or 50 µg p16
INK4a
-
L1 protein (test group). Dots represent individual mice 
with mean and standard deviation indicated. 
 
Figure 48: dose-finding experiment capsomeres - 
p16
INK4a
-ELISpot using a pool of overlapping p16 
peptides. C57BL/6 mice were immunized three times 
s.c. at biweekly intervals with 5 µg L1 (negative 
control group), 25 µg p16
INK4a
 and 5 / 25 or 50 µg 
p16
INK4a
-L1 protein (test group). Dots represent 
individual mice with mean and standard deviation 
indicated. 
 
The L1 control group developed a number of 15 IFNy spots averaged when stimulated with 
the AGVDNRECI L1 peptide. The discrepancy to the L1 control group in the p16INK4a dose 
finding experiment (see Figure 46) could be explained by the applied cell number for 
ELISpot analysis which was decreased from 1.5 (p16 dose finding experiment) to 1.3 x 10^6 
cells per well. This cell number was then applied for all further ELISpots. Based on these 
results, it was decided to increase the L1 dose for the control groups to 25 µg per mouse in 
the subsequent experiments. 
Fisher’s LSD test is a method for comparing treatment group means. The test was also 
applied for the data presented in Figure 47. A significant difference to the p16 25 µg 
negative control group was calculated for the p16L1 25 µg (p=0.0045) and 50 µg 
(p=0.0068) test groups. The results for the HPV16 L1 T cells do not show a clear dose 
response effect, however, in the 50 µg group only one mouse had a mean number 
(calculated from ELISpot triplicates) of 28 spots. In the 5 and 25 µg groups, 2 out of 5 mice 
had values lower than 30 spots. 
For the p16 cellular immune response presented in Figure 48, no significant differences 
could be detected. In this context it is necessary to mention that the p16-specific t-cell 
numbers are very low and must therefore be critically reviewed.  
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Humoral immune response determined by ELISA 
Considering the antibody responses, a definite dose-response effect is apparent for p16- as 
well as for L1-specific antibodies (see Figure 49 and Figure 50). Individual sera were scored 
as antibody-positive or negative using a cut-off value that is based on the distribution of 
absorbance values of control groups. With the VLP-capture Elisa (Figure 49), the dose-
response trend was confirmed as with increasing capsomere dose, an increasing 
absorbance value at 450nm was detected whereby all tested sera were positive for VLP-
capturing antibodies.  
 
 
 
Figure 49: dose-finding experiment capsomeres - 
VLP-capture Elisa. C57BL/6 mice were immunized 
three times s.c. at biweekly intervals with 5 µg L1, 25 
µg p16
INK4a
 (negative control group) and 5 / 25 / 50 
µg p16
INK4a
-L1 protein (test group). Dots represent 
individual mice with mean and standard deviation 
indicated. 
 
 
Mouse sera were also tested for p16 specific antibodies (Figure 50) using 5 peptide pools 
including all 13 overlapping peptides covering the complete p16 sequence (for peptide 
sequences see 5.2.3). The peptides were also tested separately (data not shown) but as 
different peptides showed reactivity in the ELISA, all were included to analyze the sera. 
Sera were considered to be positive if at least one of the tested peptide pools showed a 
value above cut-off which was calculated from the negative control group (L1 5 µg). With 5 
µg p16L1, 2 out of 5 mice were defined to be positive for p16-specific antibodies (Figure 
50), in the second group that received 25 µg of the fusion protein, 3 out of 5 mice and all 
mice that received 50 µg were tested positive for p16-specific antibodies. It is noticeable 
that the p16 control group did not develop any p16-specific antibodies and that the L1 
negative control shows quite high p16 antibody titers. This observation was made for all 
mouse experiments (see also Figure 55 and Figure 57). 
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Figure 50: dose-finding experiment capsomeres - p16
INK4a
 -petide Elisa. C57BL/6 mice were immunized three 
times s.c. at biweekly intervals with 5 µg L1 (negative control group), 25 µg p16
INK4a
 and 5 / 25 / 50 µg p16
INK4a
-
L1 protein (test group). Numbers on x-axis indicate individual mouse sera that were tested with the different 
peptide pools. The horizontal line marks the calculated cut off based on the L1 negative control values. 
 
The capsomere dose for the following experiments was defined to be 50 µg per mouse as a 
clear dose response effect could be observed, at least considering the humoral immune 
response. The L1 control (5 µg) induced only low T cell numbers as the p16 control did. 
Because of this we decided to increase the L1 dose to 25 µg and the p16INK4a dose to 50 µg 
per mouse for further experiments. 
 
10.3 Comparison of the different HPV16 L1 - p16INK4a capsomere constructs 
Cellular immune response determined by IFNy ELISpot 
Another experiment was performed to elucidate immunological differences between the 
three different capsomere constructs. Figure 51 depicts that all three fusion protein 
constructs induce high L1-specific T cell numbers in immunized mice whereby construct #3 
(L1p16L1) shows the highest T cell response with a mean of 172 spots. Also the other 
constructs #1 (L1p16) and #2 (p16L1) with mean spot numbers of 82 and 67 gave higher L1 
responses than the L1 control group with a mean of 27 spots. Fishers LSD test revealed 
significance for the comparison of the L1 control group to the test groups p16L1 (p<0.0001) 
and L1p16L1 (p=0.0002). The L1 protein was administered in lower dose for the control 
group, as it has to be considered that the 50 µg fusion protein dose does not contain 50 µg 
pure L1 but GST, p16INK4a and L1 and thereby presents a comparable L1 proportion 
altogether. The presence of p16INK4a seems to boost the L1 specific T cell response what 
could be due to the presentation of T helper epitopes in this formulation. Concerning the 
p16INK4a T cell response (shown in Figure 52) the same analysis problem occurred with this 
ELISpot as it was found previously. However, significantly higher T cell numbers could be 
detected for construct #2 (p16L1, p<0.0001) and #3 (L1p16L1, p=0.0002) compared to the 
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control group which only received L1 protein. It should be noted that the number of counted 
spots is very low and was therefore not normalized for RPMI control. As a number of up to 
13 spots was found to be regular assay background (see Figure 53 and corresponding text), 
these spot numbers must be considered to be background response that would also have 
appeared without peptide stimulation. This shows that with using the pool of overlapping 
p16 peptides for the ELISpot test, only low numbers of p16-specific T cells can be detected.  
 
 
   
Figure 51: Comparison of the 3 different capsomere 
constructs - HPV16 L1-ELISpot using the 
AGVDNRECI peptide. C57BL/6 mice were immunized 
three times s.c. at biweekly intervals with 25 µg L1, 50 
µg p16
INK4a
 (negative control group) and 50 µg of 
either L1p16 (#1), p16L1 (#2) or L1p16L1 (#3) protein 
(test group). Dots represent individual mice with mean 
and standard deviation indicated. 
Figure 52: Comparison of the 3 different capsomere 
constructs - p16
INK4a
-ELISpot using a pool of over-
lapping p16 peptides. C57BL/6 mice were immunized 
three times s.c. at biweekly intervals with 25 µg L1 
(negative control group), 50 µg p16
INK4a
 and 50 µg of 
either L1p16 (#1), p16L1 (#2) or L1p16L1 (#3) protein 
(test group). Dots represent individual mice with mean 
and standard deviation indicated. Un-normalized data. 
 
Figure 53 shows the HPV16 L1-ELISpot results split for each group, whereby L1 25 µg and 
p16INK4a 50 µg represent the control groups. Grey bars indicate assay negative control spot 
numbers that were counted from unstimulated (RPMI) cells, black bars indicate L1-specific 
T lymphocytes. Splenocytes from mice vaccinated with L1 or one of the L1 containing 
chimeric constructs produced significantly more IFNy spots when stimulated with the 
AGVDNRECI peptide compared to unstimulated cells. This is true for all test groups. The 
control group of 10 mice that only received p16INK4a protein, did not develop L1-reactive T 
cells, which demonstrates specificity of the ELISpot assay. 
The graphic also displays a boxplot diagram after Tukey to visualize the distribution of RPMI 
spot numbers in a large cohort of animals (n=50), respectively the assay negative control, 
obtained in this experiment. From this we can conclude, that spot numbers up to 13 can 
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appear although no peptide specific stimulation preceded. Mice number 14 and 25 were 
thereby identified as outliers. 
       
 
Figure 53: Comparison of the 3 different capsomere constructs - HPV16 L1-ELISpot using the AGVDNRECI 
peptide, uncorrected results for each group. Numbers on x-axis indicate individual mouse sera whereby IFNy 
spot numbers for assay negative control (RPMI) and the test peptide (L1) are shown in comparison. The boxplot 
diagram shows the distribution of the assay negative control values (unstimulated cells) for the 50 mice of this 
experiment (median= 9; 25% percentile=7; 75% percentile=13). Outliers were identified for mice #14 and 25. 
 
Humoral immune response determined by ELISA 
The VLP-capture ELISA of these sera is presented in Figure 54. All tested sera were found 
to be positive for VLP-capturing antibodies whereby construct #2 (p16L1) gave the highest 
response rates (mean A450nm = 0.660) which were even higher (p=0.0498) than the L1 
control group (mean A450nm = 0.543). 
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Figure 54: Comparison of the 3 different capsomere 
constructs - VLP-capture Elisa. C57BL/6 mice were 
immunized three times s.c. at biweekly intervals with 
25 µg L1, 50 µg p16
INK4a
 (negative control group) and 
50 µg of either L1p16 (#1), p16L1 (#2) or L1p16L1 
(#3) protein (test group). Dots represent individual 
mice with mean and standard deviation indicated. 
 
In Figure 55 the results of the p16INK4a-peptide pool ELISA are shown. Surprisingly, the 
background p16INK4a antibody response is quite high for the control group that only received 
25 µg of L1 protein as it was observed for all mouse experiments. Contrary, the p16 control 
group shows basically no response at all. The threshold was calculated on the basis of the 
true negative control group which is the one that received HPV16 L1. Construct #1 resulted 
in eight positive out of ten mice and therefore depicts with 80% positivity the highest p16-
specific antibody response that was achieved with this experiment. Also constructs #1 and 
#2 show signals in the ELISA but must be valued as background signal. 
 
 
Figure 55: Comparison of the 3 different capsomere constructs - p16
INK4a
-petide pool ELISA. C57BL/6 mice were 
immunized three times s.c. at biweekly intervals with 25 µg L1 (negative control group), 50 µg p16
INK4a
 and 
50 µg of either L1p16 (#1), p16L1 (#2) or L1p16L1 (#3) protein (test group). Numbers on x-axis indicate 
individual mouse sera that were tested with the different peptide pools. The horizontal line marks the calculated 
cut off based on the L1 negative control values. 
 
10.4 Immunogenicity of the HPV16 L1 - p16INK4a capsomeres after single 
administration 
With three mice that were immunized with 50 µg of p16L1 (construct #2), it was found that 
after single vaccination, all mice developed a HPV16 L1 specific T cell response which was 
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measured by ELISpot using the AGVDNRECI peptide. With spot numbers of 51, 110 and 
121 (mean values, normalized for RPMI control) the cellular immune response against L1 is 
rapid and strong (data not shown) comparable to that achieved after repeated 
immunizations. However, a cellular p16 response could not be detected, even though three 
additional nonameric peptides were used to stimulate the cells (5.2.3).  
 
Humoral immune responses were measured by means of ELISA and the results are shown 
in Figure 56 and Figure 57. The VLP-capture ELISA revealed that even after one 
immunization, a considerable induction of VLP-binding antibodies can be achieved in the 
majority of tested individuals and that the antibody titer induced with the capsomere 
constructs is higher than that induced with L1 protein alone. It should be noted, that the L1 
protein used for the control group was applied at 50 µg per mouse for this experiment. This 
means, that the actual L1 proportion is even higher compared to the fusion proteins as the 
protein amount for immunizations was calculated with the total target protein and the 
chimeric capsomere preparations also contain p16INK4a protein. However, it must be 
considered that only 2, respectively 3 mice per group were used for this experiment. 
 
 
Figure 56: Humoral immune response after single 
immunization - VLP-capture ELISA. C57BL/6 mice 
were immunized once s.c. with 50 µg L1, 50 µg 
p16
INK4a
 (negative control group) and 50 µg of either 
L1p16 (#1), p16L1 (#2) or L1p16L1 (#3) protein (test 
group). Dots represent individual mice with mean 
and standard deviation indicated. Significant 
differences are indicated with the respective p-
values (uncorrected Fisher’s LSD). 
 
 
The results of the p16INK4a-petide pool ELISA are depicted in Figure 57. A slightly increased 
p16INK4a-specific antibody response is visible for all three fusion protein constructs. The 
relatively high L1 background response is present as it was found before, whereas p16 
immunized mice did not develop antibodies at all.    
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Figure 57: Humoral immune response after single immunization - p16
INK4a
-petide pool ELISA. C57BL/6 mice 
were immunized once s.c. with 50 µg L1 (negative control group), 50 µg p16
INK4a
 and 50 µg of either L1p16 (#1), 
p16L1 (#2) or L1p16L1 (#3) protein (test group). Numbers on x-axis indicate individual mouse sera that were 
tested with the different peptide pools. 
 
Compared to the previously described results, it appears that boosting by repeated 
immunization is necessary for a stronger and therefore probably more effective immune 
response. 
 
10.5 p16INK4a-specific T cell reactivity verified with synthetic peptides 
The presented experiment was originally conducted to ascertain the influence of an 
adjuvant (Montanide) on the overall immune response in comparison to a vaccine 
formulation in PBS (see also 10.6). Therefore, nine mice (3 per test group) were immunized 
s.c. three times at biweekly intervals with a) the L1p16 protein in PBS as it was applied in 
the previously described experiments, b) L1p16 in Montanide (1:1) or c) with the Vicoryx 
peptide (5.2.3) in Montanide (1:1) as it is used in this formulation in an ongoing clinical trial 
[125]. The ELISpot of splenocytes was performed according to the described protocol 
(6.6.3) and in addition to the L1 peptide and the p16 overlapping peptide pool, the three 
synthetic peptides P1 (TRGSNHARI), P2 (LPVDLAEEL) and P3 (GSARVAELL) were 
included. These peptides were predicted using the prediction algorithm SYFPEITHI [138] for 
H2-Db-restricted CTL epitopes of p16INK4a. Figure 58 shows the detailed ELISpot results of 
this mouse experiment. The splenocytes were stimulated with the indicated peptides, 
respectively the p16 Pool and RPMI for the assay negative control. Each bar in the chart 
corresponds to a spot number mean value of assay triplicates and thereby shows the 
number of peptide-specific T lymphocytes that were detected. As it was observed before, a 
strong L1 cellular immune response (orange bars) is evident in all L1p16-immunized mice, 
whereby mouse number 9 shows the lowest spot number with averaged 29 spots. However, 
in comparison to the negative control (RPMI, black bars) this is a positive response as well. 
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The stimulation with the pool of overlapping p16INK4a peptides (pink bars) did not result in 
spot numbers beyond the background signal as it was observed before. Because of the 
findings from previous ELISpots, three additional p16 peptides (green bars) were included. 
Mouse #1 and #7 show a markedly increased response to all of these peptides, and also to 
stimulation with the longer Vicoryx peptide (blue bars). This provides evidence for the 
induction of a robust, polyclonal T cell response as all tested single p16 peptides resulted in 
spot numbers from 28 (mouse #1, P3) to 59 (mouse #7, P1) which are clearly 
distinguishable from the background controls. The test group that received the Vicoryx 
peptide in Montanide was only tested with this peptide whereby one mouse was found to 
properly response with over 100 spots averaged. The Vicoryx group was included in this 
experiment to analyze the immune response that can be induced in mice to this peptide that 
is currently used in a clinical trial. Taken together, in each test group one out of three 
individuals was tested positive for p16 reactivity, whereby all of the mice that received 
L1p16 protein developed an anti-L1 cellular immune response. These results demonstrate 
the general possibility to induce a p16INK4a-mediated T cell response with the chimeric 
capsomere vaccine. 
 
 
 
Figure 58: Montanide experiment - IFNy ELISpot, uncorrected results for each group. C57BL/6 mice were 
immunized three times s.c. at biweekly intervals with 50 µg of either L1p16 in PBS, L1p16 in Montanide or 
Vicoryx peptide in Montanide. Individual mouse sera are indicated on the x-axis. Spot numbers obtained after 
stimulation of splenocytes with RPMI, L1 peptide, the p16 peptide pool or different p16 peptides are shown in 
comparison. M# on x-axis indicates individual mouse sera that were tested with the different peptides. 
 
10.6 Immunogenicity of the HPV16 L1 – p16INK4a capsomeres with co-administration 
of Montanide adjuvant 
In the previously described experiments p16 reactive T cells were generally hard to detect 
with the chosen peptides. With the co-administration of Montanide adjuvant, we intended to 
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generate stronger immune responses that can be quantified using the ELISpot assay. The 
results presented in 10.5 were therefore summarized and are graphically depicted in Figure 
59 to illustrate the difference of IFNy spot numbers obtained with the L1p16 protein 
formulated in PBS vs. Montanide adjuvant. The grey bars represent mean values of spots 
that were counted for the ‘L1p16 in PBS’ immunized mice; black bars are mean values of 
the ‘L1p16 in Montanide’ group. A significant difference (p=0.0016) was found for the L1-
stimulation whereby the PBS group developed a mean number of 273 spots and the 
adjuvant supplemented group of 97 Spots. Thereby a decreased immune response for the 
adjuvant group is shown, rather than the expected improvement. Considering the other 
tested peptides, no significant differences could be elucidated. Therefore it can be 
speculated that in this experimental setting the administration of L1p16 capsomeres in 
Montanide adjuvant does not improve the cellular immune response.  
 
 
 
Figure 59: Efficacy of vaccine formulation in 
PBS vs. Montanide adjuvant. C57BL/6 mice 
were immunized three times s.c. at biweekly 
intervals with 50 µg of L1p16 in PBS or in 
Montanide adjuvant. The x-axis marks the 
peptides used for the stimulation of 
splenocytes. 
 
 
The antibody responses of individual sera obtained with a VLP-capture ELISA are 
presented in Figure 60. As the Vicoryx-group did not receive the L1 protein, these sera were 
excluded for this test. The vaccine formulation in Montanide did not lead to an increased 
production of VLP-binding antibodies. The highest signal was even measured for the L1p16 
in PBS group that did not receive the adjuvant. The mean value of the PBS group (n=3) is 
m=0.1901 AU, for the Montanide group (n=3) m=0.1239 AU; however a significant 
difference could not be detected (p=0.6803) probably because of the small number of mice 
tested. 
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Figure 60: Vaccine formulation in PBS vs. Montanide 
adjuvant - humoral immune response measured by VLP-
capture ELISA. C57BL/6 mice were immunized three 
times s.c. at biweekly intervals with 50 µg of L1p16 in 
PBS or in Montanide adjuvant. Bars represent individual 
sera. A significant difference of the two groups could not 
be detected (p=0.6803) 
 
 
Figure 61 shows the p16INK4a antibody response for the three different test groups that 
received 50 µg of either L1p16 in PBS, L1p16 in Montanide or the Vicoryx peptide in 
Montanide. It is evident that the vaccine formulation in Montanide did not improve the 
antibody response; as the highest p16 titers were measured for mouse #2 that did not 
receive the adjuvant. The antibodies titers induced by the Vicoryx peptide were found to be 
quite low.  
 
 
Figure 61: Vaccine formulation in 
PBS vs. Montanide adjuvant - 
humoral immune response 
measured by p16
INK4a
-petide ELISA. 
C57BL/6 mice were immunized 
three times s.c. at biweekly intervals 
with 50 µg of L1p16 in PBS or in 
Montanide adjuvant. Numbers on x-
axis indicate individual mouse sera. 
 
 
10.7 Conclusions 
Immunization with chimeric L1 - p16INK4a capsomeres follows a dose response effect which 
was determined using the p16L1 construct. The dosage for further experiments was defined 
to be 50 µg chimeric protein per mouse, 50 µg p16 protein and 25 µg L1 for the control 
groups. Comparison of the three constructs revealed different immunogenicity. L1p16L1 
induced highest L1-specific T cell numbers, p16L1 showed the best antibody response in 
the VLP-capture ELISA and L1p16 seemed to induce the best anti-p16 humoral immune 
response. With the last experiment performed during this thesis, finally a p16-specific 
cellular immune response could be detected in the ELISPot assay with four peptides (three 
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nonamers, one 26-mer: Vicoryx peptide) used to stimulate the splenocytes from Lp16 
immunized mice. This speaks for a polyclonal, robust CD8+ T cell response as three 
different nonameres were recognized in the ELISpot assay. It may be speculated that 
p16INK4a-reactive T cells have also been induced during the previous experiments, but to 
confirm this, further mouse studies need to be performed. The ubiquitous presence of p16-
specific antibodies argues for the induction of B-cells that may have required p16INK4a-
specific T helper responses. The strong cellular immune response to L1 in the first 
experiments shows that at least the L1 proportion of all constructs is immunogen, that the 
immunization itself is capable of inducing an immune response and that the fusion proteins 
are processed and presented by MHC molecules.  
Evaluation of a large cohort (n=50) revealed that spot numbers up to 13 can be considered 
as background response that appears even without any peptide specific stimulation in the 
applied ELISpot setting. By testing single immunizations, it turned out that boosting by 
repeated immunization is necessary for a strong, effective immune response. It was also 
found that the vaccine formulation in Montanide adjuvant did not improve the antibody 
response over the PBS formulation; although this should be confirmed using a larger cohort. 
In summary, these in vivo results show that it is in principal possible to induce L1 and p16-
specific T cells as well as antibodies targeting the human p16INK4a tumor suppressor protein. 
Furthermore, the inclusion body derived capsomere constructs are able to induce VLP-
capturing antibodies indicating a probable HPV-neutralizing effect. Immunization with the 
purified capsomeres also resulted in high L1-specific T cell numbers. The p16 overlapping 
peptide pool was found to be unsuitable for the detection of p16INK4a-specific T cells that 
were induced by immunization with the full length p16INK4a protein fused to HPV16 L1. 
However, these could be discovered with the synthetic peptides P1 (TRGSNHARI), P2 
(LPVDLAEEL) and P3 (GSARVAELL) that were predicted for H2-Db-restricted CTL 
epitopes of full length human p16 protein. 
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IV. Discussion 
In HPV-transformed precursor lesions and invasive carcinomas the cellular tumor 
suppressor p16INK4a is strongly overexpressed, whereas in normal tissues barely any 
p16INK4a expression is detectable. Therefore, p16INK4a is considered to be an interesting 
target for immunotherapy in patients with HPV-associated cancers. We designed chimeric 
particles consisting of 16INK4a and HPV16 L1, the major capsid protein of HPV and antigen 
of the available prophylactic HPV vaccines, with the aim of using the adjuvant-like effects of 
L1 particles to improve p16INK4a immune responses and at the same time generating a 
vaccine candidate with combined prophylactic (L1) and therapeutic (p16INK4a) properties. 
For this purpose, three chimeric HPV16 L1 - p16INK4a capsomere constructs were cloned 
and expressed in bacterial systems. Due to their low solubility, an inclusion body purification 
protocol was developed to purify the proteins in high amounts. The produced particles were 
then evaluated for their structural properties and immunological potential. The in vivo 
immunogenicity of the capsomeres was tested in a C57BL/6 mouse model.  
 
11 Generation of chimeric capsomeres consisting of HPV16 L1 
and p16INK4a 
11.1 Production of HPV16 L1 - p16INK4a capsomeres in E. coli 
Especially in developing countries where around 80% of cervical cancer deaths occur, the 
availability of prophylactic HPV vaccines is not optimal, respectively prophylactic vaccine 
coverage is poor and furthermore effective gynaecological screening programs are often 
absent. This explains an urgent need for an effective and save therapeutic vaccine that can 
be produced cost efficiently for the availability in these settings, as one of the greatest 
barriers towards introduction of a vaccine is its price. [21, 82, 83, 96, 151] 
This led to various approaches to produce a cost-efficient vaccine that would, in the best 
case, not even require stable cold-chains for transport and storage. There are several 
therapeutic vaccines including DNA vaccination [77], live vector-based [152] and peptide or 
protein-based vaccines [98, 153] targeting the HPV E6 and/or E7 antigens; however with 
limited success so far. The production of a protein-based vaccine in bacteria provides 
several advantages over the production in eukaryotic expression systems as bacteria can 
be cultured rapidly, inexpensively and with easy scale-up possibilities; all while high 
biomass and high protein yields are achievable. For these reasons, several therapeutic 
proteins are already successfully produced in E. coli systems, e.g. human insulin (Humulin 
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R U-500, Eli Lilly, IN, USA) and bovine growth hormone (Posilac, Monsanto, Eli Lilly, IN, 
USA). 
The recombinant production in bacteria was also the choice for the L1-based capsomeres 
generated during this thesis as L1 can be expressed and purified in high amounts from E. 
coli as demonstrated before [37, 154]. The production and effectiveness of capsomeres 
purified from bacteria was likewise explored in several studies [78, 79, 137, 149, 155]. 
Figure 62 gives an overview of the various steps that had to be carried into execution before 
immunological studies could be undertaken in vivo with the vaccine candidates. The most 
important findings that influenced further approaches are indicated as cursive text.  
 
 
Figure 62: Course of the process - generation and evaluation of the L1 - p16
INK4a
 vaccine constructs towards 
their application in immunological studies. The project started with cloning of the desired constructs into the 
expression vector pGex-4T-2. These plasmids were then transformed into the E. coli strains BL21 and Rosetta 
and expressed under various conditions. It was found that the L1-containing fusion proteins are highly insoluble. 
For this reason the originally planned GSTrap (followed by gel filtration) purification could not be performed and 
was replaced by a specifically developed inclusion body purification protocol. This purification process includes a 
denaturing and subsequent refolding step of the target proteins. After refolding, the GST-tag was found to be 
inactive and therefore further purification was challenging. However, the so produced capsomeres were found to 
be of high purity and solubility, even in concentrations in the mg range. Although electron microscopy revealed 
heterogeneous capsomere preparations with several truncated fragments identified by western blot analysis, the 
chimeric proteins were tested for their immunological potential in C57BL/6 mice as the major proportion was 
found to be full-length target protein. 
 
First of all, the three different constructs were cloned into the pGex-4T-2 expression vector 
to enable IPTG-inducible expression using a tac promotor. The L1 sequence that was used 
as template sequence was provided by L. Schädlich / L. Gissmann (DKFZ Heidelberg) and 
contained several modifications including truncations of 10 N-terminal and 29 C-terminal 
amino acids and a deletion of the helix 4 region (aa 408-431). These modifications to the L1 
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protein still allow the formation of capsomeres (consisting of 5 L1 proteins, also referred to 
as pentameres) but prevent assembly of complete VLPs [37, 68]. It was reported that the 
yield and solubility of this modified L1 protein is 2- to 6-fold higher compared to assembly 
competent L1 as interactions between the chimeric fusion protein molecules can cause 
more aggregation [144]. Based on the work of L. Schädlich and L. Gissmann, two 
constructs, namely p16INK4a-L1ΔN10Δ408-431ΔC29 and L1ΔN10Δ408-431ΔC29-p16INK4a 
were cloned. The N-terminal fusion of E7 to this modified L1 sequence was found to elicit 
highest anti-tumor activity amongst several tested constructs. The induction of neutralizing 
antibodies was less efficient but could be overcome by repeated boosting immunizations. C-
terminal fused E7 was found to induce strong antibody responses, with the possible 
drawback of thereby counteracting a strong anti-tumor response which in turn was 
speculated to be overcome by a suitable adjuvant [144]. A third construct, L1ΔN10Δ408-
431-p16INK4a-ΔC29, was generated based on the work of Murata and colleagues [129]. 
Here, the complete p16INK4a encoding sequence was substituted for the deleted L1 helix 4 
domain (aa 404-436) whereby 9 amino acids were deleted additionally as described in their 
report. They have shown that the helix 4 region can function as an alternative antigen 
display site within the L1 capsomeres thereby eliciting antibody responses against a non-
HPV encoded protein (conserved neutralizing epitope of the human respiratory syncytial 
virus (RSV) fusion (F) protein). As the helix 4 projects outwards and laterally from 
capsomeres [36] it may be more susceptible for amino acid insertions compared to other 
regions of the protein [129]. The three desired pGex-4T-2 vector constructs could be 
successfully cloned and were transformed into the expression strains BL21 and Rosetta. 
The correct insert sequences were confirmed by digestion with the appropriate restriction 
enzymes and sequencing with different primers.  
The three chimeric constructs, L1-p16INK4a p16INK4a-L1 and L1-p16INK4a-L1 as well as the 
control proteins L1 and p16INK4a were expressed in E. coli. The GST-p16INK4a protein was 
expressed soluble, whereas the L1 containing proteins were all found to be highly insoluble 
with only smallest amounts that could be purified from the supernatants after cell lysis. As 
the bulk protein remains in the pellet, this speaks for massive inclusion body production as 
observed before [144, 154, 156, 157]. Inactive protein aggregates accumulate and form 
insoluble structures. Many recombinant proteins tend to undergo misfolding and 
accumulation as inclusion bodies when overexpressed in bacterial systems. However, the 
formation of inclusion bodies provides several advantages over soluble expression as the 
protein is present in a highly enriched form and can be easily separated from other host cell 
proteins. As long as proper refolding is ensured, the purification from inclusion bodies is one 
of the most effective protein production strategies. For these reasons several proteins are 
produced by solubilization and refolding from IBs, for example ovine growth hormone [158], 
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human growth hormone [159] or the recombinant bonnet monkey zona pellucida 
glycoprotein [160] (for review see [161]). Despite these successful examples, refolding of IB 
complexes can be extremely challenging. Therefore, soluble protein expression of the 
chimeric capsomeres was intended in the first instance. To improve soluble protein 
expression, several attempts were made but did not result in markedly better solubility. The 
adaption of induction conditions and temperature [162] as well as application of osmotic 
and/or heat stress [145] did not lead to increased amounts of soluble expressed proteins. 
Therefore, the standard expression conditions (induction at OD600 2 - 3 with 0.1 mM IPTG 
for 17 h at 22°C) were used for the protein production. This expression protocol was 
adapted from a modified protocol described in the thesis of L. Schädlich [144] and was 
reported to yield sufficient amounts of soluble protein. The delay in induction until relatively 
high cell densities (OD600nm > 4.0) was also reported to be beneficial for other proteins 
[163]. In our settings, with using highly enriched TB culture medium, OD600nm values of 
maximum 3.0 could be reached until entry into stationary phase. Therefore the cultures 
were induced when two following OD600 values indicated bacterial growth arrest. The 
comparison of the two tested E. coli strains, BL21 and Rosetta, did not reveal significant 
differences concerning protein yield; however, for the E. coli BL21 strain substantial co-
expression of bacterial GroEL was observed. As these chaperones were always found to be 
co-purified, it was decided to use E. coli Rosetta for further expression and purification 
attempts. As solubility of the chimeric capsomeres could not be improved to a satisfying 
degree, we decided to proceed with the inclusion bodies. 
 
11.2 Purification of chimeric capsomeres expressed as inclusion bodies 
The insolubility observed for our L1-containing chimeric constructs was also found in 
previous studies with E6 and/or E7 fused to L1. Expression and purification of these 
chimeric fusion proteins in and from E. coli proved to be extremely challenging due to the 
high insolubility [144]. The modified L1 construct (L1ΔN10Δ408-431ΔC29) alone was 
reported to be more soluble when expressed in bacteria [76]; however this could not be 
confirmed or rather depends on the base of comparison. The N-terminal truncation and 
other modifications of L1 were introduced to improve solubility, but substantial protein loss 
and thereby inefficient purification due to insolubility was observed also with this protein 
[144]. In our case, the expression of L1 alone was very similar to that of the L1-p16INK4a-
fusion proteins. This indicates neither a supportive nor impairing effect of the p16INK4a fusion 
on the solubility of the proteins. The protein yield after purification was specified to be 0.75 
mg per liter bacterial culture being the best achievable result in a paper published by L. 
Schädlich et al. [76]. This can be attributed to analytical overexpression. To enable efficient 
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production of a recombinant protein, including up-scaling possibilities and consideration of 
economical aspects, purification of the soluble fraction would not be suitable. With the 
inclusion body purification protocol developed during this thesis, including N-
Lauroylsarcosin denaturation and refolding, target protein amounts of 29 mg (L1), 40 mg 
(L1p16), 34 mg (p16L1) and 55 mg (L1p16L1) could be obtained from 100 ml bacterial 
culture. This equates to a 727-fold increase just for the L1 protein purified from IBs 
compared to the results reported for the soluble fraction, whereby the exact same L1 vector 
construct (pGex-L1ΔN10Δ408-431ΔC29) was used. For the soluble fractions of the GST-
tagged proteins, similar amounts were purified during this thesis, but as this is obviously a 
very inefficient purification strategy with low yields, it would require large culture volumes 
and many purification runs to produce sufficient amounts for further studies. This in turn 
increases material and employee costs and would therefore not be suitable to perform in 
low resource settings. For these reasons, the purification from inclusion bodies provides 
several advantages as high protein concentrations can be produced from smaller culture 
volumes. Even cost intensive chromatographic purification does not need to be applied, 
providing another beneficial feature of the described protocol. 
The co-expressed GST-tag was initially contemplated to be used during purification as GST 
binds to glutathione with high affinity and the tagged protein can thereby be separated from 
other host cell proteins via affinity chromatography. We have evaluated various strategies to 
remove the tag from the protein preparations after inclusion body purification. Thereby it 
was found that the enzymatic activity of GST is substantially diminished, which is probably 
due to improper refolding after denaturation. Also antibody affinity, ion exchange (IEX) and 
size exclusion chromatography, which do not require GST activity, did not result in a 
sufficient separation of the tag. This indicates a strong association of GST with the target 
protein, possibly in aggregates. Another approach for further studies could be the removal 
of the tag before refolding of the protein, as this was not evaluated here. For example 
antibody affinity chromatography (Protein G or CnBr based) could be tested with the 
denatured proteins. Another alternative purification method could be the application of IEX 
with denatured proteins as it was described by Bian et al [157]. The GST-tag keeps 
otherwise insoluble proteins in solution [37, 164] and it was reported that its removal is a 
critical step with major protein losses caused by precipitation [144]. Therefore, the 
purification of chimeric proteins as full GST-fusions was suggested before [144] and even a 
clinical trial with a GST-E7 fusion protein was intended [165]. As this also bypasses the cost 
intensive thrombin mediated cleavage step, we continued with further evaluation of the 
GST-tagged chimeric L1 - p16INK4a proteins.  
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12 Evaluation of the purified chimeric capsomeres 
12.1 Evaluation of the chimeric capsomeres purified from inclusion bodies  
The capsomere preparations are stable at room temperature and after repeated freeze-
thaw cycles. The proteins were handled at room temperature most of the time, including 
purification. This increased stability of capsomeres was reported to be advantageous over 
complete VLPs [150, 166, 167]. Besides good stability characteristics, the L1 - p16INK4a 
capsomeres were found to be of rather heterogeneous structure with many unassembled 
protein molecules as visualized by TEM. Assembled capsomeres had a diameter of about 
10 nm which is consistent with previous reports [149, 167], however, a certain tendency to 
form aggregates was observed for all fusion proteins. Other groups also showed 
aggregation and poor yields for the L1ΔC34-E7 protein purified from baculovirus-infected 
insect cells [168] or for various chimeric capsomere constructs that were obtained from E. 
coli preparations [144]. Sedimentation analysis revealed the presence of small particles (1 - 
4S) which is consistent with previous studies [76, 137, 148]. An antigen capture ELISA with 
the conformation-specific anti-L1 antibody 1.3.5.15 (Ritti01, [169]) exhibited few 
conformation-specific epitopes. This suggests that the L1 - p16 fusion proteins were at least 
partially misfolded which was also reported before for L1-E7 chimeras [144]. Nevertheless, 
the structural inconsistencies did not seem to influence immunogenicity of the chimeric 
capsomeres (see 12.2) as it was also shown for L1-RSV F pentamers [129].  
The purified chimeric protein preparations also contained several truncated fragments that 
could be identified to be of L1 and p16INK4a origin. This phenomenon may be due to partial 
degradation, non-optimal gene transcription and/or ribosomal protein translation. Partial 
degradations and resulting truncated fragments were also observed previously [137]. 
Protein concentrations of the full length target proteins were therefore determined 
densitometrically to exclude those truncated fragments. With the presented inclusion body 
purification strategy it was possible to generate high concentrations of purified capsomeres 
(L1: 1.79 mg/ml; L1p16: 0.94 mg/ml; p16L1: 1.32 mg/ml; L1p16L1: 1.11 mg/ml) with 
markedly higher yields, ranging from 29 to 55 mg pure target protein obtained from 100 ml 
bacterial culture, than ever reported to date. Furthermore, the IB-derived capsomeres were 
found to be free of contaminating lipopolysaccharides (LPS), the major component of the 
outer membrane of Gram-negative bacteria like E. coli. LPS can cause severe side effects 
such as fever, tissue damage and septic shock when entering the blood stream [170-172]. 
To prevent the occurence of these LPS-caused reactions, the maximum amount for 
endotoxins allowed in i.v. injections in humans was set to be 5 endotoxin units (EU) per kg 
body weight per hour [147]. LPS contaminations can also impact the immunogenicity of e.g. 
a vaccine as demonstrated for HPV16 L1 capsomeres [130]. Therefore, different strategies 
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were developed to remove endotoxins from pharmaceutical products. Triton X-114 phase 
separation technique was found to be an effective method for removing bacterial endotoxins 
from protein preparations [130, 141] and was used during this project, too. To detect LPS 
contaminations in our purified proteins we used the Limulus Amebocyte Lysate (LAL) Test 
(Lonza) which is an “end-product endotoxin test for human and animal parenteral drugs, 
biological products, and medical devices” [173]. As the developed inclusion body 
purification includes several Triton X-100 wash steps, the L1-containing capsomere 
preparations were found to be free of endotoxins after refolding from IBs. Only the GST-p16 
protein that was purified from the soluble fraction via GSTrap affinity chromatography 
contained considerable amounts of LPS. These were successfully removed by Triton X-114 
phase separation while providing high protein recovery.  
 
12.2 Immunogenicity of the capsomere constructs 
The immunological potential of the purified chimeric capsomeres was evaluated in vivo in 
C57BL/6 mice. We could show that the immunization with chimeric p16INK4a -L1 capsomeres 
follows a dose response effect as it could be expected that the immune response increases 
with increasing antigen concentration. With the previously described H2-Db-restricted L1 
peptide (AGVDNRECI), strong T cell responses could be measured. However, the detection 
of p16INK4a-specific T cells by IFNγ ELISpot without known H2-Db-restricted epitopes was 
generally challenging. This was also previously observed for the E7 antigen fused to the 
modified L1 protein [144, 174]. A peptide pool comprising thirteen overlapping long peptides 
covering the complete p16INK4a sequence was found to be unsuitable for the detection of 
p16INK4a-specific T cells. In a last experiment that was conducted during this thesis, three 
software-predicted synthetic peptides P1 (TRGSNHARI), P2 (LPVDLAEEL) and P3 
(GSARVAELL) were used for the stimulation of splenocytes and L1p16 capsomeres were 
found to induce a polyclonal, robust cytotoxic T lymphocyte (CTL) response to these three 
different H2-Db-restricted p16INK4a peptides as determined by ELISpot assay. Furthermore, 
it appeared that the cellular response to the p16INK4a proportion was weaker than that to L1. 
This could be due to the fact that the chimeric capsomeres contain less p16INK4a protein 
than L1 as p16INK4a compromises a relative molecular weight proportion of only 18 percent 
of the fusion protein (GST: 28%; L1: 54%). This means that L1 is present in a 3-fold excess 
compared to p16INK4a. CTL responses to these two antigens might also not be balanced 
because of immunodomination of the L1 protein whereby the cellular immunity focuses 
towards one antigenic determinant [175]. Another possibility is the presence of another 
dominant antigenic epitope, which was not predicted and therefore not covered by the 
ELISpot assay. The three different fusion proteins showed similarly high levels of L1-
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specific T cells generated in response to the immunization with chimeric capsomeres. 
Therefore, the generation of p16-specific T cells seems plausible also in the other 
experiments where the predicted peptides were not yet used for the ELISpot, but the long 
overlapping peptide pool. However, p16-specific antibodies could be detected in most of the 
immunized mice. The strong cellular immune response to L1 shows that at least the L1 
proportion is immunogenic in these previous experiments. This suggests that the fusion 
proteins are accessible to the antigen presentation machinery, can be presented by MHC I 
molecules and thereby stimulate cytotoxic T cells. Splenocytes consist of different cell 
populations such as T and B lymphocytes, dendritic cells and macrophages but it can be 
assumed that we detected a cytotoxic immune response as 9-mer peptides are capable of 
stimulating CD8+ T cells. The type of cellular immune response is important for cancer 
vaccines. CD8+ T cells are considered to be necessary targets for effective strategies and 
in many cancers, the presence of tumor infiltrating CD8+ T lymphocytes positively 
correlates with a good prognosis [176].  
By testing single immunizations, it turned out that boosting by repeated immunization is 
necessary for a strong, effective immune response. Further it was found that the vaccine 
formulation in Montanide ISA 51 adjuvant did not improve the immune response over the 
PBS formulation in our setting - although this should be confirmed using a larger cohort. It 
should also be tested if the formulation in Montanide provides an advantage over PBS when 
a single immunization is applied. This is likely the case as a rapid antibody response was 
reported and it was claimed that booster injections may not be needed [177]. Montanide is 
based on metabolizable squalene oil, emulsified with mannide mono-oleate. It encapsulates 
antigens (antigen delivery vehicle) in a water-in-oil (W/O) emulsion which induces strong 
and long term immune responses and in particular CD8+ T cells [178, 179]. This adjuvant 
was used for the respective experiment as the peptide which is currently used in a clinical 
trial (Vicoryx, [125]) is also formulated in Montanide. W/O emulsions are standard vehicles 
for therapeutic vaccines against cancer and other diseases and various clinical trials in 
which thousands of individuals received Montanide with different antigens approved its 
efficacy and safety [178, 180]. 
The purified L1 - p16INK4a capsomeres were tested for contaminating endotoxins and were 
found to be free of those. Therefore, it can be assumed that the high immunogenicity of the 
particles can be attributed to L1 and not to an adjuvant effect of contaminating LPS. It 
should be considered that the GST-tag was also part of the immunized capsomeres. 
However, GST itself has also been shown to be highly immunogenic and was tested in 
clinical trials for use as a vaccine against schistosomiasis [181-184]. It was speculated that 
GST may interfere with the induction of a L1 (and therefore probably also with a p16INK4a) 
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immune response [144]. This can be moderated by the finding that GST-COPV (canine oral 
papillomavirus) L1 pentamers provide protection against provoked infections of dogs’ oral 
mucosa [149]. Also a GST-E7 protein was immunogenic and could protect mice from E7 
transfected tumor cells [165]. 
The comparison of the three different constructs revealed different characteristics with 
regard to their immunogenicity. L1p16L1 induced highest L1-specific T cell numbers, p16L1 
showed the best antibody response in the VLP-capture ELISA and L1p16 seemed to induce 
the best anti-p16 humoral immune response. Other studies by L. Schädlich et al. [144] 
showed that the E7-L1ΔN10Δ408-431ΔC29, the analogue to our p16L1 protein, had a high 
anti-tumor activity but required booster immunizations to induce efficient antibody 
responses. The C-terminal fusion L1ΔN10Δ408-431ΔC29-E7, analogue to our L1p16, 
elicited strong antibody responses. However, it is possible that a strong antibody response 
counteracts the development of a strong anti-tumor response [144], most likely because of 
the presence of pre-existing antibodies that neutralize subsequent antigen doses [185, 186]. 
Considering this, the finding that L1-VLPs induce much higher humoral immune responses 
than capsomeres [37, 68, 155], can be relativized as we mainly focus on the induction of an 
effective cellular immune response. Capsomeres are basically L1 pentameres in which the 
helix 4 region is deleted to prevent particle assembly into full VLPs. It has been speculated 
that the helix 4 itself contains an epitope that is essential for a strong antibody response 
[144] or that the assembly into larger structures than capsomeres is beneficial for high 
immunogenicity [76]. This is also supported by the finding that chimeric fusion proteins 
lacking the helix 4 region were most efficient at inducing neutralizing antibodies [144] what 
might be explained by the aggregation theory, too, as the chimeric particles showed a 
certain tendency to build agglomerates. In addition, our L1 - p16 capsomeres were mainly 
present in aggregated form with heterogeneous particles and sticky agglomerates. This 
appearance could possibly have a beneficial effect on the development of a potent anti-
tumor immune response. Further mouse experiments will be conducted to elucidate this 
possibility and to compare the different structural isoforms. 
 
13 Chimeric HPV16 L1 - p16INK4a capsomeres as a potential 
vaccine 
13.1 p16INK4a as an antigen for therapeutic HPV vaccines 
p16INK4a, also known as the cyclin-dependent kinase inhibitor 2A (CDKN2A), regulates cell 
cycle progression and promotes cellular senescence. The HPV oncogenes E6 and E7 
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degrade the key regulator proteins p53 and retinoblastoma protein (pRb) respectively and 
thereby release p16INK4a from its negative feedback loop. This in turn leads to an increased 
expression of p16INK4a protein in cervical dysplastic lesions and carcinomas. [107, 117, 118, 
122]  
The role of p16INK4a as a tumor suppressor protein is somehow controversial in HPV16 E7 
expressing cells as its biological activity is similar to that of an oncogene in these conditions 
as demonstrated by McLaughlin-Drubin and colleagues [121]. They showed that E7 
expression causes an addiction of cervical cancer cell lines to the H3K27 targeting histone 
lysine demethylase (KDM6B). E7 triggers oncogene induced stress (OIS), a cell-intrinsic 
tumor-suppressive mechanism, and thereby induces p16INK4a expression. On the other hand 
E7 simultaneously targets pRb for proteosomal degradation as pRb is a key mediator of 
OIS and p16INK4a induced senescence. This way, the E7-caused epigenetic de-repression is 
mediated by p16INK4a which is an important KDM6B downstream target and inhibitor of 
CDK4/CDK6. In cervical cancer cells, where pRb is inactivated, p16INK4a is therefore 
necessary for the survival of transformed cells. [53, 121] The increased p16INK4a expression 
in HPV-associated tumors can thus be interpreted as an attempt to stop uncontrolled 
proliferation but as p16INK4a is released from its negative feedback control by pRb 
inactivation and KDM6B overexpression, elevated levels of this protein do not lead to cell 
cycle arrest in tumor cells. An alternative hypothesis states that the pRb degradation should 
rather abrogate the p16INK4a-mediated response to oncogenic stress and thereby inhibit 
senescence [53].   
The phenomenon of p16INK4a overexpression is utilized as a surrogate marker of 
transforming HPV-infected epithelia [22, 111, 117, 120] and should now also be exploited 
for the development of a therapeutic vaccine which specifically targets p16INK4a 
overexpressing cancer cells. p16INK4a is designated as a “tumor-associated antigen”. In 
contrast to “tumor-specific antigens” like E6 and E7, a certain level of expression in normal 
tissues often exists. For our chimeric L1 - p16 vaccine candidates this could be problematic 
in terms of tolerance to this antigen [176]. However, if it is possible to generate an immune 
response to this auto-antigen, not only patients with HPV-associated cancers would benefit 
from such a vaccine as many other cancers, including renal, prostate, breast, ovarian and a 
subset of lung cancers, express high levels of p16INK4a [187-192]. Furthermore, several 
precancerous neoplasias demonstrate increased p16INK4a expression [193, 194] and a 
p16INK4a-directed vaccine might thus even prevent development of invasive cancer. The 
induction of an auto-immune response has high potential for anti-cancer therapies [195, 
196]. Breaking of immune tolerance to "self-antigens" is therefore an attractive approach for 
tumor immunotherapy that was subject of different studies before. For example basic 
fibroblast growth factor (bFGF) was shown to activate normal dermal fibroblasts and makes 
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them have analogous properties with cancer-associated fibroblast. Mice that were 
immunized with bFGF-activated fibroblasts had an apparent protection from tumor onset 
and growth [197]. Also protein/peptide-based vaccines that are combined with adjuvants to 
induce regulatory T cells (Tregs) are being investigated for their potential in therapeutic 
vaccination against chronic inflammatory conditions [198] as the activation of Tregs would 
inhibit auto-reactive T effector cells and thereby have an anti-inflammatory effect [199]. Self-
tolerance is also considered to be responsible for the limited capacity of the human immune 
system to control and prevent tumor outgrowth [195]. 
The p53 tumor suppressor protein shows several parallels to p16INK4a as it likewise prevents 
expansion of abnormal cells and its function is impaired in about 50% of human cancers 
[195]. Some of the differences and similar functions important in this context are listed in 
Table 5. In cervical carcinoma, p53 is degraded by the HPV E6 oncoprotein. Contrary to 
p16, p53 was intensively studied as a tumor antigen before and is considered to be an 
attractive target for immunological approaches [195, 200-202].  
 
Table 5: Comparison of p16
INK4a
 and p53 tumor suppressor proteins 
 p16INK4a p53 
encoding gene  CDKN2A TP53 
location 
chromosome 9 
(9p21.3) 
chromosome 17 
(17p13.1) 
MW (kDa) 15.8 43.7 
function 
tumor suppressor and cell cycle regulator 
prevent expansion of abnormal, tumorigenic cells 
cell cycle arrest at the G1/S phase 
role in cancer 
frequently mutated or deleted in various tumors; 
often overexpressed in cancer cells 
targeting HPV oncogene E7 E6 
 
p53 is used as a well-studied example here as it also is an auto-antigen analogous to 
p16INK4a is. CD4+ as well as CD8+ T cell responses to the p53 protein could be induced by 
immunizations as demonstrated by different studies [200, 202]. Anti-self p53 responses 
were generally weak and not capable to eradicate tumor cells but the p53 tolerance can be 
overcome in vivo [201]. Further studies on p53 determinants revealed the presence of more 
tolerance-inducing T cells (Th2) than of those which could promote rejection (Th1) of p53 
overexpressing cancer cells [195]. As p16INK4a was not subject of intense vaccination 
studies so far, the distribution of potential antigenic determinants for this protein remains 
elusive. If it would be the other way around for the p16INK4a protein, so that the rejection-
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inducing determinants overweight the tolerance-inducing ones, the p16INK4a vaccination 
strategy would be additionally supported. 
Altogether, it is conceivable that an intrinsic response to p16INK4a, as it was observed in 
some patients before [123], can be provoked and enhanced by vaccination. This hypothesis 
is supported by studies with other auto-antigens like p53 and first insights with a synthetic 
long peptide p16-vaccine, Vicoryx [125]. Moreover, in this thesis, encouraging results are 
presented which demonstrate the induction of p16INK4a-specific antibodies and also cytotoxic 
T lymphocytes by immunization with chimeric capsomeres comprising p16INK4a. It should be 
considered that the human p16INK4a protein used during these studies could also elicit its 
T cell-inducing function via a xenogenic effect as the antigenic epitopes were mainly 
predicted within non-conserved sequences of human and murine p16INK4a. However, with a 
vaccine containing the full-length p16INK4a protein we provide all antigenic epitopes possible 
to increase the chance for an effective immune response towards this auto-antigen. This 
would be an essential step in the area of therapeutic vaccines with the potential of inducing 
regression of p16INK4a-positive tumors. 
 
13.2 HPV16 L1 capsomere conjugation to full length p16INK4a 
The potential of chimeric virus-like particles (CVLPs) as self-adjuvanting immunogen 
delivery systems for the therapy of HPV-associated lesions and cervical cancer was 
demonstrated in different studies before [70, 174, 203, 204].  Also chimeric VLPs derived 
from bovine papillomavirus (BPV) [71, 168, 205], cotton-tail rabbit papillomavirus (CRPV) 
[206] and canine oral papillomaviruses (COPV) [81] were evaluated for their immunologic 
potential. Papillomavirus VLPs are able to induce strong immune responses and allow 
antigen presentation within a highly organized context as part of the regular array of 
assembled capsomeres [73, 74]. The oncogenes E6 and E7 were often the fusion partners 
of choice to specifically target HPV transformed cells. As VLPs were shown to be potent 
antigen carriers, other, non-HPV related antigens were also evaluated as fusion partners. 
For example the conjugation of mouse self-peptide TNF-α to papilloma VLPs leads to 
efficient induction of protective auto-antibodies  [74]. The conjugation of influenza type A M2 
protein to HPV VLPs was also found to be highly immunogenic and conferred good 
protection against lethal challenge of influenza virus in mice [72]. In another study, hepatitis 
B virus core antigen (HBcAg)-VLPs were successfully used for the display of a surface 
epitope of the tumor-associated marker claudin-18 [207].  
However, assembly into complete VLPs was found to be no pre-requisite for the induction of 
an immune response [137, 166] and that antigenic domains are contained in capsomeres 
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[78]. HPV major capsid protein L1 capsomeres were also demonstrated to be efficient 
antigen carriers for the development of conjugate vaccines. Because of the structure of 
capsomeres, they exhibit an intrinsic adjuvant-like function as it was found for assembled 
VLPs, too. Chimeric L1-E7 capsomeres were early demonstrated to enable effective MHC 
class I-restricted antigen presentation and to induce an E7-specific CTL response in mice in 
absence of an adjuvant [174]. Also non-HPV related antigens, like the respiratory syncytial 
virus fusion protein [129], were successfully presented in the context of capsomeres to 
provide a therapeutic element. The capsomere production in E. coli was another step 
towards an efficient and economic therapeutic vaccine [37, 76, 157, 208].  
Because of these encouraging results from other groups, we generated chimeric HPV16 L1 
capsomeres fused to the full length p16INK4a protein with the aim of developing a combined 
prophylactic and therapeutic vaccine, although the main focus of this project was the 
therapeutic approach. The conjugation of an antigen to VLPs was shown to abrogate the 
ability of the humoral immune system to distinguish between self and foreign [74]. This is 
interesting as p16INK4a is also a weakly immunogenic, self-derived antigen and it can be 
assumed that this holds also true for capsomeres. We decided to use the full-length p16INK4a 
protein (156 aa) to provide the possibility of CTL and T helper cell induction against several 
epitopes and thereby preventing tumor cell escape by mutation of one relevant epitope. 
This strategy was previously proven to be effective with L1-E71–60 CVLPs [174] and also 
peptide immunization studies suggest the use of at least peptides longer than 9-mers as 
they show greater efficacy [180, 202, 209]. 
 
13.3 Evaluation of the prophylactic and therapeutic potential of the chimeric 
proteins 
Women who are already infected do not benefit from the currently available prophylactic 
vaccines which are based on L1 VLPs and predominantly induce a strong humoral immune 
response against the major capsid protein of the virus [93, 94]. These antibodies then 
neutralize incoming virus particles and thereby prevent a new HPV infection. However, in 
high grade dysplasia and cervical carcinoma, no HPV capsid proteins are detectable due to 
the transformed phenotype which is released from its tightly controlled “normal” viral life 
cycle [95]. Contrary to the prophylactic vaccines, therapeutic vaccination aims in the 
induction of a strong, long lasting CD8+ cytotoxic T cell response to selectively target and 
eliminate tumor cells. Cell-based cancer immunotherapy is a promising method to treat 
cancer whereby the patients’ own immune system is harnessed to induce an anti-tumor 
response [197]. Various therapeutic attempts target the early proteins, mainly E6 and E7, 
with varying success so far [94, 97, 166, 174]. For example ProCervix (Genticel [210]), 
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which is based on an adenylate cyclase vector from Bordetella pertussis, was shown to 
induce E7-specific T cell responses in the majority of vaccinated patients. This vaccine will 
probably enter the market soon, but an important drawback is its intended application for 
HPV16/18 positive women, prior to the appearance of high grade cervical lesions. As most 
of those lesions resolve spontaneously, the actual use of ProCervix is questionable. Other 
candidate vaccines that were presented in the last years are e.g. ZYC101a, a DNA vaccine 
based on E6 and E7 fragments (HPV16 & 18) [77]; a live-attenuated Listeria 
monocytogenes vaccine Lovaxin-C [152]; MVA E2 (Modified Vaccinia Ankara virus) [211] 
and several E6 and E7 long peptide vaccines [98, 153].  
In the context of these and other studies, the problem of only type-specific immunity 
induced by E6/E7 immunization is usually not discussed. To overcome those issues, we 
developed a capsomere-based vaccine comprising the tumor suppressor protein p16INK4a 
which is strongly expressed in cervical cancer and precursor lesions independent of the 
infectious genotype as demonstrated by various studies [22, 106-108, 110, 121, 126]. Table 
6 lists some of the respective advantages and disadvantages of p16INK4a as a therapeutic 
element in comparison to the conventional E6/E7 targeting strategies.  
 
Table 6: Comparison of advantages and disadvantages of therapeutic vaccination strategies using p16
INK4a
 vs. 
E6/E7. 
vaccine target p16INK4a E6/E7  
characteristics 
 tumor suppressor protein  
 tumor-associated antigen 
 viral oncoproteins  
 tumor-specific antigens  
advantages + 
 strong overexpression in HPV-
associated cancer 
 universal cellular protein - type 
unspecific 
 potential use in other p16-
expressing cancer types 
 overexpression in HPV-
associated cancer 
 no expression in 
uninfected/untransformed cells 
 immunogenic, viral antigens 
disadvantages - 
 weak expression in normal, 
senescent cells 
 self-antigen  
 type specific oncoproteins 
 no cross-reactivity 
 despite excessive research - no 
therapeutic vaccine on the 
market yet 
 
We generated HPV16 L1 capsomeres fused to the full length p16INK4a protein. Capsomeres 
are considered to be more stable than complete VLPs what could be confirmed during this 
thesis. The circumvention of cold-chains and inexpensive production in bacterial systems 
makes them ideal vaccine candidates, especially for developing countries [148, 166]. 
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Traditional purification strategies often include a gel ﬁltration step [37, 76, 137, 167]. This is 
difficult to scale-up and translation into a production process would be challenging. The 
purification from inclusion bodies, by avoiding such a step, therefore provides obvious 
advantages for a cost effective production of the vaccine. Furthermore, the inclusion bodies 
can be easily purified to high purity, and even absence of endotoxins can be ensured with 
such a protocol.  
It was also demonstrated that the inclusion body derived proteins are able to induce 
antibody responses against VLPs and p16 peptides which could probably be further 
increased with a suitable adjuvant formulation. An effective humoral immune response is 
crucial for a prophylactic effect, and to prevent HPV infections. This underlines the potential 
of capsomere-based vaccines also as alternative prophylactic vaccine candidates that could 
be provided in low-resource settings. Moreover, the fusion proteins were able to induce a 
strong L1-specific T cell response and also p16INK4a -reactive T lymphocytes could be 
detected, even in the absence of an adjuvant. This provides the basis for CTL-mediated 
tumor cell killing and therefore a likely therapeutic effect. However, the full immunological 
potential of the chimeric L1 - p16INK4a capsomeres needs to be further evaluated in vivo with 
tumor challenging experiments. 
Altogether, vaccination with chimeric HPV16 L1 capsomeres fused to the p16INK4a protein 
presents an alternative strategy to control and treat existing HPV infections and associated 
malignancies and justifies further evaluation.  
 
13.4 Future prospects 
Combined prophylactic and therapeutic vaccination against HPV induced neoplasias and 
cervical cancer would have high benefits for already infected women and a stable, cost 
efficient vaccine could also be implemented in low resource settings. This work is a 
milestone on the development of a vaccine targeting the cellular tumor suppressor protein 
p16INK4a which is de-regulated and highly overexpressed in HPV transformed cells. Because 
of the encouraging results presented in this thesis, the project will be continued in the near 
future.  
We intend to address an alternative expression of the chimeric capsomeres without the 
GST-tag as its presence would most likely complicate regulatory approval of the vaccine 
candidates. Detailed investigations have led to the conclusion that either a pSE380 
(Invitrogen, LifeTechnologies) or a pTrc99A (former Pharmacia, GE Healthcare) plasmid 
vector could be used for the expression of the chimeric capsomeres without any tag. It is 
likely that the L1-containing proteins will form inclusion bodies upon their expression in E. 
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coli as low solubility of L1 was shown in different studies before [144, 148, 154, 157]. In this 
case, the established purification protocol could be used to obtain high amounts of LPS-free 
fusion protein as it was demonstrated in this dissertation.  
With the purified capsomeres, further in vivo studies are planned to evaluate their full 
immunological potential. Therefore we will compare the three constructs L1p16, p16L1 and 
L1p16L1 in another experiment, especially with respect to the inducible p16INK4a T cell 
response. Moreover, tumor protection and regression experiments are planned. However, 
beforehand a murine cell line needs to be generated which expresses the human p16INK4a 
protein. Preliminary experiments (data not shown) suggest that transfection using 
Nucleofection (Amaxa) will be suitable to introduce a p16INK4a encoding plasmid into RMA-S. 
These cells do not express murine p16INK4a as demonstrated by western blot of whole cell 
lysates (see Figure 67, VII Appendix), and could therefore be used as a negative control for 
the tumor challenge experiments, too. 2F11 cells could be an alternative for these attempts 
as they also do not show intrinsic p16INK4a expression. If it is not possible to generate a 
stable human- p16INK4a expressing murine cell line with RMA-S or 2F11 cells, C3 or TC-1 
cells could be used to establish p16INK4a-expressing tumors in mice as both cell lines do 
express murine p16INK4a. This model would either require a xenogenic effect of mice 
vaccinated with human p16INK4a or would require the design of murine p16INK4a vaccine 
constructs in addition. 
 
 
References  121 
V. References 
 
1. Parkin DM: The global health burden of infection-associated cancers in the 
year 2002. IntJCancer 2006, 118:3030-3044. 
2. Doorbar J: The papillomavirus life cycle. JClinVirol 2005, 32 Suppl 1:S7-15. 
3. Grm HS, Bergant M, Banks L: Human papillomavirus infection, cancer & 
therapy. Indian JMedRes 2009, 130:277-285. 
4. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz 
LE: Prevalence of HPV infection among females in the United States. JAMA 
2007, 297:813-819. 
5. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee 
F, Franco EL: The natural history of type-specific human papillomavirus 
infections in female university students. Cancer EpidemiolBiomarkers Prev 2003, 
12:485-490. 
6. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson 
G, McGoogan E: Multiple high risk HPV infections are common in cervical 
neoplasia and young women in a cervical screening population. JClinPathol 
2004, 57:68-72. 
7. Doorbar J: Molecular biology of human papillomavirus infection and cervical 
cancer. ClinSci(Lond) 2006, 110:525-541. 
8. Stanley M: Immunobiology of HPV and HPV vaccines. GynecolOncol 2008, 
109:S15-S21. 
9. Cervical Cancer [http://www.cancer.gov/cancertopics/types/cervical] 
10. Zervixkarzinom. In 032 - 033 ((DKG) DK ed. Frankfurt: Arbeitsgemeinschaft der 
Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF); 2012. 
11. Beckmann MW, Mehlhorn G, Thiel F, Breuel C, Fasching PA, Ackermann S: 
Therapiefortschritte beim primären Zervixkarzinom. Dtsch Arztebl International 
2005, 102:979-. 
12. Bernard HU: The clinical importance of the nomenclature, evolution and 
taxonomy of human papillomaviruses. JClinVirol 2005, 32 Suppl 1:S1-S6. 
13. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA: The 
biology and life-cycle of human papillomaviruses. Vaccine 2012, 30 Suppl 
5:F55-70. 
14. Chow LT, Broker TR, Steinberg BM: The natural history of human papillomavirus 
infections of the mucosal epithelia. APMIS 2010, 118:422-449. 
15. Pim D, Banks L: Interaction of viral oncoproteins with cellular target molecules: 
infection with high-risk vs low-risk human papillomaviruses. APMIS 2010, 
118:471-493. 
16. Lajer CB, von BC: The role of human papillomavirus in head and neck cancer. 
APMIS 2010, 118:510-519. 
17. Riechelmann H: [Human papilloma virus in head and neck cancer]. 
Laryngorhinootologie 2010, 89:43-48, quiz. 
18. Harwood CA, Surentheran T, Sasieni P, Proby CM, Bordea C, Leigh IM, 
Wojnarowska F, Breuer J, McGregor JM: Increased risk of skin cancer 
associated with the presence of epidermodysplasia verruciformis human 
papillomavirus types in normal skin. BrJDermatol 2004, 150:949-957. 
19. Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M: Regulation of 
cellular zinc balance as a potential mechanism of EVER-mediated protection 
against pathogenesis by cutaneous oncogenic human papillomaviruses. 
JExpMed 2008, 205:35-42. 
20. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, 
Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical 
References  122 
cancer: a worldwide perspective. International biological study on cervical 
cancer (IBSCC) Study Group. JNatlCancer Inst 1995, 87:796-802. 
21. Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries--key 
challenges and issues. N Engl J Med 2007, 356:1908-1910. 
22. von Knebel Doeberitz M, Reuschenbach M, Schmidt D, Bergeron C: Biomarkers 
for cervical cancer screening: the role of p16(INK4a) to highlight transforming 
HPV infections. Expert Rev Proteomics 2012, 9:149-163. 
23. A Snapshot of Cervical Cancer 
[http://www.cancer.gov/aboutnci/servingpeople/snapshots/cervical.pdf] 
24. Modis Y, Trus BL, Harrison SC: Atomic model of the papillomavirus capsid. 
EMBO J 2002, 21:4754-4762. 
25. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human 
papillomavirus type 1 capsids by expression of the L1 protein alone or by 
coexpression of the L1 and L2 capsid proteins. JVirol 1993, 67:315-322. 
26. von Knebel DM: New markers for cervical dysplasia to visualise the genomic 
chaos created by aberrant oncogenic papillomavirus infections. EurJCancer 
2002, 38:2229-2242. 
27. Zheng ZM, Baker CC: Papillomavirus genome structure, expression, and post-
transcriptional regulation. Front Biosci 2006, 11:2286-2302. 
28. Amador-Molina A, Gonzalez-Montoya JL, Garcia-Carranca A, Mohar A, Lizano M: 
Intratypic changes of the E1 gene and the long control region affect ori 
function of human papillomavirus type 18 variants. J Gen Virol 2013, 94:393-
402. 
29. Johansson C, Somberg M, Li X, Backstrom Winquist E, Fay J, Ryan F, Pim D, 
Banks L, Schwartz S: HPV-16 E2 contributes to induction of HPV-16 late gene 
expression by inhibiting early polyadenylation. EMBO J 2012, 31:3212-3227. 
30. Ganguly N: Human papillomavirus-16 E5 protein: oncogenic role and 
therapeutic value. Cell Oncol (Dordr) 2012, 35:67-76. 
31. Pillai MR, Lakshmi S, Sreekala S, Devi TG, Jayaprakash PG, Rajalakshmi TN, Devi 
CG, Nair MK, Nair MB: High-risk human papillomavirus infection and E6 protein 
expression in lesions of the uterine cervix. Pathobiology 1998, 66:240-246. 
32. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL: 
Arrangement of L2 within the papillomavirus capsid. J Virol 2008, 82:5190-
5197. 
33. Stauffer Y, Raj K, Masternak K, Beard P: Infectious human papillomavirus type 
18 pseudovirions. JMolBiol 1998, 283:529-536. 
34. Fahey LM, Raff AB, Da Silva DM, Kast WM: A major role for the minor capsid 
protein of human papillomavirus type 16 in immune escape. J Immunol 2009, 
183:6151-6156. 
35. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC: Structures 
of bovine and human papillomaviruses. Analysis by cryoelectron microscopy 
and three-dimensional image reconstruction. Biophys J 1991, 60:1445-1456. 
36. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure of small virus-
like particles assembled from the L1 protein of human papillomavirus 16. 
MolCell 2000, 5:557-567. 
37. Chen XS, Casini G, Harrison SC, Garcea RL: Papillomavirus capsid protein 
expression in Escherichia coli: purification and assembly of HPV11 and 
HPV16 L1. JMolBiol 2001, 307:173-182. 
38. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human 
papillomavirus and cervical cancer. Lancet 2007, 370:890-907. 
39. Ruschoff J, Aust A, Middel P, Heinmoller E: [Anal cancer: diagnostic and 
differential diagnostic issues]. Pathologe 2011, 32:336-344. 
40. Perry ME: The specialised structure of crypt epithelium in the human palatine 
tonsil and its functional significance. J Anat 1994, 185 ( Pt 1):111-127. 
References  123 
41. Boscolo-Rizzo P, Del Mistro A, Bussu F, Lupato V, Baboci L, Almadori G, MC DAM, 
Paludetti G: New insights into human papillomavirus-associated head and neck 
squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013, 33:77-87. 
42. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM: Role of 
heparan sulfate in attachment to and infection of the murine female genital 
tract by human papillomavirus. J Virol 2009, 83:2067-2074. 
43. Abban CY, Meneses PI: Usage of heparan sulfate, integrins, and FAK in HPV16 
infection. Virology 2010, 403:1-16. 
44. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM: The initial steps leading 
to papillomavirus infection occur on the basement membrane prior to cell 
surface binding. Proc Natl Acad Sci U S A 2009, 106:20458-20463. 
45. Schiller JT, Day PM, Kines RC: Current understanding of the mechanism of HPV 
infection. Gynecol Oncol 2010, 118:S12-17. 
46. Ledwaba T, Dlamini Z, Naicker S, Bhoola K: Molecular genetics of human 
cervical cancer: role of papillomavirus and the apoptotic cascade. Biol Chem 
2004, 385:671-682. 
47. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF: Establishment of human 
papillomavirus infection requires cell cycle progression. PLoS Pathog 2009, 
5:e1000318. 
48. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, 
Kast WM: The evolving field of human papillomavirus receptor research: a 
review of binding and entry. J Virol 2013, 87:6062-6072. 
49. Bergant Marusic M, Ozbun MA, Campos SK, Myers MP, Banks L: Human 
papillomavirus L2 facilitates viral escape from late endosomes via sorting 
nexin 17. Traffic 2012, 13:455-467. 
50. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, Schiller JT, 
Helenius A: Entry of human papillomavirus type 16 by actin-dependent, 
clathrin- and lipid raft-independent endocytosis. PLoS Pathog 2012, 
8:e1002657. 
51. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: 
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to 
promote cell growth. EMBO J 1999, 18:2449-2458. 
52. Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ: The human papillomavirus 
type 16 E7 gene product interacts with and trans-activates the AP1 family of 
transcription factors. EMBO J 1996, 15:1950-1960. 
53. McLaughlin-Drubin ME, Crum CP, Munger K: Human papillomavirus E7 
oncoprotein induces KDM6A and KDM6B histone demethylase expression and 
causes epigenetic reprogramming. Proc Natl Acad Sci U S A 2011, 108:2130-
2135. 
54. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes 
premature cell senescence associated with accumulation of p53 and 
p16INK4a. Cell 1997, 88:593-602. 
55. Busch C, Geisler J, Knappskog S, Lillehaug JR, Lonning PE: Alterations in the p53 
pathway and p16INK4a expression predict overall survival in metastatic 
melanoma patients treated with dacarbazine. JInvest Dermatol 2010, 130:2514-
2516. 
56. Piette J, Neel H, Marechal V: Mdm2: keeping p53 under control. Oncogene 1997, 
15:1001-1010. 
57. Roden RB, Day PM, Bronzo BK, Yutzy WH, Yang Y, Lowy DR, Schiller JT: 
Positively charged termini of the L2 minor capsid protein are necessary for 
papillomavirus infection. JVirol 2001, 75:10493-10497. 
58. Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D: Generation of soluble 
NKG2D ligands: proteolytic cleavage, exosome secretion and functional 
implications. Scand J Immunol 2013, 78:120-129. 
59. Patel S, Chiplunkar S: Host immune responses to cervical cancer. 
CurrOpinObstetGynecol 2009, 21:54-59. 
References  124 
60. Stanley M: Immune responses to human papillomavirus. Vaccine 2006, 24 
Suppl 1:S16-S22. 
61. Kanodia S, Fahey LM, Kast WM: Mechanisms used by human papillomaviruses 
to escape the host immune response. CurrCancer Drug Targets 2007, 7:79-89. 
62. Zhang B, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, Roman A: The E5 protein of 
human papillomavirus type 16 perturbs MHC class II antigen maturation in 
human foreskin keratinocytes treated with interferon-gamma. Virology 2003, 
310:100-108. 
63. Fausch SC, Da Silva DM, Rudolf MP, Kast WM: Human papillomavirus virus-like 
particles do not activate Langerhans cells: a possible immune escape 
mechanism used by human papillomaviruses. JImmunol 2002, 169:3242-3249. 
64. Drijkoningen M, De Wolf-Peeters C, Degreef H, Desmet V: Epidermal Langerhans 
cells, dermal dendritic cells, and keratinocytes in viral lesions of skin and 
mucous membranes: an immunohistochemical study. Arch Dermatol Res 1988, 
280:220-227. 
65. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM: Physical 
interaction of human papillomavirus virus-like particles with immune cells. 
IntImmunol 2001, 13:633-641. 
66. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical 
application. NatRevCancer 2002, 2:342-350. 
67. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major 
capsid protein self-assembles into virus-like particles that are highly 
immunogenic. ProcNatlAcadSciUSA 1992, 89:12180-12184. 
68. Bishop B, Dasgupta J, Chen XS: Structure-based engineering of papillomavirus 
major capsid l1: controlling particle assembly. VirolJ 2007, 4:3. 
69. Caspar DL, Klug A: Physical principles in the construction of regular viruses. 
Cold Spring HarbSympQuantBiol 1962, 27:1-24. 
70. Rudolf MP, Fausch SC, Da Silva DM, Kast WM: Human dendritic cells are 
activated by chimeric human papillomavirus type-16 virus-like particles and 
induce epitope-specific human T cell responses in vitro. JImmunol 2001, 
166:5917-5924. 
71. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH: Papillomavirus virus-like 
particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000, 
273:374-382. 
72. Ionescu RM, Przysiecki CT, Liang X, Garsky VM, Fan J, Wang B, Troutman R, 
Rippeon Y, Flanagan E, Shiver J, Shi L: Pharmaceutical and immunological 
evaluation of human papillomavirus viruslike particle as an antigen carrier. 
JPharmSci 2006, 95:70-79. 
73. Chackerian B, Lowy DR, Schiller JT: Induction of autoantibodies to mouse CCR5 
with recombinant papillomavirus particles. ProcNatlAcadSciUSA 1999, 96:2373-
2378. 
74. Chackerian B, Lowy DR, Schiller JT: Conjugation of a self-antigen to 
papillomavirus-like particles allows for efficient induction of protective 
autoantibodies. JClinInvest 2001, 108:415-423. 
75. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M: A direct comparison of 
human papillomavirus type 16 L1 particles reveals a lower immunogenicity of 
capsomeres than viruslike particles with respect to the induced antibody 
response. JVirol 2008, 82:5472-5485. 
76. Schadlich L, Senger T, Gerlach B, Mucke N, Klein C, Bravo IG, Muller M, Gissmann 
L: Analysis of modified human papillomavirus type 16 L1 capsomeres: the 
ability to assemble into larger particles correlates with higher immunogenicity. 
JVirol 2009, 83:7690-7705. 
77. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, 
Silverman M, Urban RG, Hedley ML, Beach KJ: ZYC101a for treatment of high-
grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet 
Gynecol 2004, 103:317-326. 
References  125 
78. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human papillomavirus 
type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. 
JVirol 1998, 72:6151-6154. 
79. Fligge C, Giroglou T, Streeck RE, Sapp M: Induction of type-specific neutralizing 
antibodies by capsomeres of human papillomavirus type 33. Virology 2001, 
283:353-357. 
80. Kreider JW, Bartlett GL: The Shope papilloma-carcinoma complex of rabbits: a 
model system of neoplastic progression and spontaneous regression. 
AdvCancer Res 1981, 35:81-110. 
81. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, 
Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein 
completely prevents the development of viral mucosal papillomas. 
ProcNatlAcadSciUSA 1995, 92:11553-11557. 
82. Stanley MA: Human papillomavirus vaccines. RevMedVirol 2006, 16:139-149. 
83. Kawana K, Yasugi T, Taketani Y: Human papillomavirus vaccines: current 
issues & future. Indian JMedRes 2009, 130:341-347. 
84. Keam SJ, Harper DM: Human papillomavirus types 16 and 18 vaccine 
(recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008, 68:359-372. 
85. Frederick PJ, Huh WK: Evaluation of the interim analysis from the PATRICIA 
study group: efficacy of a vaccine against HPV 16 and 18. ExpertRevAnticancer 
Ther 2008, 8:701-705. 
86. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis 
B, Naud P, De Carvalho NS, et al: Efficacy of a bivalent L1 virus-like particle 
vaccine in prevention of infection with human papillomavirus types 16 and 18 
in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765. 
87. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, 
Koutsky LA, Malm C, Lehtinen M, et al: Prophylactic quadrivalent human 
papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young 
women: a randomised double-blind placebo-controlled multicentre phase II 
efficacy trial. Lancet Oncol 2005, 6:271-278. 
88. Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT: Interaction of 
papillomavirus virus-like particles with human myeloid antigen-presenting 
cells. ClinImmunol 2003, 106:231-237. 
89. Fausch SC, Da Silva DM, Kast WM: Differential uptake and cross-presentation 
of human papillomavirus virus-like particles by dendritic cells and Langerhans 
cells. Cancer Res 2003, 63:3478-3482. 
90. Da Silva DM, Fausch SC, Verbeek JS, Kast WM: Uptake of human papillomavirus 
virus-like particles by dendritic cells is mediated by Fcgamma receptors and 
contributes to acquisition of T cell immunity. JImmunol 2007, 178:7587-7597. 
91. Wang Z, Christensen N, Schiller JT, Dillner J: A monoclonal antibody against 
intact human papillomavirus type 16 capsids blocks the serological reactivity 
of most human sera. JGenVirol 1997, 78 ( Pt 9):2209-2215. 
92. Frazer IH: Measuring serum antibody to human papillomavirus following 
infection or vaccination. GynecolOncol 2010, 118:S8-11. 
93. Hung CF, Monie A, Alvarez RD, Wu TC: DNA vaccines for cervical cancer: from 
bench to bedside. ExpMolMed 2007, 39:679-689. 
94. Kanodia S, Da Silva DM, Kast WM: Recent advances in strategies for 
immunotherapy of human papillomavirus-induced lesions. IntJCancer 2008, 
122:247-259. 
95. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, 
Lowy DR, Kast WM, Schiller JT: Chimeric papillomavirus virus-like particles 
elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor 
model. ProcNatlAcadSciUSA 1998, 95:1800-1805. 
96. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, Wu TC: Immunotherapy for 
cervical cancer: Research status and clinical potential. BioDrugs 2010, 24:109-
129. 
References  126 
97. Albers AE, Kaufmann AM: Therapeutic human papillomavirus vaccination. 
Public Health Genomics 2009, 12:331-342. 
98. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon 
AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al: Vaccination against 
HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 
361:1838-1847. 
99. Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP: 
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the 
common neutralizing epitope for the L2 minor capsid protein of HPV-6 and 
HPV-16. J Virol 2003, 77:8386-8393. 
100. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC: 
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with 
vulval intraepithelial neoplasia. Br J Cancer 2010, 102:1129-1136. 
101. Novagene: iFOLD® Protein Refolding System 1. In User Protocol, vol. TB457. pp. 
7: EMD Chemicals Inc; 2009:7. 
102. Radulovic S, Brankovic-Magic M, Malisic E, Jankovic R, Dobricic J, Plesinac-
Karapandzic V, Maciag PC, Rothman J: Therapeutic cancer vaccines in cervical 
cancer: phase I study of Lovaxin-C. J BUON 2009, 14 Suppl 1:S165-168. 
103. Magalhaes PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A, Jr.: 
Methods of endotoxin removal from biological preparations: a review. J Pharm 
Pharm Sci 2007, 10:388-404. 
104. invitrogen: XCell II™ Blot Module - User Manual. vol. IM9051, MAN0000740 
edition; 2009. 
105. Jochmus I, Schafer K, Faath S, Muller M, Gissmann L: Chimeric virus-like 
particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and 
therapeutic vaccine. ArchMedRes 1999, 30:269-274. 
106. Kalof AN, Cooper K: p16INK4a immunoexpression: surrogate marker of high-
risk HPV and high-grade cervical intraepithelial neoplasia. AdvAnatPathol 2006, 
13:190-194. 
107. Mulvany NJ, Allen DG, Wilson SM: Diagnostic utility of p16INK4a: a reappraisal 
of its use in cervical biopsies. Pathology 2008, 40:335-344. 
108. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, 
Malamou-Mitsi V, Paraskevaidis E: p16(INK4a) immunostaining in cytological 
and histological specimens from the uterine cervix: a systematic review and 
meta-analysis. Cancer TreatRev 2009, 35:210-220. 
109. Yildiz IZ, Usubutun A, Firat P, Ayhan A, Kucukali T: Efficiency of 
immunohistochemical p16 expression and HPV typing in cervical squamous 
intraepithelial lesion grading and review of the p16 literature. PatholResPract 
2007, 203:445-449. 
110. Volgareva GM, Zavalishina LE, Andreeva I, Shtil' AA, Frank GA: [Cell protein 
p16INK4a hyperexpression in epithelial malignancies induced by human 
papillomaviruses]. ArkhPatol 2008, 70:57-61. 
111. Reuschenbach M, Clad A, von Knebel Doeberitz C, Wentzensen N, Rahmsdorf J, 
Schaffrath F, Griesser H, Freudenberg N, von Knebel Doeberitz M: Performance of 
p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade 
cervical dysplasia in women with abnormal screening results. Gynecol Oncol 
2010, 119:98-105. 
112. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control 
causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707. 
113. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert 
E, Day RS, 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially 
involved in genesis of many tumor types. Science 1994, 264:436-440. 
114. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y: 
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related 
CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994, 
8:2939-2952. 
References  127 
115. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification of human and 
mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol 
Cell Biol 1995, 15:2682-2688. 
116. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4 proteins, p19 
and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and 
CDK6. Mol Cell Biol 1995, 15:2672-2681. 
117. Cho NH, Kim YT, Kim JW: Alteration of cell cycle in cervical tumor associated 
with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei MedJ 
2002, 43:722-728. 
118. Serrano M: The tumor suppressor protein p16INK4a. ExpCell Res 1997, 237:7-
13. 
119. Madej T, Addess KJ, Fong JH, Geer LY, Geer RC, Lanczycki CJ, Liu C, Lu S, 
Marchler-Bauer A, Panchenko AR, et al: MMDB: 3D structures and 
macromolecular interactions. Nucleic Acids Res 2012, 40:D461-464. 
120. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as 
biomarkers for the improved diagnosis of cervical neoplasia. Cancer 
EpidemiolBiomarkers Prev 2008, 17:2536-2545. 
121. McLaughlin-Drubin ME, Park D, Munger K: Tumor suppressor p16INK4A is 
necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci U S A 
2013, 110:16175-16180. 
122. Munger K, Phelps WC: The human papillomavirus E7 protein as a transforming 
and transactivating factor. BiochimBiophysActa 1993, 1155:111-123. 
123. Reuschenbach M, Waterboer T, Wallin KL, Einenkel J, Dillner J, Hamsikova E, 
Eschenbach D, Zimmer H, Heilig B, Kopitz J, et al: Characterization of humoral 
immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with 
HPV-associated cancers. IntJCancer 2008, 123:2626-2631. 
124. Reuschenbach M, von Knebel DM: p16INK4a peptide vaccination trials. 2010. 
125. VicOryx S486: Phase I/IIa Study of Immunization With a p16INK4a Peptide 
Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-
associated Cancers. EUDRACT2011-000948-18. 2011. 
126. Yu L, Wang L, Zhong J, Chen S: Diagnostic value of p16INK4A, Ki-67, and 
human papillomavirus L1 capsid protein immunochemical staining on cell 
blocks from residual liquid-based gynecologic cytology specimens. Cancer 
Cytopathol 2010, 118:47-55. 
127. Huang MZ, Li HB, Nie XM, Wu XY, Jiang XM: An analysis on the combination 
expression of HPV L1 capsid protein and p16(INK4a) in cervical lesions. 
DiagnCytopathol 2009. 
128. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, Nakajima T: 
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-
based cytology samples from uterine cervical lesions. Cancer 2008, 114:83-88. 
129. Murata Y, Lightfoote PM, Rose RC, Walsh EE: Antigenic presentation of 
heterologous epitopes engineered into the outer surface-exposed helix 4 loop 
region of human papillomavirus L1 capsomeres. VirolJ 2009, 6:81. 
130. Schadlich L, Senger T, Kirschning CJ, Muller M, Gissmann L: Refining HPV 16 L1 
purification from E. coli: reducing endotoxin contaminations and their impact 
on immunogenicity. Vaccine 2009, 27:1511-1522. 
131. Ljunggren HG, Ohlen C, Hoglund P, Franksson L, Karre K: The RMA-S lymphoma 
mutant; consequences of a peptide loading defect on immunological 
recognition and graft rejection. Int J Cancer Suppl 1991, 6:38-44. 
132. Ljunggren HG, Karre K: Host resistance directed selectively against H-2-
deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985, 
162:1745-1759. 
133. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, 
Wu TC: Treatment of established tumors with a novel vaccine that enhances 
major histocompatibility class II presentation of tumor antigen. Cancer Res 
1996, 56:21-26. 
References  128 
134. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter 
Schegget J, Melief CJ, Kast WM: Vaccination with cytotoxic T lymphocyte 
epitope-containing peptide protects against a tumor induced by human 
papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23:2242-2249. 
135. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J, Momburg F, 
Hammerling GJ, Rammensee HG: Priming of cytotoxic T lymphocytes by five 
heat-aggregated antigens in vivo: conditions, efficiency, and relation to 
antibody responses. Eur J Immunol 1997, 27:2391-2399. 
136. Gey GO, Bang FB, Gey MK: Responses of a variety of normal and malignant 
cells to continuous cultivation, and some practical applications of these 
responses to problems in the biology of disease. Ann N Y Acad Sci 1954, 
58:976-999. 
137. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita 
M, Schafer K, Sehr P, et al: Human papillomavirus type 16 L1 capsomeres 
induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 
mice. JVirol 2003, 77:4635-4645. 
138. Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanović S: 
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 
1999, 50:213-219. 
139. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F: Worldwide 
trends in cervical cancer incidence: Impact of screening against changes in 
disease risk factors. European Journal of Cancer 2013, 49:3262-3273. 
140. Harper DM: Currently approved prophylactic HPV vaccines. Expert Review of 
Vaccines 2009, 8:1663-1679. 
141. Aida Y, Pabst MJ: Removal of endotoxin from protein solutions by phase 
separation using Triton X-114. J Immunol Methods 1990, 132:191-195. 
142. Garland SM, Skinner SR, Brotherton JM: Adolescent and young adult HPV 
vaccination in Australia: achievements and challenges. Prev Med 2011, 53 
Suppl 1:S29-35. 
143. Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic 
human papillomavirus L1 virus-like particle vaccine clinical trial results. 
Vaccine 2008, 26, Supplement 10:K53-K61. 
144. Schädlich L: Development of prophylactic and therapeutic second generation 
vaccines against the human papillomavirus type 16. University of Heidelberg, 
2009. 
145. Oganesyan N, Ankoudinova I, Kim SH, Kim R: Effect of osmotic stress and heat 
shock in recombinant protein overexpression and crystallization. Protein Expr 
Purif 2007, 52:280-285. 
146. Amersham Pharmacia Biotech: Protein Purification Handbook. 2001. 
147. Petsch D, Anspach FB: Endotoxin removal from protein solutions. J Biotechnol 
2000, 76:97-119. 
148. Waheed MT, Thones N, Muller M, Hassan SW, Razavi NM, Lossl E, Kaul HP, Lossl 
AG: Transplastomic expression of a modified human papillomavirus L1 
protein leading to the assembly of capsomeres in tobacco: a step towards 
cost-effective second-generation vaccines. Transgenic Res 2011, 20:271-282. 
149. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, Schlegel R: 
Immunization with a pentameric L1 fusion protein protects against 
papillomavirus infection. J Virol 2001, 75:7848-7853. 
150. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA: Quantitative 
disassembly and reassembly of human papillomavirus type 11 viruslike 
particles in vitro. J Virol 1998, 72:32-41. 
151. Kling M, Zeichner JA: The role of the human papillomavirus (HPV) vaccine in 
developing countries. IntJDermatol 2010, 49:377-379. 
152. Maciag PC, Radulovic S, Rothman J: The first clinical use of a live-attenuated 
Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in 
patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983. 
References  129 
153. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, van der Minne CE, 
Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, 
Hellebrekers BW, et al: A placebo-controlled randomized HPV16 synthetic long-
peptide vaccination study in women with high-grade cervical squamous 
intraepithelial lesions. Cancer Immunol Immunother 2012, 61:1485-1492. 
154. Zhang W, Carmichael J, Ferguson J, Inglis S, Ashrafian H, Stanley M: Expression 
of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, 
renaturation, and self-assembly of virus-like particles in vitro. Virology 1998, 
243:423-431. 
155. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M: A direct comparison of 
human papillomavirus type 16 L1 particles reveals a lower immunogenicity of 
capsomeres than viruslike particles with respect to the induced antibody 
response. J Virol 2008, 82:5472-5485. 
156. Lai WB, Middelberg AP: The production of human papillomavirus type 16 L1 
vaccine product from Escherichia coli inclusion bodies. Bioprocess Biosyst Eng 
2002, 25:121-128. 
157. Bian T, Wang Y, Lu Z, Ye Z, Zhao L, Ren J, Zhang H, Ruan L, Tian H: Human 
papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and 
therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther 2008, 
7:1329-1335. 
158. Khan RH, Rao KB, Eshwari AN, Totey SM, Panda AK: Solubilization of 
recombinant ovine growth hormone with retention of native-like secondary 
structure and its refolding from the inclusion bodies of Escherichia coli. 
Biotechnol Prog 1998, 14:722-728. 
159. Kim MJ, Park HS, Seo KH, Yang HJ, Kim SK, Choi JH: Complete solubilization 
and purification of recombinant human growth hormone produced in 
Escherichia coli. PLoS One 2013, 8:e56168. 
160. Govind CK, Gahlay GK, Choudhury S, Gupta SK: Purified and refolded 
recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-B 
expressed in Escherichia coli binds to spermatozoa. Biol Reprod 2001, 
64:1147-1152. 
161. Panda AK: Bioprocessing of therapeutic proteins from the inclusion bodies of 
Escherichia coli. Adv Biochem Eng Biotechnol 2003, 85:43-93. 
162. Mukhopadhyay A: Inclusion bodies and purification of proteins in biologically 
active forms. Adv Biochem Eng Biotechnol 1997, 56:61-109. 
163. Jaganaman S, Pinto A, Tarasev M, Ballou DP: High levels of expression of the 
iron-sulfur proteins phthalate dioxygenase and phthalate dioxygenase 
reductase in Escherichia coli. Protein Expr Purif 2007, 52:273-279. 
164. Esposito D, Chatterjee DK: Enhancement of soluble protein expression through 
the use of fusion tags. Curr Opin Biotechnol 2006, 17:353-358. 
165. Fernando GJ, Murray B, Zhou J, Frazer IH: Expression, purification and 
immunological characterization of the transforming protein E7, from cervical 
cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999, 
115:397-403. 
166. Stanley M, Gissmann L, Nardelli-Haefliger D: Immunobiology of human 
papillomavirus infection and vaccination - implications for second generation 
vaccines. Vaccine 2008, 26 Suppl 10:K62-K67. 
167. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL: Expression of the 
human papillomavirus type 11 L1 capsid protein in Escherichia coli: 
characterization of protein domains involved in DNA binding and capsid 
assembly. J Virol 1997, 71:2988-2995. 
168. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, 
Gissmann L: Chimeric papillomavirus-like particles. Virology 1997, 234:93-111. 
169. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, Waterboer T, Pawlita M: 
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus 
types. J Gen Virol 2008, 89:117-129. 
References  130 
170. Rietschel ET, Schade U, Jensen M, Wollenweber HW, Luderitz O, Greisman SG: 
Bacterial endotoxins: chemical structure, biological activity and role in 
septicaemia. Scand J Infect Dis Suppl 1982, 31:8-21. 
171. Opal SM: Endotoxins and other sepsis triggers. Contrib Nephrol 2010, 167:14-
24. 
172. Beutler B, Rietschel ET: Innate immune sensing and its roots: the story of 
endotoxin. Nat Rev Immunol 2003, 3:169-176. 
173. US Food and Drug Administration: Guideline for Validation of Limulus 
Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and 
Animal Parenteral Drugs, Biological Products, and Medical Devices.  (US 
Department of Health and Human Services ed.; 1998. 
174. Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, 
Jochmus I: Immune response to human papillomavirus 16 L1E7 chimeric virus-
like particles: induction of cytotoxic T cells and specific tumor protection. 
IntJCancer 1999, 81:881-888. 
175. Chen W, McCluskey J: Immunodominance and immunodomination: critical 
factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer 
Res 2006, 95:203-247. 
176. Palena C, Schlom J: Vaccines against human carcinomas: strategies to 
improve antitumor immune responses. J Biomed Biotechnol 2010, 2010:380697. 
177. Corradin GdG, G: Novel Adjuvants for Vaccines. Curr Med Chem – Anti-
Inflammatory & Anti-Allergy Agents 2005, 4. 
178. Tefit JN, Serra V: Outlining novel cellular adjuvant products for therapeutic 
vaccines against cancer. Expert Rev Vaccines 2011, 10:1207-1220. 
179. Aucouturier J, Dupuis L, Ganne V: Adjuvants designed for veterinary and human 
vaccines. Vaccine 2001, 19:2666-2672. 
180. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH: 
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant 
induces a vanishing CTL response, whereas long peptides induce sustained 
CTL reactivity. J Immunol 2007, 179:5033-5040. 
181. Capron A, Capron M, Dombrowicz D, Riveau G: Vaccine strategies against 
schistosomiasis: from concepts to clinical trials. Int Arch Allergy Immunol 2001, 
124:9-15. 
182. Capron A, Riveau G, Capron M, Trottein F: Schistosomes: the road from host-
parasite interactions to vaccines in clinical trials. Trends Parasitol 2005, 21:143-
149. 
183. Siddiqui AA, Siddiqui BA, Ganley-Leal L: Schistosomiasis vaccines. Hum Vaccin 
2011, 7:1192-1197. 
184. McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin 
Microbiol Rev 2008, 21:225-242. 
185. Da Silva DM, Pastrana DV, Schiller JT, Kast WM: Effect of preexisting 
neutralizing antibodies on the anti-tumor immune response induced by 
chimeric human papillomavirus virus-like particle vaccines. Virology 2001, 
290:350-360. 
186. Da Silva DM, Schiller JT, Kast WM: Heterologous boosting increases 
immunogenicity of chimeric papillomavirus virus-like particle vaccines. 
Vaccine 2003, 21:3219-3227. 
187. Ikuerowo SO, Kuczyk MA, von WR, Shittu OB, Jonas U, Machtens S, Serth J: 
p16INK4a expression and clinicopathologic parameters in renal cell 
carcinoma. EurUrol 2007, 51:732-737. 
188. Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A: 
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary 
and metastatic human prostate cancer. Cancer Lett 2002, 185:191-199. 
189. Milde-Langosch K, Riethdorf S: Role of cell-cycle regulatory proteins in 
gynecological cancer. J Cell Physiol 2003, 196:224-244. 
References  131 
190. Herschkowitz JI, He X, Fan C, Perou CM: The functional loss of the 
retinoblastoma tumour suppressor is a common event in basal-like and 
luminal B breast carcinomas. Breast Cancer Res 2008, 10:R75. 
191. Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F: 
Independent prognostic significance of cell cycle regulator proteins 
p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally 
debulked patients: a translational research subprotocol of a randomised study 
of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study 
Group. Br J Cancer 2007, 96:306-313. 
192. Andujar P, Wang J, Descatha A, Galateau-Salle F, Abd-Alsamad I, Billon-Galland 
MA, Blons H, Clin B, Danel C, Housset B, et al: p16INK4A inactivation 
mechanisms in non-small-cell lung cancer patients occupationally exposed to 
asbestos. Lung Cancer 2010, 67:23-30. 
193. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, 
Ramon y Cajal S: p16(Ink4a) overexpression in cancer: a tumor suppressor 
gene associated with senescence and high-grade tumors. Oncogene 2011, 
30:2087-2097. 
194. Burd Christin E, Sorrentino Jessica A, Clark Kelly S, Darr David B, Krishnamurthy J, 
Deal Allison M, Bardeesy N, Castrillon Diego H, Beach David H, Sharpless 
Norman E: Monitoring Tumorigenesis and Senescence In Vivo with a 
p16INK4a-Luciferase Model. Cell 2013, 152:340-351. 
195. Bueter M, Gasser M, Lebedeva T, Benichou G, Waaga-Gasser AM: Influence of 
p53 on anti-tumor immunity (review). Int J Oncol 2006, 28:519-525. 
196. Moudgil KD, Sercarz EE: The self-directed T cell repertoire: its creation and 
activation. Rev Immunogenet 2000, 2:26-37. 
197. Li X, Wang Y, Zhao Y, Yang H, Tong A, Zhao C, Shi H, Li Y, Wang Z, Wei Y: 
Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-
activated fibroblasts. J Cancer Res Clin Oncol 2014, 140:271-280. 
198. Keijzer C, van der Zee R, van Eden W, Broere F: Treg inducing adjuvants for 
therapeutic vaccination against chronic inflammatory diseases. Front Immunol 
2013, 4:245. 
199. Wigren M, Nilsson J, Kolbus D: Lymphocytes in atherosclerosis. Clin Chim Acta 
2012, 413:1562-1568. 
200. Fedoseyeva EV, Boisgerault F, Anosova NG, Wollish WS, Arlotta P, Jensen PE, 
Ono SJ, Benichou G: CD4+ T cell responses to self- and mutated p53 
determinants during tumorigenesis in mice. J Immunol 2000, 164:5641-5651. 
201. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH: 
Identification and design of p53-derived HLA-A2-binding peptides with 
increased CTL immunogenicity. Scand J Immunol 2001, 53:357-364. 
202. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller 
RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, et al: Antitumor 
efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002, 
62:6187-6193. 
203. Stanley MA: Progress in prophylactic and therapeutic vaccines for human 
papillomavirus infection. ExpertRevVaccines 2003, 2:381-389. 
204. Paz De la RG, Monroy-Garcia A, Mora-Garcia ML, Pena CG, Hernandez-Montes J, 
Weiss-Steider B, Gomez-Lim MA: An HPV 16 L1-based chimeric human 
papilloma virus-like particles containing a string of epitopes produced in 
plants is able to elicit humoral and cytotoxic T-cell activity in mice. VirolJ 2009, 
6:2. 
205. Slupetzky K, Shafti-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M, Kirnbauer 
R: Chimeric papillomavirus-like particles expressing a foreign epitope on 
capsid surface loops. JGenVirol 2001, 82:2799-2804. 
206. Fausch SC, Da Silva DM, Kast WM: Heterologous papillomavirus virus-like 
particles and human papillomavirus virus-like particle immune complexes 
activate human Langerhans cells. Vaccine 2005, 23:1720-1729. 
References  132 
207. Klamp T, Schumacher J, Huber G, Kuhne C, Meissner U, Selmi A, Hiller T, Kreiter 
S, Markl J, Tureci O, Sahin U: Highly specific auto-antibodies against claudin-18 
isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor 
cells and inhibit the growth of lung metastases. Cancer Res 2011, 71:516-527. 
208. Xie M, Li S, Shen W, Li Z, Zhuang Y, Mo X, Gu Y, Wu T, Zhang J, Xia N: 
[Expression, purification and immunogenicity analysis of HPV type 18 virus-
like particles from Escherichia coli]. Sheng Wu GongCheng XueBao 2009, 
25:1082-1087. 
209. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R: Effective 
therapeutic anticancer vaccines based on precision guiding of cytolytic T 
lymphocytes. Immunol Rev 2002, 188:177-182. 
210. A therapeutic HPV vaccine candidate: ProCervix 
[http://www.genticel.com/products/procervix/] 
211. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, 
Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R: 
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by 
therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 
2006, 13:592-597. 
 
Abbreviations  133 
VI. Abbreviations 
 
aa amino acid 
AC affinity chromatography 
Amp ampicillin 
APC antigen-presenting cell 
aqua bidest. bidestilled water 
AU absorption units 
bp base pairs 
BPV bovine papillomavirus 
BSA bovine serum albumin 
CDK cyclin dependent kinase 
cDNA complementary DNA 
CIN cervical intraepithelial neoplasia 
ConA concavalin A 
COPV canine oral papillomavirus 
CRPV cotton-tail rabbit papillomavirus 
CTL cytotoxic T lymphocytes 
CV column volumes 
CVLP chimeric virus like particle 
DC dendritic cell 
DMSO Dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DTT Dithiothreitol 
E. coli Escherichia Coli 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immuno sorbent assay 
ELISpot enzyme-linked immunosorbent spot assay 
EM electron microscopy 
EtBr ethidium bromide 
EV epidermodysplasia verruciformis 
FBS fetal bovine serum 
Ger Germany 
GST glutathione S-transferase 
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GuHCl guanidine hydrochloride 
HNSCC head and neck squamous cell carcinoma 
HPV human papillomavirus 
HRP horse raddish peroxidase 
IB inclusion bodies 
IEX ion exchange chromatography 
IFNγ interferon gamma 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
Kan kanamycin 
LB Luria-Bertani broth or lysogeny broth  
LC Langerhans cell 
LCR long control region 
LPS lipopolysaccharides 
MDM murine double minute 
MHC major histocompatibility complex 
MPL monophosphoryl lipid A 
MWCO molecular weight cut-off 
NK cell natural killer cell 
NMSC nonmelanoma skin cancer 
OD optical density 
ORF open reading frame 
PAGE Polyacrylamid gel electrophoresis 
Pap test Papanicolau test 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
Rb retinoblastoma 
RNA ribonucleic acid 
Ros E. coli Rosetta  
rpm rounds per minute 
RT room temperature 
SCC squamous cell carcinoma 
SDS sodium sodecyl sulfate 
SDS-PAGE denaturing SDS polyacrylamide gel electrophoresis 
SEC size exclusion chromatography 
SIL squamous intraepithelial lesion 
SV40 simian virus type 40 
Taq thermophilus aquaticus 
Abbreviations  135 
TB terrific broth  
TBE Tris-Borate-Edta Buffer 
TBS Tris-buffered saline 
TEM transmission electron microscopy 
TLR toll-like receptor 
TMB 3,3’,5,5’ tetramethylbenzidine 
TNF tumor necrosis factor 
Tris Tris (hydroxymethyl) aminomethane 
tRNA transfer ribonucleic acid 
US United States 
VLP virus like particle 
w/v weight per volume 
x-gal 5-bromo-4-chloro-3-indolyl b-galactoside 
 
Short notations for chimeric proteins consisting of the modified L1 and p16INK4a: 
#1 L1ΔN10∆h4ΔC29-p16INK4a L1-p16INK4a  L1p16 
#2 p16INK4a -L1ΔN10∆h4ΔC29 p16INK4a-L1 p16L1 
#3 L1ΔN10∆h4-p16INK4a-ΔC29 L1-p16INK4a-L1  L1p16L1 
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Figure 63: Plasmid map pGex-L1ΔN10∆h4ΔC29-p16
INK4a
 with restriction sites BamHI, NsiI and HindIII. Primers 
and their binding positions within the plasmid are indicated in pink. Translated ORFs are marked with a yellow 
arrow (genproducts: AmpR  β-lactamase; lacI  lac repressor; GST-L1p16 insert  GST-L1-p16INK4a chimeric 
protein, 92.4 kDa); Created with SnapGene. 
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Figure 64: Plasmid map pGex-p16
INK4a
-L1ΔN10∆h4ΔC29 with restriction sites BamHI and HindIII. Primers and 
their binding positions within the plasmid are indicated in pink. Translated ORFs are marked with a yellow arrow 
(genproducts: AmpR  β-lactamase; lacI  lac repressor; GST-p16L1 insert  GST-p16INK4a-L1 chimeric 
protein, 92.1 kDa); Created with SnapGene. 
 
 
 
Figure 65: Plasmid map pGex-L1ΔN10∆h4-p16
INK4a
-L1ΔC29 with restriction sites BamHI and HindIII. Primers 
and their binding positions within the plasmid are indicated in pink. Translated ORFs are marked with a yellow 
arrow (genproducts: AmpR  β-lactamase; lacI  lac repressor; GST-L1p16L1 insert  GST-L1-p16INK4a-L1 
chimeric protein, 91.2 kDa); Created with SnapGene. 
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Peak name /  
marker protein 
Retention 
(ml) 
MW  
(kDA) 
Blue Dextran  
(void volume) 
7.0 > 2000 
Thyroglobulin 8.29 669 
Ferritin 9.71 440 
Aldolase 11.72 158 
Conalbumin 13.33 75 
Ovalbumin 14.53 43 
 
 
Figure 66: Calibration of the Superdex200® gel filtration column using the high molecular weight calibration kit 
(GE Healthcare). 100 μl of the marker proteins (0.3 - 5 mg/ml) were loaded on the column and eluted in buffer 
Lmod (5.4.2). The proteins were detected by measuring the absorbance at 280 nm during elution. The void 
volume of the column (> 850 kDa) was determined using Blue Dextran.  
 
 
Figure 67: Murine p16
INK4a
 expression in different mouse cell lines. The anti-p16 western blot (F-4) of Ripa cell 
lysates reveals similar p16
INK4a
 expression levels in C3 and TC-1 cells whereby no expression could be detected 
in 2F11 and RMA-S cells.  
 
 
 
 
